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Abstract 
 
Context  Diabetes remission is frequent after biliopancreatic diversion (BPD) in morbidly 
obese patients with type 2 diabetes (T2DM). Data, mechanisms, and clinical indications in 
nonobese T2DM patients are scanty. 
Objective  To assess remission and investigate insulin sensitivity and ß-cell function after 
BPD in non-morbidly obese patients with long-standing T2DM. 
Design, setting and patients  Clinical research study comparing 15 T2DM patients (age 
551 years, duration 16±2 years, BMI=28.3±0.6 kg/m2, HbA1c=8.61.3%) with 15 gender-, 
age-, and BMI-matched nondiabetic controls. Before surgery, and 2 months and one year 
later, a 3-hour OGTT, a 5-hour mixed meal test, and a 3-hour euglycemic clamp were 
performed. 
Intervention  BPD (gastric resection, distal jejunum anastomosed to remaining stomach, 
biliopancreatic tract anastomosed to ileum 75cm from the ileocecal valve). 
Results  Glycemia improved in all patients, but remission (HbA1c<6.5% and normal 
OGTT) occurred in 6/15.  Insulin resistance (19.8±0.8 µmol
.
min
-1.
kgffm
-1
, p<0.001 vs 40.9±5.3 
of controls) resolved already at 2 months (34.2±2.8) and was sustained at one year (34.7±1.6), 
although insulin-mediated suppression of endogenous glucose production remained impaired. 
In contrast, ß-cell glucose sensitivity (19[12] pmol
.
min
-1.
m
-2.
mM
-1 
vs 96[73] of controls, 
p<0.0001) rose (p=0.02) only to 31[26] at one year, and was lower in non-remitters (16[18]) 
than remitters (46[33]). 
Conclusions  In nonobese patients with long-standing T2DM, BPD improves metabolic 
control but induces remission in only ~30% of patients.  Peripheral insulin sensitivity is 
restored early after surgery, and similarly in remitters and non-remitters, indicating a weight-
independent effect of the operation. The initial extent of ß-cell incompetence is the main 
predictor of the metabolic outcome. 
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1. INTRODUCTION 
1.1. Epidemiology of Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is known a long time but still today is not 
completely understood. Affecting million of individuals T2DM is responsible, each year, for 
about 5% of all deaths worldwide. Diabetes results from the interaction of genetic 
predisposition and environmental factors (Stumvoll, 2005). Several genetic defects are 
involved in alteration of glucose metabolism. Environmental factors could be responsible by 
enhance or not these genetic predispositions leading to T2DM (Modan, 1986).  
 According to the International Diabetes Federation (IDF) the number of people with 
type 2 diabetes is rising rapidly worldwide. It is associated with the economic development, 
ageing populations, increasing urbanization, dietary changes, reduced physical activity and 
changes in other lifestyle patterns. Diabetes prevalence in the population is increasing around 
the world: 366 million of persons were diagnosed as diabetic in 2011 and by 2030 this 
number will rise to 552 million (IDF Atlas, 2011).  
There are three main types of diabetes: insulin dependent diabetes mellitus (IDDM) or 
type 1 diabetes (T1DM), non insulin dependent diabetes mellitus (NIDDM) or T2DM and 
gestational diabetes (GDM). Others types are also recognized and are resulting of 
malnutrition and therefore named as related diabetes mellitus (MRDM) or as consequence of 
certain conditions or syndromes and known as secondary diabetes (Bennett, 1992). 
Type 2 diabetes is the most common type of diabetes. Results from an impairment of 
normal glucose homeostasis that progresses and becomes a chronic disease exhibiting the 
hyperglycaemia and glucose intolerance as principal symptoms (DeFronzo, 1992).  
Impairment in glucose metabolism is lead to the incapacity of the body in produce enough 
insulin to maintain euglycaemia or to responding to its effects, generating an acute increasing 
and chronically higher concentration of glucose and insulin in the blood.  
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T2DM usually occurs in adults, but actually is also seen in children and adolescents, as 
result of children obesity and unhealthy dietary behaviour. People who develops T2DM 
(90%), are usually middle-aged (45-64 years), not elderly (>65 years), 80% live in low and 
middle-income countries. Type 2 diabetes mellitus usually occurs after that the subject have 
progressed from the normal glucose tolerance (NGT) state to impaired glucose tolerance 
(IGT) and finally, to T2DM. Because symptoms may take years to appear or be recognized, 
meanwhile body is progressively damaged by the excess of blood glucose (Stumvoll, 2005).  
Diagnosis of T2DM is based on measurements of fasting plasma glycaemia (FPG) and 
glycosilated haemoglobin (HbA1c%) but oral glucose tolerance test (OGTT) is the standard 
method to diagnose incipient diabetes. When diabetes becomes chronic, derived 
hyperglycaemia can leads to serious damage to many of the body's systems. Bring to 
debilitating micro and macrovascular diseases as nephropathy, retinopathy and neuropathy.  
Cardiovascular complications constitute the major cause of morbidity and mortality in 
patients with diabetes. Intensive glycaemic control can prevents the development and 
progression of microvascular complications in patients with type 1 or type 2 diabetes (Brown, 
2010).  
 
1.2. Natural History of Type 2 Diabetes Mellitus 
In subjects with normal tolerance to glucose, plasma glucose concentrations are 
maintained within a narrow range as result of simultaneous release of glucose into circulation 
and uptake of glucose from plasma by the cells stimulated by insulin hormone (DeFronzo, 
1992). Metabolism of glucose is an essential step to sustain life by generation of energy to the 
body and to avoid long glucose contact with systems that could be damaged. Glucose flux 
through from intestine and liver to bloodstream and finely into the cells is the initial condition 
to generate energy and store energy (Tripathy, 2010). Defects in one or more of these systems 
could cause impairment in sensitization of tissues by glucose, insulin secretion and insulin 
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stimulated glucose uptake originating hyperglycaemia and disequilibrium in the glucose 
homeostasis (Leahy, 2005). Because in T2DM the body exhibit impaired ability to respond to 
insulin (DeFronzo, 1992), the pancreas must to increase its secretion of insulin to offset the 
insulin resistance maintaining the normal glucose tolerance. The progression from NGT to 
impaired glucose tolerance (IGT) to T2DM is characterized by progressive 
hyperinsulinaemia. ß-cell dysfunction starts when pancreatic ß-cells fails to maintain 
hyperinsulinaemia necessary to cope insulin resistance leading to the development of IGT and 
eventually overt T2DM (Kan, 1993). Insulin resistance is observed in skeletal muscle, liver 
and adipocytes (Cusi, 2010). The relative contribution of defects in insulin action and ß-cell 
function for the pathogenesis of T2DM remains still unclear (Tripathy, 2010). 
To avoid the progression from NGT to IGT and finally to T2DM, -cell must be able 
to regulate its secretion of insulin hormone in precise doses to cope insulin resistance 
presented by peripheral tissues. In fact, only insulin resistance is not sufficient to cause loss of 
homeostasis in glucose metabolism if -cell function is preserved enough to offset insulin 
resistance. This is commonly observed in obese subjects with NGT. In whom insulin output 
can be 10-fold higher than in lean individuals and returns to normal levels after weight-loss. 
However, -cell dysfunction is necessary and sufficient to produce hyperglycaemia. 
Whether obese insulin resistant subjects, shown an increase in -cell mass. Decrease 
by 80-90% in -cell mass is required before sufficient insulinopenia develops to cause overt 
T2DM (Ferrannini, 2010). It seems that other factors in addition to -cell lost must be 
responsible for the impairment of insulin secretion. Many acquired factors also play a role in 
the pathogenesis of the disease and information from DNA transcript: protein and metabolite 
profiles may better capture the genetic influences on metabolism than studying single genes. 
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1.3. Obese Type 2 Diabetes Mellitus 
Most subjects with T2DM are obese. The common occurrence of obesity in T2DM, 
and the observation that obesity precedes the deterioration of glucose homeostasis, lead to the 
hypothesis that, at least for obese subjects, obesity was the risk condition resulting in T2DM 
(DeFronzo, 1992).  
Prospective studies among Pima Indians demonstrate that obesity precedes the 
development of T2DM (Tulloch-Reid, 2003). Obesity therefore must be viewed as a risk 
factor for the development of the disease rather than a consequence, or complication, of the 
diabetic condition. The increase in the prevalence of obesity appears to be associated with an 
increased prevalence of risk factors for cardiovascular disease and T2DM, including 
hypertension and reduced glucose tolerance (Meisinger, 2006). Duration of obesity is an 
additional risk factor for the development of T2DM. Although obesity is a major risk factor 
for T2DM in Pima Indians, the presence of diabetes in one or both parents has been shown to 
be a major dependent risk factor (Mallikarjun, 2009). Obese, adult Pima offspring of a 
diabetic parent are at much greater risk of developing T2DM than the obese, adult offspring 
of two non-diabetic parents. Obesity was formerly believed to be a risk factor for T2DM as a 
result of being associated with insulin resistance. Prando et al. have shown that, on average, 
obese subjects are more insulin resistant than lean subjects (Prando, 1998). 
Diabetes risk is determined not only by the degree of obesity (Eckel, 2011). The 
adiposity in T2DM patients is predominantly located around the centre of the body, in the 
abdomen, subscapular and triceps regions. Increased upper body fat, including visceral 
adiposity, as reflected in increased abdominal girth or waist-to-hip ratio, is associated with 
insulin resistance (Kahn, 2001) metabolic syndrome and cardiovascular disease. Although 
obesity is commonly associated with T2DM and has been clearly established to precede its 
development, it is neither a sufficient nor a necessary metabolic abnormality to cause T2DM. 
One or more of the other metabolic abnormalities that occur in subjects with T2DM, together 
12 
 
with genetic susceptibility, must also be present in the obese subject before T2DM develops. 
Obesity is associated with higher fat free acids (NEFA), low-grade inflammation: tumour 
necrosis factor alpha, interleukin-6 and protein C-reactive (TNF, IL6, CRP), and lower 
adiponectin levels. Other potential mechanisms that have been put forward to explain the 
insulin resistance, include increased lipid oxidation and glucose toxicity (DeFronzo, 1992)  
impaired incretin effect observed in obesity and T2DM can contribute with β-cell dysfunction 
leading to the inability of insulin secretion to offset body's insulin resistance resulting in 
impairment of glucose homeostasis (Nauck, 1997). 
At least three mechanisms have been proposed to link obesity to insulin resistance and 
predispose to T2DM: 1) increased production of adipokines/cytokines, including TNF, 
resistin and retinol binding protein-4 (RBP-4), that contribute to insulin resistance as well as 
reduced levels of adiponectin (Deng, 2010); 2) ectopic fat deposition, particularly in the liver 
and also in skeletal muscle, and the dysmetabolic sequelae (Larson-Meyer, 2011); and 3) 
mitochondrial dysfunction, evident by decreased mitochondrial mass or function. 
Mitochondrial dysfunction could be one of the most important underlying defects linking 
obesity to diabetes, both by decreasing insulin sensitivity and by compromising β-cell 
function (Bournat, 2010). 
 
1.4. Nonobese Type 2 Diabetes Mellitus 
It is not clear if nonobese and obese forms of T2DM have a similar natural history 
(Prando, 1998; Eckel, 2011). The obese form of T2DM is the most common, accounting for 
the majority of cases in caucasoides and other populations such as the Americans Indians, 
Mexican-Americans, Micronesians and Polynesians. On the other hand, in populations of Far 
East including Japan, China, Taiwan and Korea, the nonobese form is more common 
(Bennett, 1992 and IDF Atlas, 2011). Insulin resistance and impaired insulin secretion are 
usually present in patients with classic type 2 diabetes as well as in most patients with 
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impaired glucose tolerance. Both play important roles in determining if diabetes development 
and also in determining the magnitude of the accompanying hyperglycaemia and others 
metabolic abnormalities. Lean subjects, first-degree T2DM relatives showed impairment in 
insulin secretion whereas insulin sensitivity was normal (Pimenta, 1995). Lean subjects with 
normal glucose tolerance and first-degree T2DM relatives showed defective insulin secretion 
relative to insulin sensitivity, lower insulin sensitivity compared with controls and correlation 
between NEFA and insulin resistance (Perseghin, 1997). But not only obesity can be 
implicated in the development of insulin resistant state. Non obese individuals can present 
insulin resistance by numerous others mechanisms: high fat diets (Gupta, 2012), decreased 
physical fitness, increased visceral fat accumulation (Eckert, 2012), smoking, pregnancy and 
certain used medications (Gupta, 2012). It seems that in nonobese T2DM genetic 
susceptibility may contribute more to the onset of the disease than environmental component 
does (Rhodes, 2002). When matched for obesity, normal glucose tolerant, first-degree 
relatives of patients with T2DM had impaired insulin secretion but were not insulin resistant 
(Van Haeften, 1998; Pimenta, 1995). Normal glucose tolerant monozygotic twins of someone 
with T2DM had impaired β-cell function, but normal insulin sensitivity; moreover, 
monozygotic twins who had developed impaired glucose tolerance had the same degree of 
impaired insulin secretion as those who had maintained normal glucose tolerance, but they 
had greater body mass index and waist-to-hip ratio and were insulin resistant (Vaag, 1995). 
Prando and associates studied 147 nonobese and 215 obese subjects to assess the possible 
differences in insulin secretion and its link with treatment failure with oral hypoglycaemic 
agents. Obese group showed  higher percentage of dietetic control, high insulin secretion with 
comparable levels of insulin sensitivity. As conclusion of this study obese have high insulin 
secretion than nonobese subjects, especially in the early years of disease and secondary failure 
in hypoglycaemic treatment is linked with progressive impairment in insulin secretion for 
both obese and nonobese T2DM individuals (Prando, 1998). Arner et al., studied elderly 
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patients divided in four groups nonobese and obese with and without diabetes. In nonobese 
hyperglycaemic subjects, however, there was no evidence of peripheral insulin resistance with 
marked secretory defect involving both the first and second phase response (Arner, 1991). 
Moreover obese diabetic patients were more insulin resistant than nonobese diabetic patients 
and showed only the first phase insulin response decreased. The second phase was slightly 
enhanced, in contrast with nonobese diabetic subjects that presented lower first-and second-
phase insulin secretion (Felber, 2002).  
 
1.5. Pathogenesis of Type 2 Diabetes Mellitus 
The pathogenesis of T2DM is multi-factorial and includes both genetic factors and 
environmental elements that affect insulin secretion, insulin function and higher hepatic 
glucose production (DeFronzo, 2004). Genetically, the pancreas responsible to produce 
insulin at exactly doses, may cannot be able to produce enough insulin to offset the insulin 
resistance state, given rise to hyperglycaemia. The environment may impair the insulin ability 
to stimulate glucose uptake by the cells. It provokes hyperglycaemia that could or not be 
resolved by increase in β-cell function as reviewed by Ferrannini  (Ferrannini, 2010). This 
dynamic equilibrium between  β-cell function, represented by β-cell glucose sensitivity, i.e., 
the ability of β-cell in secret exactly amounts of insulin to offset increments in plasma glucose 
concentration and the ability of insulin-dependent tissues to recognize promptly insulin 
hormone and internalizes glucose molecules represent the two major defects observed during 
the progression of normal glucose tolerance to IGT and finally T2DM. They must be viewed 
simultaneously because any impairment in one will reflect in a defective response in the 
other.   
In normal glucose tolerant subjects, the increase in insulin secretion that occurs 
simultaneously with insulin resistance is described by a hyperbolic relationship (Kahn, 1993). 
Not only insulin concentration in plasma is impaired but also qualitative changes in insulin 
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secretion are observed in insulin resistant state (O'Rahilly, 1988). Indeed, defects in insulin 
secretion pulses have been reported as inversely correlated with peripheral insulin sensitivity 
(Hunter, 1996). Proinsulin, molecule that can be used to measure the correct rate of insulin 
synthesis, is increased in states of impaired glucose tolerance (IGT and T2DM). Higher 
glucagon and proinsulin were associated with insulin resistant status (Ferrannini, 2007) 
reflecting the incapacity of β-cell to synthesises insulin correctly and the insulin to inhibit 
glucagon secretion by pancreatic α-cells.   
Thus, we can conclude that type 2 diabetic subjects manifest multiple disturbances in 
glucose homeostasis, including: (1) impaired insulin secretion; (2) insulin resistance in 
muscle, liver, and adipocytes; and (3) abnormalities in splanchnic glucose uptake. 
 
1.5.1. Insulin resistance 
Insulin resistance is present when the biological effects of insulin are less than 
expected for glucose disposal in skeletal muscle, suppression of endogenous glucose 
production in liver and to mediate lipid metabolism on adipose tissue (DeFronzo, 1992). 
Insulin resistance is present in lean or obese patients with T2DM, in whom precedes and 
predicts the hyperglycaemia (Bogardus, 1991), contributing to metabolic syndrome (Reaven, 
1988) or being responsible together with the hyperinsulinaemia by the insulin resistance 
syndrome (Ferrannini, 1992). Augmented ß-cell response represents a compensatory 
adaptation by the ß-cells to offset the defect in insulin action (Mari, 2005a). During the 
progression from NGT to IGT there is an increase in insulin resistance and secretion. In the 
long term, the increased demand for insulin led to ß-cell exhaustion, the development of 
fasting hyperglycaemia and overt diabetes (Abdul-Ghani, 2006). 
Skeletal muscle is the primary site of insulin action in the postprandial state, 
accounting for about two thirds of glucose uptake. The liver is responsible by uptake the other 
one third of glucose, both via insulin dependent mechanisms (Abdul-Ghani, 2010). During 
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euglycaemic hyperinsulinaemic clamp, hyperinsulinaemia inhibits glucose production by the 
liver and insulin secretion (Ferrannini, 1999). So the glucose uptake stimulated by insulin 
during the clamp is represented almost only by the muscle metabolism. The skeletal muscle of 
lean T2DM and obese subjects with normal glucose tolerance (NGT) is resistant to insulin 
(Felber, 2002).  
In nonobese healthy subjects with strong familiar history of T2DM (FH+ subjects) 
insulin resistance is present long before the development of impairment in glucose 
metabolism and as severe as in established T2DM (Mari, 2005b; Jensen, 2002).  
Liver insulin resistance plays an important role in the T2DM pathogenesis. Mild-age 
subjects divided by glucose tolerance status were studied during OGTT and low-dose insulin 
infusion rate to assessing glucose rate of appearance (Ra) using [6-
3
H] glucose as glucose 
tracer. Hepatic insulin resistance appears as an early and important defect that characterizes 
subjects with IGT and mild diabetes (Båvenholm, 2001). In the postabsorptive state liver is 
responsible to produce glucose to exactly match the obligatory needs of the brain and other 
tissues that utilize glucose independently of insulin, this uptake of glucose is not impaired in 
T2DM and is basically equal at basal and postabsorptive state. After glucose ingestion, insulin 
is released into the portal vein and carried to the liver where binds to specific receptors on the 
hepatocytes and suppresses hepatic glucose output. Liver insulin resistance results in impaired 
suppression of HPG contributing to hyperglycaemia. In T2DM subjects with moderate 
hyperglycaemia and higher fasting insulin plasma concentrations, an increase in basal HPG 
has been demonstrated been closely correlated with the degree of fasting hyperglycaemia 
(Ferrannini, 1999). Hepatic insulin resistance may drive an increase in insulin secretion to 
prevent an increase in hepatic glucose production (HGP) and hyperglycaemia. This chronic ß-
cell demand may accelerate the progression to T2DM. Excessive HPG is an important factor 
in the development of fasting hyperglycaemia. Examining HGP rates in 200 men of similar 
age, with a range of glucose tolerance degrees, Tripathy et al. have showed that although in 
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absolute terms the endogenous glucose production (EGP) was not high until late in the stages 
of glucose intolerance, hepatic insulin resistance was already evident in subjects with IGT 
(Tripathy, 2004). Because augmented HPG occurs even in the presence of hyperinsulinaemia, 
a powerful inhibitor of HGP, it is believed that hepatic resistance to insulin is present in 
postabsorptive state and contributes to the excessive output of glucose by the liver. Because 
hyperglycaemia also suppresses HGP there may also be glucose resistance with respect to the 
inhibitory effect of hyperglycaemia on hepatic glucose output (Faerch, 2009). 
Insulin also control fat metabolism stimulating fat storage and/or fat free acids 
(NEFA) release (Groop, 1989). Circulating NEFA levels are markedly increased in obesity 
and T2DM and evidences suggests a fundamental role of NEFA to induce insulin resistance in 
peripheral tissues. Prolonged exposition of skeletal muscle and myocytes to high levels of 
NEFA leads to severe insulin resistance by affecting intracellular signalling pathways in cells 
(Roden, 2004). When white tissue ability for storage circulating lipids is exceed, NEFA 
storage starts in others tissues such as liver and skeletal muscle. However, an increased mass 
stored triglycerides especially in adipocytes and in visceral or deep subcutaneous adipose 
tissue depots, leads to large adipose cells, which become resistant to the ability of insulin to 
suppress lipolysis. It leads to increased release and circulating levels of NEFAs which 
aggravates insulin resistance (decreases glucose uptake and oxidation) in skeletal muscle and 
liver. When these NEFAs accumulates in other organs than the adipose tissue (ectopic fat 
storage), they further promote insulin resistance in liver and muscle cells and damage the β-
cells in the pancreas. This is known as “lipotoxicity”. The link between intra-hepatic lipids in 
non-alcoholic fatty liver disease (NAFLD) and hepatic insulin resistance seems tight as well. 
The excess of NEFAs also promotes hepatic triglyceride production and therefore the 
dyslipidemia usually seen in T2DM. Ectopic fat is strongly associated with insulin resistance 
(Gastaldelli, 2011).  
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Adipocytes synthesize and secrete a host of proteins that collectively are designated as 
adipocytokines that have local, autocrine and paracrine effects, as well as systemic effects. 
Low-grade inflammation is associated not only with obesity but also with cardiovascular 
disease and T2DM (Pickup, 1998). Circulating concentrations of inflammatory markers, such 
as CRP and IL-6 are independent predictors of the future development of type 2 diabetes in a 
prospective case-cohort study within the population-based MONICA/KORA Augsburg cohort 
(Herder, 2011), but failed in another cohort study: the Framingham Heart Study (Dallmeier, 
2012). Tumour necrosis factor alpha (TNF-α) have direct effect on insulin sensitivity in 
skeletal muscle and it has been demonstrated in vitro, in vivo in animals and in vivo in humans 
(Hotamisligil, 2003). A number of other adipocytokines have been identified, including IL-6, 
plasminogen activator inhibitor-1 (PAI-1), resistin, IL-1, leptin, adiponectin, and visfatin, all 
of them exhibiting positive, such adiponectin (Pajvani, 2003) or negative (TNF-α, IL6, 
resistin) effects on insulin sensitivity. Activation of inflammatory pathways by 
adipocytokines has been shown to inhibit insulin signal transduction by causing 
serine/threonine phosphorilation of IRS-1 in multiple insulin-sensitive tissues, including 
muscle, liver and adipocytes (Hotamisligil, 1996). Thus, expression and secretion into plasma 
of these and other cytokines could provide a link between insulin resistance and low-grade 
inflammation in T2DM (Shoelson, 2006). There are several possible explanation for how 
inflammation in adipose tissue lead to systemic (muscle and liver) insulin resistance in 
humans: 1) decrease insulin responsiveness in adipose tissue leads to increased lipolysis and 
elevated NEFA concentrations, which are known to cause insulin resistance in muscle and 
liver; 2) adipokines released by adipocytes and resident macrophages are released into the 
circulation and act at distal sites (skeletal muscle and liver), and activate inflammatory (c-Jun 
N-terminal kinase (JNK), nuclear factor kappa-light-chain-enhancer of activated β-cells 
(NFK-β) pathways, to impair insulin signalling (Shoelson, 2006; Pajvani, 2003; Pickup, 
1998). 
19 
 
1.5.2. Insulin Secretion 
Abnormalities in insulin secretion are present in subjects with IGT and in patients with 
type 2 diabetes (Beck-Nielsen, 1994). Indeed, subjects with IGT can remain in these 
conditions for several years, or revert to NGT or progress to T2DM (Ferrannini, 2011). 
Diabetic subjects showed the same abnormalities observed in IGT people but without normal 
glycaemic control .  
Usually during the progression from IGT to T2DM, basal insulin concentrations may 
be raised several fold than the normal value (Tripathy, 2004), especially in obese 
hyperglycaemic patients. However, basal -cell secretory function must is not normal, 
because the prevailing plasma glucose level also must be taken into account. Hyperglycaemia 
is the major stimulus for insulin secretion, and when normal individuals are made 
hyperglycaemic by glucose infusion, circulating levels are much higher than those found in 
T2DM. Ehrmann et al. has shown that subjects with IGT secrete less insulin at any given 
glucose level than NGT subjects matched for a similar degree of insulin resistance and obesity 
(Ehrmann, 2002).  
Normal insulin secretion is biphasic and is composed by an early burst of insulin 
release for about 10 minutes, followed by a graded and progressive release of insulin that 
persists parallel with hyperglycaemic stimulus. Henquin, studying this phenomenon showed 
that the first phase insulin secretion is represented by the release of insulin secretory granules. 
There are a reserve of insulin localized near to the plasmatic membrane of the β-cell and 
immediately releasable (Henquin, 2000). Glucose is a powerful generator of insulin secretion 
by stimulation of both pathways involved in insulin secretion: the triggering pathway that 
occurs early and starts when glucose enters inside β-cells by facilitated diffusion. Glucose is 
then metabolized, generating by glycolysis a rise in ATP-to-ADP ratio, closure of ATP-
sensitive K+ (KATP) channels, membrane depolarization, opening of voltage-operated Ca2+ 
channels, Ca2+ influx, rise in cytoplasmic free Ca2+ concentration ([Ca2+]i), and activation 
20 
 
of the insulin exocytosis. The mechanism of the amplifying pathway is less known.  Increase 
in β-cell metabolism also generates amplifying signals that augment the efficacy for the Ca2+ 
on the exocytose machinery. Stimulatory hormones and neurotransmitters modestly increase 
the triggering signal and strongly activate amplifying pathways biochemically distinct from 
that set into operation by nutrients. Many drugs can increase insulin secretion in vitro, but 
only few have a therapeutic potential (Henquin, 2004). 
This biphasic response is identifiable after intravenous glucose load (IVGTT) (Seltzer, 
1967). T2DM subjects have reduced first phase response to oral or intravenous glucose load 
already at an early stage of their disease (Swinburn, 1995). However, loss of first phase 
insulin secretion does not appear to be the primary defect responsible for T2DM even if the 
loss of first phase of insulin secretion have been linked with the increased in EGP observed in 
T2DM (Luzi, 1989).   
Although insulin resistance is considered the initiating event in the pathogenesis of 
T2DM, β-cell dysfunction must be present for the hyperglycaemia initiation (Ferrannini, 
2010). Initially in the T2DM progression increments in FPG can be observed and correlated 
with insulin resistance. At this point, a compensatory mechanism is already present. In fact, 
when β-cell function is expressed in relation to insulin resistance observed that β-cell 
dysfunction is present longer before T2DM (Gastaldelli, 2004 a). As long as the β-cell is able 
to secrete sufficient amounts of insulin to offset the severity of insulin resistance, glucose 
tolerance remains normal (Gastaldelli, 2011).  
 
2. Bariatric Surgery 
Diet, exercise and prescription medication remain the cornerstones of type 2 diabetes 
mellitus therapies, but the long-term success rates of lifestyle and drug modifications are 
disappointing. Despite a vast variety of pharmacological therapies, long-term glycaemic 
control is difficult, and use of large number of drugs introduces a proportionate risk of 
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hypoglycaemia. Moreover, most diabetes medications promote weight gain and weight gain 
in turn, exacerbate the severity of T2DM.  
In cases where classic strategies prove insufficient, several types of gastrointestinal 
(GI) surgery offer alternatives to treat obesity and T2DM. Among severely obese patients, 
bariatric operations cause significant sustained weight loss, improve obesity-related 
comorbidities, and reduce mortality in the long term. Currently, bariatric surgery is 
considered appropriate for individuals with a body mass index (BMI) >35 kg/m
2
 and serious 
obesity-related comorbidities, including T2DM. Operations involving intestinal bypasses 
exert particularly dramatic effects on diabetes. Mounting evidence indicates that these 
remarkable effects result not only from weight loss but also from weight-independent 
antidiabetic mechanisms. Consequently, conventional bariatric procedures and new 
experimental GI operations are being used to treat T2DM associated with obesity and, 
increasingly, among less obese or merely overweight patients.  
Bariatric procedures were initially classified as restrictive, malabsortive, or combined, 
reflecting the purported mechanism of weight loss. Restrictive procedures reduce the volume 
of the stomach to decrease food intake and induce early satiety. Malabsortive procedures, 
such as biliopancreatic diversion (BPD), shorten the small intestine to decrease nutrient 
absorption. Combined procedures, such as the Roux-en-Y gastric bypass (RYGB), 
incorporate both restrictive and malabsortive elements.  
 
2.1. Diabetes Resolution and Improvement after bariatric surgery 
Observational evidences suggest that bariatric surgery is associated with 60% to 80% 
rate of diabetes resolution, defined as discontinuation of all diabetes-related medications and 
blood glucose levels within the normal range (Vetter, 2009). Recovery from type 2 diabetes 
was established in 76,8% of the patients who underwent bariatric surgery (Buchwald, 2009). 
In the surgically treated group of SOS study, T2DM had disappeared in 72% after 2 years. In 
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the conventionally treated group it was 21%. These percentages seem related to the operative 
procedures that are used. 
The remarkable control of diabetes in severely obese patients together with results 
from experimental studies showing that GI operations can improve diabetes in both obese and 
nonobese animals have lead to the concept that surgery may be beneficial for moderately 
obese patients with T2DM. 
 
2.2 Mechanisms of diabetes remission after gastrointestinal surgery 
2.2.1 Weight loss effects 
Weight reduction leads to a decline in insulin resistance, better metabolic regulation of 
patients with T2DM, lower blood pressure and less atherogenic lipid profile (Sjöström, 2004). 
The Diabetes Prevention Program reported a 58% reduction of the diabetes incidence after 
modest weight loss of 5.6 kg on average (Knowler, 2002). The 'Swedish obese subjects' 
(SOS) study has shown that long-term weight reduction, achieved by bariatric surgery 
improves the cardiovascular risk profile and decreases the overall mortality (Knowler, 2002). 
In the Pima Indians with normal tolerance to glucose long-term weight changes have been 
associated with reciprocal change in insulin action (Weyer, 2000).  However, weight loss did 
not explain all amelioration observed in morbidly obese subjects after bariatric surgery. 
Observations that glycaemic control improves early after surgery, before important 
weight loss, has led to the recognition that bariatric surgery induces modifications that are 
independent of weight loss.  Comparisons between BPD and RYGB effects on glucose 
metabolism realized by Muscelli et al. demonstrated differentiated changes in insulin 
sensitivity in face of paired weight loss (Muscelli, 2005). Camastra et al. reported that RYGB 
surgery promotes early (one month) improvement in glucose metabolism by increasing 
hepatic insulin sensitivity more than in peripheral tissues. Moreover, studying the same 
subjects after two years, improvement in peripheral IS was correlated with weight loss 
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(Camastra,  2011). Others investigated the effect of BPD surgery and found that diversely of 
RYGB, IS and first phase insulin secretion improved in a few days after surgery (Salinari, 
2009). 
Weight loss has been also linked to amelioration of β-cell function and insulin 
secretion. Homeostasis model (HOMA-), Acute insulin response (AIR) and mathematical 
modelling were used to assess this parameter (Briatore, 2008; Ferrannini, 2009; Camastra, 
2011). Morbidly obese T2DM patients restored first phase insulin secretion earlier after BPD 
(Briatore, 2008). Using mathematical modelling to assess the β-cell function after BPD and 
RYGB surgery, Mari et al. showed that all of 3 mathematical model parameters improved 
after weight loss induced by surgery (Mari, 2006). Among these parameters, β-cell glucose 
sensitivity is the main determinant of IGT and T2DM, rate sensitivity and potentiation being 
relatively minor factors. 
Finally, several peptides expressed and releases by adipose tissue are metabolically 
active and are also changed by bariatric surgery.  
 
2.2.2. Effects of BPD on Insulin Sensitivity 
Insulin resistance is present when the biological effects of insulin are less than 
expected for one or more of the insulin action: glucose disposal in skeletal muscle, 
suppression of endogenous glucose production primarily in liver (Rizza, 2010) and to mediate 
lipid metabolism on adipose tissue (Ferrannini, 1999). Most of available evidence suggests 
that insulin resistance is the primary metabolic disturbance in T2DM and that the augmented 
ß-cell response represents a compensatory adaptation by the ß-cells to offset the defect in 
insulin action (Ferrannini, 1992; Arner, 1991). Most T2DM are obese and obese 
normoglycaemic subjects are also insulin resistant. Overweight and the adiposity are 
determinants of insulin sensitivity (Ferrannini, 1997) and loss of weight by diet or surgery is 
able to enhance IS (Sjöström, 2013). It is known that weight loss promoted by bariatric 
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surgery improve IS in subjects with NGT, IGT and T2DM.  However some investigators have 
found greater defect on insulin secretion (AIR) than in IS in non obese T2DM patients (Arner, 
1991). Subjects with non-morbidly obesity (BMI < 35 kg/m2) showed an improved IS after 
loss of 5kg in average and only 1.5 kg of fat mass (Chiellini, 2009). Suggesting that more than 
the quantity, site of fat accumulation instead of amount of fat gained or lost is very important. 
Moreover when fat is removed selectively by surgeries as liposuction, does not promote 
improvements in IS as could be expected (Ferrannini, 2009). Ectopic fat has been linked with 
IR independently of total body fat mass (Gastaldelli, 2011). On the other hand, omental 
adipose tissue is lipolytically active and releases a large quantity of fatty acids. These fatty 
acids are converted into triglycerides. The liver in turn produces increased free fatty acids and 
releases the same into the systemic circulation which contributes to peripheral insulin 
resistance directly as well as by increasing muscle triglyceride. Removal of visceral fat from 
diabetic mice have restored IS (Gabriely, 2002) but RYGB plus omentectomy showed no 
additional improvement in IS that observed in control group (Lima, 2010). 
Two groups of obese patients (with or without T2DM) underwent BPD demonstrated 
that the obese T2DM group had before surgery high FPG, IR (measured by HOMA-IR) and 
lesser AIR (IVGTT). One month after surgery FPG and HOMA-IR were reduced at levels 
similar to those observed in the obese non-diabetic control group while AIR increases only in 
T2DM subjects, but without achieves normal values (Briatore, 2008). Two years after BPD 
surgery obese non diabetic have showed levels of IS greater than lean control subjects and 
greater than obese non diabetic subjects underwent RYGB (Muscelli, 2005). NGT, IGT and 
T2DM subjects were submitted to BPD and compared to two control groups, lean and obese 
subjects that underwent abdominal surgery for other reasons (mainly cholecystectomy and 
abdominal hernia).  IS did not change in the control groups while increased only 10 days after 
BPD surgery in all patients  before any significant weight loss. The improvement in IS could 
not be explain by changes in NEFA, adiponectin or leptin concentrations (Mari, 2006).  
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Obesity is a state of heightened inflammation as noted by increased serum levels of 
inflammatory markers like TNF-α and IL-1. These molecules induce insulin resistance by 
inhibition of insulin signal transduction. Interleukin-6 (IL-6) and TNF-α have been shown to 
contribute to hepatic insulin resistance in animal models (Barbuio, 2007). Bariatric surgery 
has been shown to decrease the levels of IL-1, whereas there is no consensus about the change 
in TNF-α and IL-6 after bariatric surgery (Bruun, 2007; Vazquez, 2005).  
Results as presented above leads to the hypothesis that some unknown regulator 
factors of insulin sensitivity are directly affected by BPD as well as by RYGB surgery. In 
fact, Rubino et al. showed that exclusion of duodenum from the alimentary transit in non-
obese rats Goto-Kakyzaky (T2DM model) improved glucose metabolism as observed in BPD 
surgery (Rubino, 2004 b). 
 
2.2.3. Effects of BPD on β-cell function 
 Maintenance of normal glucose tolerance is dependent on the finely tuned balance 
between insulin secretion and insulin action (Reaven, 1989 e Wogensen 1991 e Ferrannini, 
1997).  NGT subjects show insulin sensibility that varies greatly but nevertheless glucose 
tolerance remains normal in function of β-cell compensation that offset tissue resistance to 
insulin. Biliopancreatic diversion is able to enhance both IS and β-cell function earlier after 
surgery and these effects of BPD have been observed after long term (Pontiroli, 2010; 
Muscelli, 2005).  The progression from normal glucose tolerance to IGT and finally to T2DM 
is characterized by progressive hyperinsulinaemia, loss of β-cell mass that leads to the 
incapacity of β-cell to offset tissue insensitivity. A basic genetic defect in the insulin gene has 
been proposed to explain the disturbance in insulin secretion but anyone was able to prove or 
find any significant abnormalities (Das, 2006). The most likely explanation for the acquired 
defect in insulin secretion relates to the concept of glucose toxicity (Del Prato, 2009). The 
pathological sequence that leads to T2DM would be the superposition of obese-related insulin 
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resistance upon a β-cell with a geneticatilly limited capacity to compensate (Gerich, 2000). 
Studying obese and non obese T2DM subjects Prando el al. found that mainly in the earlier 
years of disease obese T2DM showed higher levels of insulin secretion than non obese T2DM 
subjects; that BMI was more related with insulin resistance and that after several years (10 
years) the differences in insulin secretion between obese and non obese were negligible 
(Prando, 1998; Arner, 1991). The impact of bariatric surgery in obese subjects with or without 
T2DM has been done using the acute insulin response (AIR), homeostasis model (HOMA-B), 
insulinogenic index and mathematical modelling. All authors described improvements in β-
cell function after BPD and after RYGB when the comparison has been made. Obese NGT 
and T2DM subjects have been studied for AIR using glucose and arginina stimulus (Briatore, 
2010). One month after BPD fasting insulin, Homa-IR, AIR for glucose and arginine 
improved but AIR in T2DM did not were similar for NGT and T2DM.  
Effects of BPD on β-cell function has been explored using mathematical modelling to 
assess insulin secretion by deconvolution of C-peptide proposed by Van Cauter (Van Cauter, 
1992) and revised by Mari A. (Mari, 2008) and to assess the relationship between insulin 
secretion and glucose concentration (β-cell glucose sensitivity - BCGS). After BPD obese 
subjects showed improvements in all parameters of mathematical model. BPD induces a 
reduction of insulin secretion rate at fasting and during meal or OGTT stimulation. Guidone 
et al, found a correlation between decrease in insulin sensitivity and β-cell glucose sensitivity 
(Guidone, 2006). Camastra et al, studying morbidly obese T2DM subjects before and after 
Roux-en-Y showed that patients were more insulin resistant (IR) with decreased -cell 
function when compared with control group. Patients revert completely the IR and -cell 
function proportionally with weight loss (Camastra, 2007). 
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2.3. The entero-insular axis 
Food intake, transit and absorption are regulated by a complex network including the 
gastrointestinal system, the liver and the brain (Cummings, 2007 b). Surgical rearrangements 
of gastrointestinal tract may can change hormones concentrations and per consequence, 
alteration in glucose metabolism. Changes in gastro-intestinal hormones (GI) have been 
analysed for those bariatric surgeries that alter food transit. Glucagon-like peptide 1 (GLP-1) 
is a potent insulin agonist that is secreted by L-cells of the distal ileum in response to ingested 
nutrients and is inactivated by the enzyme dipeptidyl peptidase IV (DPP-IV). GLP-1 
potentiates insulin release in a glucose dependent manner. Insulin increases affect α-cells 
inhibiting glucagon secretion (Holst, 2007). GLP-1 response to a mixed meal or OGTT is 
impaired in obesity and T2DM and increases after RYGB and BPD (Rubino, 2004a; 
Laferrère, 2008; Mingrone, 2009).  Muscelli et al. have quantified the incretin effect on 
insulin secretion during a mixed meal test followed by an intravenous glucose test that 
duplicate previous MTT glycaemic values but without meal stimulation. GLP-1 and GIP 
account for 50% to 60% of nutrients stimulated insulin release (Muscelli, 2006) increases -
cell mass trough regulation of proliferation, neogenesis, and apoptosis (Hansotia, 2005). It is 
not clear what the precise mechanisms is by which GLP-1 release is raced up by anatomical 
rearrangements that either by-pass the duodenum and upper jejunum (RYGB) or exclude the 
larger part of the entire gastrointestinal tract from food transit (BPD). Moreover GLP-1 also 
delays digestion and blunts postprandial glycaemia and acts on the central nervous systems to 
induce satiety and decrease food intake (Gutzwiller, 1999). 
Glucose dependent insulinotropic peptide is secreted by K-cells of the proximal gut in 
response to carbohydrate and lipid rich meals. It acts on pancreatic β-cells to increase insulin 
secretion through the same mechanism as GLP-1, although it is less potent, and also 
stimulates lipoprotein lipase activity (Meier, 2002). But does not affect gastric emptying or 
satiety.  
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Others non-incretins gut peptides that also modulate glucose metabolism have changed 
your plasma profile after bariatric surgery. Neuropeptide YY (PYY), like GLP-1 is secreted 
by the L-cells of the distal intestine. Peptide YY is present in 2 molecular forms: PYY 1-36 
and PYY 3-36 a cleavage product. PYY increases satiety and delays gastric emptying through 
neuropeptide Y-receptors subtypes in the central and peripheral nervous systems. Intravenous 
PYY 3-36 increases satiety and decreases food intake in humans (Vetter, 2009). Ghrelin is 
another hormone secreted in response to meal stimulation by cells from gastric fundus and 
proximal intestine and acts on the hypothalamus to regulate appetite. Systemic ghrelin levels 
increases before a meal and decreases afterward, stimuling appetite, and food intake and 
suppressing energy expenditure and fat catabolism. There is a negative correlation between 
body weight and serum ghrelin levels. Increases in ghrelin level after surgery or diet suggest 
its role in body weight regulation (Karra, 2010).  
 Rubino et al. found that excluding a short segment of proximal intestine from food 
passage improved glucose tolerance, whereas restoring duodenal transit re-established glucose 
intolerance. This observation has lead to the foregut hypothesis, which holds that contact of 
nutrients with duodenal mucosa generates signals (hormonal and/or neural) that interfere with 
glucose metabolism and insulin action; by-passing duodenal passage (as RYGB and BDP) 
would remove this inhibition (Rubino, 2004 b). 
 
3. Protocol End-points 
We hypothesizing that changes promoting by BPD on intestinal limb and as 
consequence on entero-insular axis will be able to decrease plasma glucose concentration, 
promoting improvements in HbA1c%, in insulin secretion (ISecr) and action (M value). 
Similar as observed in morbidly obese subjects (BMI≥40kg/m2) after bariatric surgery, we 
expect that changes are to be stable in the long time. Based in observations in morbidly obese 
and T2DM very obese subjects (BMI≥35kg/m2) we expect great reduction or disappearance 
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of insulin resistance (IR) and improvement of β-cell function, represented here by parameters 
obtained from mathematical model applied on MMT data (Fasting insulin secretion, Total 
insulin secretion, beta-cell glucose sensitivity, rate sensitivity and potentiation factor) with 
consecutive improvement of clinical T2DM symptoms and others components of metabolic 
syndrome. Bariatric surgery is actually used as weight loss treatment in patients with BMI 
≥40 kg/m2 or BMI ≥35 kg/m2 with comorbidities. To our patients excessive weight loss is not 
desirable. Surgery was re-designed to avoid it. We have targeted a BMI not lesser than 22 
kg/m
2
 as acceptable final body mass index. 
To assess metabolic effects of BPD in non morbidly obese subjects we have used 3 
different stimulus. 
1. Oral glucose tolerance test (OGTT), 
2. Mixed meal tolerance test (MTT), 
3. Euglycaemic hyperinsulinaemic clamp (CLAMP). 
During the tests we measured: 
 plasma glucose response to standard OGTT in order to determine glucose 
tolerance status before and post surgery, 
 plasma glucose, Fat free acids, insulin, C-peptide, glucagon and GLP-1 
response to a mixed meal stimulation, 
 insulin secretion during MTT using C-peptide deconvolution and β-cell 
function by mathematical modelling, 
 whole body glucose uptake by euglycaemic hyperinsulinaemic clamp and 
inhibition of hepatic glucose production (EGP) by tracer methods, 
 Lipid profile : total cholesterol, HDL and LDL-cholesterol and triglycerides, 
 Liver profile: ALT, AST an GGT 
 Body weight, waist and hip circumference 
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Results obtained by this protocol can be used to better understanding the 
pathophysiological mechanisms of T2DM; BPD effects on T2DM and mechanisms of T2DM 
remission after bariatric surgery. 
 
4. MATERIAL AND METHODS 
4.1. Study Population 
Fifteen patients (6 men, 9 women, 551 years, BMI=28.3±0.6 kg/m2, range 24.5-33.1 
kg/m
2
) with T2DM (duration 16±2 years, range 6-27 years, HbA1c=8.5±0.4%, range 6.8-
11.5%) on treatment with metformin+sulfonylureas (Oral Hypoglicemiants Agents - OHA, 
n=6) or OHA plus insulin (n=9, mean dose=30 IU/day, range 10-90 IU/day) participated in 
the study. All of them had shown history of poor metabolic control under OHA treatment and 
comorbidities linked to T2DM. Patients were studied at baseline (Pre), ~2 months after 
surgery (Post1), and one year after surgery (Post2). Each patient underwent a 3-hour oral 
glucose tolerance test (OGTT), a 5-hour mixed meal test (MTT), and a euglycaemic 
hyperinsulinaemic clamp (CLAMP) on separate days over two weeks (Fig. 1). The tests were 
performed after an overnight fast; antidiabetic medications were withdrawn 3 days before 
testing. When required to avoid hyperglycaemia, regular insulin was used until 8 hours before 
the metabolic tests. 
Fifteen nondiabetic volunteers, matched to the patient group by gender, age (51±3 
years), and BMI (30.2±0.9 kg/m
2
), served as a control group; they all received the MTT, and 
eight of them also received the euglycaemic clamp.  
Patients were submitted to the metabolic tests and surgery at the San Martino Hospital 
- Genova, Italy from 2008 to 2012 instead control group subjects were studied at Santa Chiara 
Hospital - Pisa in the same period. 
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4.2. Subjects Enrolment 
Inclusion criteria: 
 Both genders, age between 35 and 65 years old; 
Type 2 diabetes diagnoses longer than 5 years, poor glycaemic control (HbA1c ≥ 8%) 
on standard of care diabetes therapy;  
 Presence of some comorbidities (dyslipidemia, hypertension, neuropathy, retinopathy, 
cardiovascular disease or stroke), 
 Possibility to participate to the follow-up protocol. 
 
Exclusion criteria: 
 Anti-glutamic acid decarboxylase (GAD) antibodies or plasma C-peptide lesser than 
0.5 ng/ml, 
 Liver cirrhosis, renal failure, history of malignancy or malignant neoplasm in place, 
severe inflammatory, neurological or cardiovascular complications in act, 
 Pregnancy or any condition that at the discretion of the head of the study could 
represent risk to the patient or could affect the protocol results. 
Diabetes remission was defined as an HbA1c ≤6.5%, fasting plasma glucose (FPG) ≤7 
mmol/l, and a 2-hour plasma glucose ≤11.1 mmol/l during the OGTT without any anti-
diabetic medication. 
 
Fig. 1: Schematic protocol representation. 
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4.3. Oral Glucose Tolerance Test (OGTT)   
A standard 75-g oral glucose tolerance test (OGTT) was performed in each patient 
(Fig. 2). Venous blood samples were collected at -30, 0, 30, 60, 90, 120, and 180 min after 
glucose load from catheter localized in antecubital vein for determination of plasma glucose 
concentrations. Patients were studied after a rest period and keep lying for all study. Results 
obtained from OGTT were used to evaluate a) glucose tolerance status before and after 
surgery and b) T2DM remission after surgery.  
 
Fig. 2: Schematic representation of oral glucose tolerance test - OGTT 
 
 
 
 
 
 
 
4.4. Mixed Meal Tolerance Test (MMT)  
 Meal stimulation was performed, in a separate day, at fasting state, following a 30 
minutes stabilization period.  Patients were invited to eat one boiled egg, 50-g of parmesan 
cheese, and 75-g of an aqueous glucose solution. The MMT composition was: 54% 
carbohydrate, 30% lipid, 16% protein, totalizing 561 kcal (Fig. 3).  Venous blood samples 
were collected at -30, 0, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, and 300 min from a 
catheter placed at antecubital vein. Plasma samples were drawn and stored for future 
measurements. Plasma glucose insulin and C-peptide concentrations were assayed to assess ß-
cell function using C-peptide deconvolution associated to mathematical modelling to 
reconstruct insulin secretion rates. Time course of plasma glucagon, GLP-1 (glucagon-like 
peptide 1) and Fat free acids (NEFA) were also assessed.  
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Fig. 3: Schematic representation of mixed meal tolerance test - MMT 
 
 
 
 
 
4.5. Euglycaemic Hyperinsulinaemic clamp  
Euglycaemic Hyperinsulinaemic clamp was performed after 3 hours basal period (Fig. 
4). Primed-continuous infusion of 6,6-
2
[H5] glucose (0.22 mol
.
min
-1.
kg
-1
; prime: 22.0 
mol/kg*[FPG/5]) were started at -180 minutes in an antecubital vein and continued 
throughout the study. At time -120, -40, -20, -10 and 0 min blood samples were obtained from 
an arterialised vein for measurement of glucose, NEFA, insulin, C-peptide and for tracer 
determinations. At time zero, a primed-continuous insulin (Humulin R; Eli Lilly, Indianapolis, 
IN, USA) insulin infusion (240 pmol
.
min
-1.
m
-2
) was started and continued for 180 minutes. At 
time zero, 6,6-
2
[H5] glucose was decreased (from 0.22 to 0.11 mol
.
min
-1.
kg
-1
) and continued 
until the end of the clamp. During the clamp, a variable rate of 20% of dextrose solution, 
enriched with 6,6-
2
[H5] glucose, was infused to maintain euglycaemia. Plasma glucose levels 
were measured every 5 minutes throughout the clamp. Patients that had FPG ≥5.5 pmol/l 
received the same glucose clamp technique described above with a minimum (0.5 mg
.
min
-1.
m
-
2
) of 20% glucose solution infusion until reach the euglycaemia or until the time 80 min, when 
plasma glucose concentration were clamped at the plasma glucose level observed at this time. 
Blood samples were drawn at each 20 min for measurement of glucose, NEFA, insulin, C-
peptide and for tracer determinations. Additional plasma samples were stored to future 
determinations. 
 
 
34 
 
Fig. 4: Schematic representation of euglycaemic hyperinsulinaemic clamp - CLAMP 
 
 
 
 
 
 
 
4.6. Surgery   
Patients were submitted to a modified biliopancreatic diversion (BPD) procedure. 
During BPD a 60% gastric resection with stapled closure of the duodenal stump was made 
resulting in a residual stomach volume of 400-500 ml; the small bowel was then transected 
~2.5 meters from the ileocecal valve, and the distal end was anastomosed to remaining 
stomach forming the alimentary limb. The proximal end of the ileum, comprising the 
remaining small bowel carrying the biliopancreatic juice and excluded from food transit, was 
anastomosed to the alimentary limb at ~75 cm from the ileocecal valve forming the common 
limb where nutrients and biliopancreatic juice mix (Fig. 5). 
 
Fig. 5: Schematic representation of modified BPD for non-morbidly obese T2DM 
subjects. 
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4.7. Analytical procedures  
Plasma glucose was measured by the glucose oxidase technique (Analox GM-9, Analox 
Instruments USA Inc, Lunenburg, MA, USA). Serum insulin and C-peptide were measured 
by a specific time-resolved immunofluorometric assay (TR-IFMA) (AutoDELFIA, Insulin 
and C-peptide kit, Wallac Oy, Turku, Finland). Plasma glucagon was assayed by 
radioimmunoassay (Millipore Corporation, Billerica, MA, USA), total plasma glucagon-like 
peptide-1 (GLP-1) was assayed by ELISA technique (Millipore Corporation, Billerica, MA, 
USA). Blood samples for C-peptide, insulin and glucagon were drawn using a protease 
inhibitor (5 l/ml of 10 mg/ml gabexate mesilate); for GLP-1 measurements blood was drawn 
into tubes containing a DPP-IV inhibitor (Diprotin A, 10 mM, Sigma Aldrich, Saint Louis, 
MO, USA). No significant cross-reactivity was declared by kits manufacturers. The 
sensitivity ranges are: 0.003 nmol/l and 1.39 pmol/l for the C-peptide and insulin assay, 
respectively, 18.5 pg/ml for glucagon, and 1.5 pM for GLP-1. 
 Gas chromatography/mass spectrometry - GCMS (GC, Hewlett Packard 5890 series II 
plus and MS, Hewlett Packard 5972) was used to determine 6,6-[
2
H2]glucose enrichment in 
the plasma. The method employs deproteinization of plasma samples with methanol (for 
liquid chromatography - Merck KGaA, Germania) followed by a derivatization of the labelled 
and non-labelled glucose with a solution of acetic anhydride (for liquid chromatography - 
Sigma Aldrich, Saint Louis, MO, USA)  and pyridine (for liquid chromatography - Merck 
KGaA, Germania) in order to produce the corresponding glucose penta-acetate derivative. 
Samples were injected in GCMS in a solution of ethyl-acetate (for liquid chromatography - 
Sigma Aldrich, Saint Louis, MO, USA). The ratio between labelled and non-labelled glucose 
was used to calculate the endogenous glucose production. 
Fat free acids (NEFA) were measured by standard spectrophotometric methods (NEFA 
kit, Wako Chemicals GmbH, Neuss, Germany) on a Synchron Clinical System CX4 
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(Beckman Instruments, Fullerton, USA). Triglycerides, serum total cholesterol, HDL and 
LDL-cholesterol were assayed in central laboratory by standard techniques. 
 
4.8. Insulin secretion  
Van Cauter described at 1991 a two-compartment model that estimates insulin secretion 
rates from C-peptides concentrations in plasma (Van Cauter, 1991) after determination of C-
peptide clearance using iv injection of biosynthetic C-peptide in a broad range of individuals 
with different status of glucose tolerance and BMI. Based on these findings, a simple 
procedure to derive standard parameters for C-peptide clearance taking into account degree of 
obesity, sex, and age was defined. The model  β-cell function was resolved from the MTT 
using a mathematical model that describes the relationship between insulin secretion and 
glucose concentration (Mari, 2006).
  
The model expresses insulin secretion (in pmol per min 
per square metre of body surface area) as the sum of two components.  The first component 
represents the dependence of insulin secretion on absolute glucose concentration at any time 
point during the MTT, and is characterised by a dose-response function relating the two 
variables.  The characteristic parameter of the dose-response, i.e., the mean slope within the 
observed glucose range, is denoted as Beta-cell glucose sensitivity (BCGS) by analogy with 
insulin sensitivity (slope of the dose-response of insulin-mediated glucose uptake vs. insulin 
concentrations). Thus, glucose sensitivity as used here is not meant to measure the multiple 
cellular phenomena responsible for glucose sensing (or stimulus/secretion coupling) but only 
as a metrics for the in vivo output of all glucose sensing pathways.  
In the mathematical model, the dose-response is modulated by a potentiation factor, 
which accounts for the fact that during an acute stimulation insulin secretion is higher on the 
descending phase of hyperglycaemia than at the same glucose concentration on the ascending 
phase.  The second insulin secretion component, denoted as rate sensitivity, represents the 
dependence of insulin secretion on the rate of change of glucose concentration.  The model 
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parameters were estimated from glucose and C-peptide concentration by regularised least-
squares. 
 
4.9. Data and Statistical Analysis  
 Insulin sensitivity was calculated as the M value during the final 40 min of the 3-hour 
clamp (normalized to the fat-free mass, µmol
.
min
-1.
kgffm
-1
) as well as the ratio of the M value 
to the mean plasma insulin concentration measured during the same interval (M/I, in units of 
µmol
.
min
-1.
kgffm
-1.
mM
-1
).   
Glucose, C-peptide, glucagon and GLP-1  areas under the time-concentration curves 
(AUC) were calculated by the trapezium rule.  
The pre-hepatic insulin-to-glucagon molar concentration ratio was estimated by the 
following formula: (ISR(t)/hPF + [I(t)])/{[Gg(t)] * (1 + MCRGg/hPF)} where ISR(t) is the 
insulin secretion rate at time t, hPF is hepatic plasma  flow; [I(t)] and [Gg(t)] are the measured 
(peripheral) plasma concentrations of insulin and glucagon at time (t); and MCRGg is the 
metabolic clearance rate of glucagon. The hPF was estimated by multiplying the cardiac index 
(3.2 L
.
min
-1.
m
-2
) by a plasma-to-blood ratio of 0.6, and by assuming that hepatic blood flow is 
30% of cardiac index (= 0.576 L
.
min
-1.
m
-2
).  MCRGg was taken to be 0.537 L
.
min
-1.
m
-2
 
(Fisher, 1976). 
Data are given as means ± SEM (or median and interquartile range for variables with a 
non-normal distribution).  Groups were compared by the Mann-Whitney test. BPD effect was 
analyzed using by Wilcoxon signed rank test.  Time series were analyzed by ANOVA for 
repeated measures.   
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4.10. Ethical Considerations  
The study was approved by the local ethics committee. The nature and purpose of the 
study were carefully explained to all participants before they provided written consent to 
participate. 
 
5. RESULTS 
5.1. Anthropometrical and fasting data 
At baseline, patients had higher fasting plasma glucose (FGP), fat free acids (NEFA) 
and triglycerides than controls (CT group), but similar BMI (Table 1).  
Surgery caused weight loss (an average of -12 kg at 2 months, -14 kg at one year), 
while HbA1c decreased from 8.61.3 to 6.70.9% at 2 months to 6.01.0% at 1 year. Waist 
and hip decreased was proportioned to weight loss and was associated with the time after 
surgery. The ratio between waist and hip (W/H ratio) decreased from 1.010.09 to 0.960.08 
at 2 months and 0.940.04 at 1 year (p=0.0001) (Fig. 6).  
FPG decreased after surgery about 60% in both follow-ups, but, remained higher than 
in CT group (p=0.0007 at Post 1 and Post 2) (Table 1). By the defined remission criteria, 
diabetes was in full remission in 6 patients, at 1 year. At 1year, only remitter patients showed 
FPG at normal levels (5.70.5 mmol/l; p = ns vs. CT), whereas in non-remitters FPG was 
8.30.4 mmol/l, p=0.005 vs. CT group (Table 5).  
Fasting plasma insulin, C-peptide (FPC-pep) and NEFA decreased early after surgery 
(Post1) and did not change in the long term (Post2). Fasting plasma glucagon and GLP-1, 
similar to CT group at baseline, were not affected by BPD (Table 1).  
Total and LDL cholesterol at baseline were similar to the CT group, and decreased to 
levels significantly lower than in the later group at both post surgery evaluations.  HDL 
cholesterol decreased only at Post 1, whereas plasma triglycerides, higher than in the CT 
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group at baseline, did not change after the BPD (Table 1). The lipid profile and all its changes 
were similar between remitters and non remitters (Table 6). 
Two months after surgery, all patients stopped OHA and 8 remained on insulin 
therapy alone (mean dose=14 IU/day); at 1 year, 6 patients were still on insulin therapy (mean 
dose=12 IU/day). 
 
5.2. Oral glucose tolerance test data 
The plasma glucose response to the OGTT was largely improved already at 2 months, 
and changed little thereafter (Fig. 7). Two hours plasma glucose, similar to the FPG, also 
decreased about 60% at Post 1 and Post 2, from 211.4 mmol/l at baseline to 130.8 and 
120.9 mmol/l respectively (p=0.008 and p=0.004 vs. Pre). After surgery, the OGTT glucose 
response changed mainly regarding the plasma concentration and little the time course of the 
curve (Fig. 7). Maximal plasma concentrations were reached around 90' and 120' minutes 
after glucose loading. Mean values for glucose peak were 271.5 mmol/l at baseline, 180.8 
and 180.8 mmol/l at two months and one year after surgery respectively (p=0.001 by 
ANOVA). Area and incremental area under plasma glucose curve decreased early after 
surgery and did not change after 1 year (p=0.001 by ANOVA) (Fig. 7).    
 
5.3. Mixed meal tolerance test data 
Results from MMT showed prompt improvement in glucose metabolism already at 
two months after surgery and stable time course at 1 year. Therefore, biliopancreatic diversion 
caused clear improvement in the plasma glucose response to meal stimulation (Table 2 and 
Fig. 8). Before surgery, the plasma glucose AUC was significantly higher than in control 
group (5.50.1 and 1.80.4 mol.l-1.h-1; p≤0.001). One year later AUC glucose decreased 
significantly compared to baseline values, to 3.10.2 (mol.l-1.h-1) p=0.001, but was yet higher 
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than in CT group p≤0.001. At baseline, insulin response to MMT was blunted in diabetic 
patients (Fig. 8 and Table 2).  After surgery, decreased to levels lower than in the control 
group, both, at fasting and after meal stimulation, and assessed as area under the curve or 
incremental AUC. The decreased response was observed soon at 2 months and did not change 
at 1 year (p<0.01 for both follow-up periods).  
Glucagon and GLP-1 responses to MMT were also investigated. While AUC glucagon 
(p= ns vs. CT) showed a little but significant increment 2 months after surgery that returned to 
baseline levels at 1 year after surgery; AUC GLP-1, similar to control group at baseline, 
increased significantly at both Post1 and Post2 evaluations (p=0.002 and p=0.03, 
respectively). The elevated plasma NEFA response decreased during the MMT till to reach 
levels similar to the control group at 1 year. Analysing the incremental area under the curves 
from MMT for glucagon, GLP-1 and NEFA we observed different responses by each one. 
The incremental area of glucagon increased significantly at 2 months after surgery returning 
to levels similar to the control group at 1 year. The same response was also observed for 
incremental area of NEFA, while GLP-1 incremental area, greater than the control group at 
baseline, increased even more in both follow-up periods (Fig. 9 and Table 2). 
The estimated mean prehepatic insulin-to-glucagon molar concentration ratio was 
significantly higher in patients than controls, and after surgery decreased significantly to 
similar values (Table 2). However, the profile of the curves remained blunted as compared to 
the CT group (Fig 15). 
Results from MMT were also divided by remitters and non remitters according our 
strict stated criteria (Table 7). Analysing these results, we observed that both groups, 
remitters and non-remitters, were very similar at baseline. However, remitters showed higher 
incremental AUC insulin and C-peptide and lower AUC GLP-1 than non remitters. At 2 
months follow-up remitters showed lower plasma glucose AUC and higher insulin and C-
peptide responses. Finally, at one year follow-up, plasma glucose values were lower in 
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remitters and C-peptide response was still higher when compared with non remitters. All of 
other variables studied were similar between the groups (Table 7).  
 
5.4. β-cell function during MMT 
Insulin secretion assessed by mathematical modelling and deconvolution of C-peptide 
during MMT showed the blunted and protracted profile typical of T2DM (Fig. 10), such that 
fasting insulin secretion was higher than in controls but total insulin output during the 5 hours 
of the MMT was similar (Table 3).   All three parameters of ß-cell function, i.e., glucose 
sensitivity, rate sensitivity, and potentiation, were severely compromised in the patients at 
baseline; following surgery, each of them improved significantly (Table 3), but only 
potentiation was normalized.  In particular, ß-cell glucose sensitivity was still markedly 
depressed in comparison with the control group (Fig. 11-12). At baseline, parameters of ß-cell 
function as fasting ISR as well total ISR were higher in those that remitter of T2DM than in 
non-remitters. This difference was not observed 2 months after surgery. But at this moment ß-
cell glucose sensitivity (BCGS) was higher in remitters that in non-remitters even if without 
statistical significance p=0.07. However, at one year we observed significant difference in 
BCGS, 46[33] to 16[18] (pmol
.
min
-1.
m
-2.
mM
-1
) for remitters and non-remitters respectively, 
p=0.006 (Table 8). 
 
5.5. Euglycaemic hyperinsulinaemic clamp data 
Before surgery, insulin sensitivity was markedly depressed in patients as compared to 
controls (p=0.0002), but it doubled at 2 months post surgery, and remained essentially 
unchanged at 1 year (p<0.0001 by ANOVA repeated measures testing) (Fig. 13 and Table 4). 
Insulin concentration obtained during the clamp steady state was lower after surgery than at 
baseline. These results agreed to the increase in insulin clearance observed during the clamp 
(data not show).  
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Before surgery, EGP was higher in patients than controls both under fasting conditions 
and during the clamp.  At both times after surgery, fasting EGP was significantly lower than 
preoperatively, and no longer different from controls.  Post-operatively, during the clamp 
EGP was significantly better than before surgery, but still higher than in controls (Fig. 14 and 
Table 4). Before surgery, insulin-mediated glucose disposal was markedly depressed in 
patients as compared to controls, whether in absolute terms (i.e., µmol/min from the tracer-
determined Rd) or as the M value from the clamp (p=0.0002).  At 2 months postsurgery, 
insulin-mediated glucose disposal had increased to levels no longer significantly different 
from controls, and remained essentially unchanged at 1 year.  
None of the insulin action parameters were different between remitters and non 
remitters and the observed improvements were similar in these groups at both post surgery 
evaluations (Table 9). 
 
6. DISCUSSION 
We studied non-morbidly obese subjects (BMI<33 kg/m
2
) characterized by long-
standing, poorly controlled T2DM in spite of active pharmacological treatment.  As expected, 
they were strongly insulin resistant in peripheral tissues (as reduced insulin-mediated glucose 
uptake under euglycaemic conditions), in the liver (as elevated fasting EGP and reduced EGP 
suppression during the clamp), and in adipose tissue (manifest as raised NEFA in the face of 
hyperinsulinaemia).  Furthermore, all indices of ß-cell function were severely compromised; 
in particular, ß-cell glucose sensitivity (i.e., the intrinsic ability of the ß-cell to sense and 
respond to dynamic glucose changes in a timely and quantitatively appropriate fashion) was 
only 20% of that of age- and BMI-matched nondiabetic controls.  Insulin release was 
therefore sustained at near-normal levels by the elevated glucose concentrations.  The 
hormonal milieu of these abnormalities included hyperinsulinaemia – compensatory to the 
degree of insulin resistance – and a heightened glucagon response to the meal. 
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Biliopancreatic diversion improved diabetes control in all patients and induced 
diabetes remission, according our strict criteria, in 40% of them. Although not all patients 
experimented complete remission of T2DM, all of them showed ameliorations in  glucose 
metabolism: minor fasting plasma glucose and glycaemic excursion during OGTT, 
diminution of HbA1c%, better daily glycaemic control with pharmacological treatment and 
minor insulin secretion (Fig. 6 and 7) both at fasting state and during MMT stimulus. 
Nocturnal long-action insulin treatment was chose as antihyperglycemic therapy for who still 
diagnosed diabetic by OGTT after surgery. Furthermore, there was an important improvement 
in the lipid profile, particularly LDL cholesterol (Table 1).   
Surgery induced weight loss but not excessively. Patients did not exhibit BMI lower 
than 20 kg/m
2
 or related difficulties to eat or vomit. Waist and hip ratio decreases (Fig. 6) but 
the body architecture observed before surgery: high deposit of abdominal fat, keep on even if 
weight was reduced one year after surgery. Blood pressure, hepatic enzymes or blood test 
were not altered in pre-operatory state (normal ranges) and did not change significantly after 
surgery (data not show). 
Withal there was almost a complete normalization of peripheral insulin sensitivity, 
augmented suppression of EGP during clamp and diminution of NEFA stimulated by insulin 
and an improvement in ß-cell function parameters that was still lower than observed in CT 
group.  
One year after the surgery, glucose levels at fasting and in response to OGTT were 
still higher than in CT group, while fasting insulinaemia and insulin response to the meal test 
were lower (Table 2). We can observe (Fig. 8 and 9)  a decrease in the plasmatic 
concentrations but the curves time did not change, remaining flatter than those observed in the 
CT group. BPD possibly did not alter gastric emptying; observed as the peak of plasma 
glucose concentration during stimulation, in the OGTT and MTT. When insulin secretion was 
analyzed by C-peptide deconvolution (Fig. 10) there is a little change in the curve profile one 
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year after surgery. Total insulin secretion decreases in comparison with baseline followed by 
a drop during the last 3 hours. 
Similar results were observed by ß-cell parameters. In fact, ß-cell glucose sensitivity, 
potentiation and rate sensitivity improved after surgery but were still much reduced.  Final 
ßCGS values corresponds to only 30% of the control values, demonstrating the severe insulin 
secretion dysfunction observed before surgery is still present at the late follow-up (Fig. 12). 
Studying obese diabetic subjects before and after Roux-an-Y bypass, Nannipieri showed that 
BCGS was the stronger indicator of diabetes remission (Nannipieri, 2011).  
Remitters and non remitters groups were very similar at baseline. Minor fasting and 
total ISR evidenced a worse ß-cell dysfunction in non remitters. In fact, BCGS did not 
differed at baseline 20 [4] and 11 [17] for remitters and non remitters respectively, but were 
higher in remitters in the Post2 (p=0.006). Remitters had similar age, diabetes duration, 
baseline BMI and HbA1c as non-remitters, but lost slightly more weight (16 vs.13 kg). The 
difference was very small even if, in both follow-up evaluations had final weight lower than 
the CT group. Importantly, at follow-up, insulin sensitivity, fasting insulin secretion and β-
cell function were lower in non remitters after surgery (Table 9). 
Several works have showed high rates for T2DM remission after bariatric surgery in 
morbidly obese (BMI≥40kg/m2), mainly with procedures that greatly restrain food intake 
(RYGB) or absorption (BPD). These procedures share the common feature of an early 
delivery of nutrients to the distal small intestine, bypassing duodenum and in part the 
jejunum. Just because different procedures induced specific alterations in gastrointestinal tract 
and in the response to the meal T2DM remission have been explained as result of various 
transformations promoted by surgery.  
The first effect of bariatric surgery that collaborates to the improvement in glucose 
homeostasis is the weight loss. Is well known that body fat in specially, visceral adiposity is 
linked with diminution of insulin action (Kahn, 2001), hyperglycaemia, increase in EGP and 
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levels of circulating NEFA that in their turn can impair -cell function by lipotoxicity (Groop, 
1989; Gastaldelli, 2004b; Roden, 2004). A prospective study of ten obese patients with T2DM 
undergoing biliopancreatic diversion, with re-study after 2 years, demonstrated weight change 
from 136 to 89 kg. This was accompanied by a fall in the FPG, HbA1c, improvement in IS and 
-cell function (Camastra, 2007). It is certain that massive weight loss plays important role in 
consolidating the long-term antidiabetic effects of bariatric surgery, but  only weight loss 
cannot explain all amelioration seen after surgery. Our patients have loss only 4 kg at the first 
follow-up time (p= ns) but improved M value from 38 [8] to 82 [41] (µmol.min
-1
kgffm
-
1
.pmol
-1
) (p=0.0007). Previous studies have been show that in non-diabetic morbidly obese 
patients undergoing BPD levels of insulin sensitivity were higher than those of lean controls; 
this improvement in insulin sensitivity was not correlated with weight loss in BPD treated 
patients. In contrast, in the patients treated with Roux en Y, the improvement of M value was 
predicted by the general relation between glucose disposal and body mass. In this way, the 
underlying mechanisms to the metabolic improvement should be quite different between these 
surgical procedures (Muscelli, 2005).  Our patient group was very insulin resistant at pre-
operatory state and showed an improvement in IS early after surgery, when weight loss was 
only by 12%. Relationship with improvement in insulin sensitivity as M value correct by 
insulin during clamp steady state (M/I) was observed only at one year taking in account the 
difference () between M/I and BMI from baseline and one year (p=0.001). It is important to 
attempt that early after surgery the relationship did not observed.  
As discuss above, fasting plasma glycaemia and glucose levels in response to OGTT 
falls after bariatric surgery. Diminution of hyperglycaemia contributes to amelioration of 
insulin signalling, action and -cell function. Acute mild hyperglycaemia decreases insulin 
secretion in normal subjects (Toschi, 2002) whereas insulin induced mild hypoglycaemia 
lowered insulin secretion during both glucose and arginine stimulus. Hyperinsulinaemia is 
commonly observed in obese with IGT or T2DM and in naïve diabetics (Ferrannini, 1997) in 
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response to hyperglycaemia but not in lean diabetic subjects (Eckell, 2011). Progression of 
IGT to T2DM is associated with impairment in β-cell function and in insulin action (Reaven, 
1989). Intensive glucose lowering treatment showed to be able to reduce harmful effects of 
hyperglycaemia on β-cell function (Alvarsson, 2003).  Bariatric surgery causes rapid 
diminution in plasma glucose concentrations, promptly enhance IS and β-cell function in 
morbidly obese subjects (Camastra, 2007; Camastra, 2011 and Muscelli, 2005). After surgery 
our patients have had rapid diminution of glucose concentration, increase in IS and β-cell 
function, similar as observed in morbidly obese patients. However, β-cell function remain still 
lower than in CT group (Fig. 11), demonstrating that dysfunction in lean diabetic is different 
that observed in obesity. Maybe due to genetic predisposition to β-cell dysfunction  being 
more present in lean diabetics than in obese with T2DM (Arner, 1991). Thus, alterations 
promoted by bariatric surgery in obese are more effective than in lean subjects.  
Only few studies have reported the efficacy of gastrointestinal surgery in non-
morbidly obese diabetic patients after biliopancreatic diversion (Chiellini, 2009), Roux-en-Y 
gastric bypass (Lee, 2008), gastric banding (Coehn, 2006) or others procedures such 
duodenal-jejunal exclusion (Geloneze, 2009), ileal interposition (DePaula, 2011); both in 
humans and animals models (Rubino, 2004 b and Zhang, 2011).  They reported similar or 
higher rates of diabetes remission, using less restrict definition for diabetes remission or using 
non gold standard methods to evaluate insulin sensitivity and insulin secretion.    
The rationale to offer metabolic surgery to nonobese subjects with T2DM is that 
alterations promoted by surgery in gastrointestinal limb can induce changes in gastrointestinal 
hormones that influence positively glucose homeostasis. There are two main hypothesis: the 
hindgut hypothesis and foregut hypothesis. The hindgut hypothesis also called the "lower 
intestinal hypothesis" suggests that rapid delivery of nutrients to the distal bowel improves 
glucose metabolism by enhancing GLP-1 and other anorexigenic gut peptides (Ferrannini, 
2010). This intestinal rearrangement speeds the delivery of nutrients to the distal intestine, 
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which causes exaggerated GLP-1 and PYY levels and improves glucose tolerance and insulin 
secretion without affecting body weight and food intake. In rodents, ileal interposition caused 
GLP-1 increment also with intact stomach (Cummings, 2007 a). Our patients demonstrated 
after surgery an important increment in plasma GLP-1 unchanged plasma glucagon. The time 
course GLP-1 plasma curves changed and passed to exhibit a peak in plasma concentration 
after meal, similar as we can observe in CT group (Fig. 9). At the same time, insulin:glucagon 
ratio decreased (Fig. 15). It is important to attempt that insulin:glucagon ratio decreases even 
if total insulin secretion was lower than in pre-operatory state; contributing to reduce EGP.  
Augmented levels of GLP-1 also contribute to reduce EGP independently of glycaemia. 
Seghieri et al. have demonstrated that GLP-1 infusion at physiological post-prandial 
concentrations have direct on EGP inhibition in normal subjects during pancreatic clamp 
(Seghieri, 2013). Thus increase in GLP-1 observed after surgery could be partially responsible 
by augmented inhibition of EGP observed during euglycaemic hyperinsulinaemic clamp. On 
the other hand, there is the foregut hypothesis or the foregut exclusion theory, in which 
causing food bypass the duodenum and proximal jejunum prevents the secretion of as-yet 
unidentified putative signal that promotes insulin resistance and type 2 diabetes (Rubino, 
2008). 
From our study is not possible to clarify the mechanisms involved in diabetes control.  
However, we can speculate that the higher GLP-1 levels are the consequence of the rapid 
delivery of food to the distal parts of the gastrointestinal tract.  The caloric restriction and the 
weight loss might have contributed to the insulin sensitivity increment. The withdrawn of 
some degree of glucose toxicity must also be considered among the factors.  There are no 
other studies regarding the mechanisms of diabetes remission after BPD surgery in diabetic 
patients with BMI lower than 33kg/m
2
.  
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LDL cholesterol decreased at the same proportion reported to morbidly obese patients 
submitted to BPD (Corradini, 2005) and can be attributed to the fat malabsorption described 
to this surgery. 
One limitation of this study is the small number of participants.  In this way, is not 
possible to rule out diabetes duration or initial insulin secretion dysfunction as predictive 
factors.  It is possible that an earlier intervention could have higher diabetes remission 
percentages.   
In summary, in nonobese patients with long-standing T2D biliopancreatic diversion 
improved metabolic control in all but induced remission in only one third of them.  While 
modest weight loss contributed to the outcome, increases in both insulin sensitivity and ß-cell 
function were primarily responsible for bringing down glucose and HbA1c levels.  Peripheral 
insulin sensitivity was restored to control levels already 2 months after surgery, and similarly 
in remitters and non-remitters, indicating a weight-independent effect of the operation.  
Hepatic insulin sensitivity, however, was still compromised one year postsurgery, possibly 
because of an unfavourable prehepatic insulin-to-glucagon concentration ratio.  In contrast, ß-
cell dysfunction was still prevailing at one year, and its degree distinguished remitters from 
non-remitters.  Thus, the initial extent of ß-cell incompetence emerges as the main predictor 
of the metabolic outcome of BPD, and may condition relapse of hyperglycaemia beyond one 
year postsurgery. 
 
7. Publications 
During my PhD I have worked in several protocols. Generally, protocols were 
designed to better understanding the pathophysiological events underlying T2DM and 
obesity, specially related with the effects of gastrointestinal surgeries on T2DM resolution. 
We also assessed the physiological basis of these diseases by clinical trials, protocols 
designed by pharmaceuticals industries to investigate pharmacological effects of  their 
49 
 
products on T2DM and obesity - "Sitagliptina" - Merck Sharp & Dome, "Exenatide" - Amylin 
Corporation and "SGLT-2- inhibitor - Boehringer Inglheim. 
This thesis has been submitted to the publication at The Journal of Clinical 
Endocrinology & Metabolism and it is available in electronic version at Pubmed Central at 
http://www.ncbi.nlm.nih.gov/pubmed/23666972 with the title: Biliopancreatic diversion in 
nonobese patients with type 2 diabetes: impact and mechanisms; as well an two another 
manuscripts, titled: Visceral fat resection in humans: effect on insulin sensitivity, beta-cell 
function, adipokines, and inflammatory markers. Submitted to the Obesity (Silver Spring) and 
also available at Pubmed Central at http://www.ncbi.nlm.nih.gov/pubmed/23404948 and 
Human Insulin Resistance is Associated with Increased Plasma Levels of 12α-hydroxylated 
Bile Acids. Submitted to the Diabetes journal and available at Pubmed Central at 
http://www.ncbi.nlm.nih.gov/pubmed/23884887.  
 Publications realized from the beginning of the PhD until today are presented below. 
 
Biliopancreatic Diversion in Nonobese Patients With
Type 2 Diabetes: Impact and Mechanisms
Brenno Astiarraga, Amalia Gastaldelli, Elza Muscelli, Simona Baldi,
Stefania Camastra, Andrea Mari, Francesco Papadia, Giovanni Camerini,
Gianfranco Adami, Nicola Scopinaro, and Ele Ferrannini
Department of Clinical and Experimental Medicine (B.A., E.M., S.B., S.C., E.F.), University of Pisa School
of Medicine, 56100 Pisa, Italy; CNR Institute of Clinical Physiology (A.G.), 56124 Pisa, Italy; Institute of
Biomedical Engineering (A.M.), 35127 Padova, Italy; and Department of Surgery (F.P., G.C., G.A., N.S.),
University of Genova, 16147 Genova, Italy
Context: Diabetes remission is frequent after biliopancreatic diversion (BPD) in morbidly obese
patients with type 2 diabetes (T2D). Data, mechanisms, and clinical indications in nonobese T2D
patients are scanty.
Objective: The objective of the studywas to assess remission and investigate insulin sensitivity and
-cell function after BPD in nonobese patients with long-standing T2D.
Design, Setting, and Patients: This was a clinical research study comparing 15 T2D patients (aged
55  1 years, duration of 16  2 years, body mass index of 28.3  0.6 kg/m2, glycosylated hemo-
globin 8.6%  1.3%) with 15 gender-, age-, and body mass index-matched nondiabetic controls.
Before surgery and 2 months and 1 year later, a 3-hour oral glucose tolerance test, a 5-hour
mixed-meal test, and a 3-hour euglycemic clamp were performed.
Intervention: The intervention includedaBPD (distal gastrectomy, proximal ileumanastomosed to
remaining stomach, biliopancreatic limb anastomosed to ileum 50 cm from the ileocecal valve).
Results: Glycemia improved in all patients, but remission (glycosylated hemoglobin  6.5% and
normal oral glucose tolerance test) occurred in 6 of 15 patients. Insulin resistance (19.8  0.8
mol  min1  kgffm
1, P  .001 vs 40.9  5.3 of controls) resolved already at 2 months (34.2 
2.8) and was sustained at 1 year (34.7  1.6), although insulin-mediated suppression of en-
dogenous glucose production remained impaired. In contrast, -cell glucose sensitivity (19 [12]
pmolmin1  m2mM1 vs 96 [73] of controls, P .0001) rose (P .02) only to 31 [26] at 1 year
and was lower in nonremitters (16 [18]) than remitters (46 [33]).
Conclusions: In nonobese patients with long-standing T2D, BPD improves metabolic control but
induces remission in only approximately 40% of patients. Peripheral insulin sensitivity is restored
early after surgery and similarly in remitters and nonremitters, indicating a weight-independent
effect of the operation. The initial extent of -cell incompetence is the main predictor of the
metabolic outcome. (J Clin Endocrinol Metab 98: 2765–2773, 2013)
Bariatric surgery has powerful effects to improve glu-cose metabolism (1, 2) and has been associated with
reduced rates of type 2 diabetes (T2D) (3), cardiovascular
events (4), andmortality (5, 6). Detailedmetabolic studies
have shown that adjustable gastric banding (7, 8), Roux-
en-Y gastric bypass (9, 10), biliopancreatic diversion (11–
14), and ileal transposition (15) all enhance both insulin
action and -cell function more effectively than conven-
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tional medical therapy (7, 16–18). Although drastic
weight loss and, in the early postoperative period, caloric
restriction certainly make a contribution to better glucose
tolerance, surgery itself may trigger weight-independent
mechanisms that eventually translate into favorable met-
abolic effects. This postulate is basedon early animal stud-
ies (19) and, in humans, on evidence that metabolic
changes sometimes precede sizable weight loss or are dis-
proportionate to the amount of weight lost (20). In this
regard, theweight of evidence indicates that different bari-
atric proceduresmay engage putativeweight-independent
mechanisms to different extents or involve altogether dif-
ferent mechanisms (21, 22). In any event, this possibility
has generated enthusiasm for bariatric surgery as a treat-
ment forT2D(23) andhas encouragedabroadeningof the
body mass index (BMI) range as an indication for surgery
in diabetic patients (24).
Among bariatric surgeries, biliopancreatic diversion
(BPD) induces the most dramatic changes in body weight
and the highest diabetes remission rates (1). In very obese
T2Dpatients (BMI 35 kg/m2), BPD is followed by rapid
normalization of insulin sensitivity and improved -cell
function (11–14). In T2Dpatients with a BMI less than 35
kg/m2, an early trial of5 subjects (25) showedachievement
of good glycemic control 1 month after surgery, and a
larger study of 30 patients followed up for up to 2 years
(26) suggested differences in outcome, depending on ini-
tial BMI. In the present series of well-characterized pa-
tients with long-standing T2D and BMI less than 30 kg/
m2, we assessed remission at 1 year by stringent criteria
and carried out detailed investigations of insulin sensitiv-
ity and -cell function [combining oral glucose tolerance
test (OGTT), mixed meal, and euglycemic insulin clamp
with tracer glucose] before, 2 months, and 1 year after
BPD in comparison with gender-, age-, and BMI-matched
nondiabetic controls.
Materials and Methods
Study population
We studied Caucasian 15 patients (6 men, 9 women; aged
55  1 years; BMI 28.3  0.6 kg/m2, range 24.5–29.9 kg/m2)
withT2D [duration162years, range 6–25years; glycosylated
hemoglobin (HbA1c) 8.5% 0.4% (66 23 mmol/mol), range
8.0%–11.5% (47–98 mmol/mol)] on treatment with
metforminsulfonylureas (OHA, n  6 of 15) or OHA plus
insulin (n  9 of 15, mean dose 30 IU/d, range 10–90 IU/d).
Patients were engaged only in light physical activity, mostly oc-
cupational. Twelve patients were nonsmokers (5 were ex-smok-
ers 14 years) and 3 were smokers (1 pack/d). Each patient
underwent a 3-hour OGTT, a 5-hour mixed-meal test (MTT),
and a 3-hour euglycemic hyperinsulinemic clamp on separate
days over 2 weeks. All tests were performed after an overnight
fast; antidiabeticmedicationswerewithdrawn3daysbefore test-
ing. When required to avoid hyperglycemia, regular insulin was
used until 8 hours before themetabolic studies. Each patient was
studied at baseline (before), approximately 2 months after sur-
gery (2 months), and 1 year after surgery (12 months). Diabetes
remission was defined as an HbA1c less than 6.5% (44 mmol/
mol), a fastingplasmaglucose less than7.0mmol/L, anda2-hour
plasma glucose less than 11.1 mmol/L 2 hours into the OGTT
without antidiabetic medication.
Fifteen nondiabetic volunteers from our database were
matched to the patient group by gender, age (51 3 years), and
BMI (30.2  0.9 kg/m2, range 24.6–35.4 kg/m2) and served as
a weight-matched control group; they all received theMTT, and
8 of them also received the euglycemic clamp.
Study subjects were informed about the procedures and risks
and provided their written consent. The protocol was approved
by the institutional Ethics Committee of the University of
Genova.
Surgery
With the BPD procedure, a two thirds distal gastric resection
with stapled closure of the duodenal stump results in a residual
stomach volume of 400–500 mL; the small bowel is then tran-
sected 300 cm from the ileocecal valve, and the distal end is
anastomosed to remaining stomach (alimentary limb).Theprox-
imal end of the ileum, comprising the remaining small bowel
carrying thebiliopancreatic juice andexcluded fromfood transit,
is anastomosed to the common limb 50 cm from the ileocecal
valve (26).
Oral glucose tolerance test
A standard 75-g OGTT was performed in each patient. Ve-
nous blood samples were collected at 30, 0, 30, 60, 90, 120,
and 180 minutes after the glucose load for determination of
plasma glucose concentrations.
Mixed-meal tolerance test
Meal stimulation was performed following a 30-minute sta-
bilization period. Patients were invited to eat 1 egg, 50 g of
parmesan cheese, and 75 g of an aqueous glucose solution (54%
carbohydrate, 30% lipid, 16%protein, 561 kcal). Venous blood
samples were collected at 30, 0, 10, 20, 30, 45, 60, 90, 120,
150, 180, 240, and 300 minutes for analytical measurements.
Euglycemic hyperinsulinemic clamp
Insulin (Humulin R; Eli Lilly, Indianapolis, Indiana) was in-
fused at a rate of 240 pmol  min1  m2 for 3 hours. At times
20,10and0, 20, 40, 60, 80, 100, 120, 140, and180minutes,
samples were drawn from a heated dorsal hand vein (to obtain
arterialized blood) for the measurement of glucose tracers and
insulin concentrations. Plasma glucose levels were measured ev-
ery 5 minutes to adjust an exogenous glucose infusion. Patients
with fasting hyperglycemia (5.5 mmol/L) received only the in-
sulin infusion until euglycemia or until time 80 minutes, when
plasma glucose was clamped at the level attained at this time.
Three hours before starting the clamp, a primed [22.0 mol/
kg*(fasting glycemia/5)]-continuous (0.22 mol  min1  kg1)
infusion of 6,6-2[H2] glucose was administered via an antecu-
bital vein catheter. At time zero, the tracer infusion rate was
decreased (to 0.11 mol  min1  kg1) and continued until the
end of the clamp. During the clamp, a variable rate of 20% of
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dextrose solution, enriched with 6,6-2[H2] glucose, was infused
to maintain euglycemia (9).
Analytical procedures
Plasma glucose was measured by the glucose-oxidase tech-
nique (Analox GM-9), plasma insulin and C-peptide by electro-
chemiluminescence (on a COBAS e411 instrument; Roche, In-
dianapolis, Indiana). Plasma triglycerides, free fatty acids
(FFAs), and serum high-density lipoprotein (HDL) cholesterol
were assayed in duplicate by standard spectrophotometricmeth-
ods on a Synchron Clinical System CX4 (Beckman Instruments,
Fullerton, California). 6,6-[2H2]glucose enrichment was mea-
sured by gas chromatography/mass spectrometry as described
previously (27). Plasma glucagon was assayed by RIA, total
plasma glucagon-like peptide-1 (GLP-1) by an ELISA method
(Millipore Corporation, Billerica, Massachusetts). Blood sam-
ples for C-peptide, insulin, and glucagon were drawn using a
protease inhibitor (5l/mL of 10mg/mL gabexate mesilate); for
GLP-1 measurements blood was drawn into tubes containing a
dipeptidyl peptidase-IV inhibitor (Diprotin A, 10 mM; Sigma
Aldrich, St Louis, Missouri).
No significant cross-reactivity was declared by the manufac-
turers of the kits. The sensitivity ranges are 0.003 nmol/L and
1.39 pmol/L for the C-peptide and insulin assay, respectively,
18.5 pg/mL for glucagon, and 1.5 pM for GLP-1.
Data analysis
Insulin sensitivity was calculated as the whole-body insulin-
mediated glucose uptake (Mvalue,micromoles perminute1 per
kilogramffm
1) during the last 40 minutes of the clamp normal-
ized to fat-free mass. The 6,6-2[H2] glucose data were analyzed
as previously described (27) to calculate glucose rates of appear-
ance anddisappearance in the fasting state andduring the clamp.
Endogenous glucose production (EGP) was obtained as the dif-
ference between the time course of the glucose rates of appear-
ance and exogenous glucose infusion rate.
-Cell function during the MTT was resolved using a math-
ematical model (28) describing the relationship between insulin
secretion and glucose concentration. In brief, the model consists
of 3 blocks: 1) a model fitting the glucose concentration profile,
thepurposeofwhich is to smoothand interpolateplasmaglucose
concentrations; 2) a model describing the dependence of insulin
(or C-peptide) secretion on glucose concentration; and 3) a
model of C-peptide kinetics, ie, the 2-exponential model pro-
posed by Van Cauter et al (29), in which the model parameters
are individually adjusted to the subject’s anthropometric data.
The dependence of insulin secretion rate on absolute glucose
concentration at each time point during theMTT is described by
a dose-response function relating the 2 variables. Themain char-
acteristic parameter of the dose response, ie, the mean slope
within the observed glucose range, is denoted as -cell glucose
sensitivity by analogy with insulin sensitivity (slope of the dose
response of insulin mediated glucose uptake vs insulin concen-
trations). The dose-response function is modulated by a time-
dependent potentiation factor, indexed as the ratio of its value at
2 hours into the MTT to the corresponding basal value. The
dependence of insulin secretion rate on the rate of change of
plasma glucose levels is denoted as rate sensitivity.
The prehepatic insulin to glucagonmolar concentration ratio
was estimated by the following formula:
(ISR(t)/hPF  [I(t)])/{[Gg(t)] * (1 MCRGg/hPF)}
where ISR(t) is the insulin secretion rate at time t, hPF is
hepatic plasma flow; [I(t)] and [Gg(t)] are the measured
(peripheral) plasma concentrations of insulin and gluca-
gon at time t; and MCRGg is the metabolic clearance rate
of glucagon. hPFwas estimated bymultiplying the cardiac
index (3.2 L  min1  m2) by a plasma to blood ratio of
0.6 and by assuming that hepatic blood flow is 30%of the
cardiac index (0.576 L  min1  m2). MCRGg was taken
to be 0.537 L  min1  m2 (30).
Statistical analysis
Data are given as means  SEM (or median [interquartile
range] for variables with a skewed distribution). Areas under the
Table 1. Metabolic Characteristics From MMTa
Controls Patients Before
Patients at
2 Months
Patients at
12 Months Pb
n (M/F) 15 (5/10) 15 (9/6) 15 (9/6) 15 (9/6) –
Fasting glucose, mmol/L 5.3  0.1 12.2  0.5c 8.3  0.6c 7.3  0.4c .0001
Fasting insulin, pmol/L 63  7 105  35c 46  6 36  5c 0.04
Triglycerides, mmol/L 1.0  0.1 1.9  0.2c 1.9  0.2c 1.9  0.3c ns
Total cholesterol, mmol/L 4.8  0.2 5.3  0.4 3.5  0.2c 3.5  0.1c .0003
HDL cholesterol, mmol/L 1.0  0.1 1.2  0.1 1.0  0.1 1.1  0.1 .007
LDL cholesterol, mmol/L 3.2  0.2 3.3  0.4 1.5  0.1c 1.8  0.1c .0001
AUC glucose, mol  L1  h1 1.8  0.4 5.5  0.1c 3.4  0.2c 3.1  0.2c .0001
AUC insulin, nmol  L1  h1 79 [73] 66 [42] 40 [12]c 40 [23]c .003
AUC glucagon, g  L1  h1 18 [9] 20 [10] 22 [18]c 22 [8] .14
Mean prehepatic insulin to
glucagon ratio
8.8 [8.9] 17.6 [10.5]c 13.4 [9.5] 9.6 [7.2] .01
AUC FFA, mmol  L1  h1 70 [23] 155 [120]c 124 [70]c 79 [74] .0001
AUC GLP-1, ng  L1  h1 15 [10] 15 [7] 26 [13]c 24 [10] .003
Abbreviations: F, female; LDL, low-density lipoprotein; M, male; ns, not significant.
a Data are mean  SEM or median [interquartile range].
b P  .05 for the comparison of before and 2 and 12 months by repeated-measures ANOVA.
c P  .05 vs controls.
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time-concentration curve (AUC) and incremental AUCs were
calculated by the trapezium rule. Groups were compared by the
Mann-Whitney test. Time series were analyzed by ANOVA for
repeated measures; for these tests, variables with skewed distri-
bution were log transformed. Group differences over time series
were analyzed by 2-way ANOVA for repeated measures. Statis-
tical analyses were performed using JMP 7.0 (SAS Institute,
Cary, North Carolina); P  .05 was considered statistically
significant.
Results
Surgery caused weight loss (an average of 12 kg at 2
months and14 kg at 1 year), whereas HbA1c decreased
from8.6% 1.3% to 6.7% 0.9%
at 2 months to 6.0%  1.0% at 1
year (P  .0001). After surgery, pa-
tients remained in the hospital for 1
week on a low-carbohydrate diet.
During this period, glycemia was
carefully controlled with insulin.
One week after surgery, no patient
resumed OHA, and 8 were switched
to long-acting insulin alone (mean
dose 14 IU/d) titrated on fasting gly-
cemia with the aim of maintaining
HbA1c at approximately 7%. At 1
year, 6 patients were still on insulin
(mean dose 12 IU/d). By the defined
criteria, diabetes remitted in 4 pa-
tients at 2 months and in a total of 6
patients at 1 year. At this time, low-
density lipoprotein-cholesterol con-
centrations were markedly reduced
(to levels significantly lower than in
controls), whereas plasma triglycer-
ides did not show significant changes
andHDL cholesterol concentrations
were marginally reduced.
At baseline, patients had higher
fasting and postprandial plasma glu-
cose concentrations than weight-
matched controls (Table 1). In the
patient group, the plasma glucose re-
sponse to the MMT was much im-
proved already at 2 months and
changed little thereafter (Figure 1).
Both fasting andpostmeal plasma in-
sulin declined significantly after sur-
gery to levels that were lower than in
the control group (Table 1). At base-
line, insulin secretion showed the
blunted and protracted profile typi-
cal of T2D (Figure 1), such that fast-
ing insulin secretion was higher than in weight-matched
controls, but total insulin output during the 5 hours of the
MTT was similar (Table 2). All 3 parameters of -cell
function, ie, glucose sensitivity, rate sensitivity, and po-
tentiation, were severely compromised in the patients at
baseline; after surgery, each of them improved signifi-
cantly (Table 2), but only potentiationwas normalized. In
particular, -cell glucose sensitivity was still markedly de-
pressed in comparison with the control group (Figure 2).
Before surgery, EGP was higher in patients than con-
trols both under fasting conditions and during the clamp
(Table 2). At both times after surgery, fasting EGP was
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Figure 1. Time course of plasma glucose concentrations (top panel) and insulin secretion rates
(bottom panel) in nondiabetic control subjects and diabetic patients before and 2 and 12 months
after biliopancreatic diversion. Plots are mean  SEM; the blue shaded area is mean  SEM of
controls. ISR, insulin secretion rate.
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significantly lower than preoperatively and no longer dif-
ferent from controls. Postoperatively, clamp EGPwas sig-
nificantly better thanbefore surgery but still higher than in
controls. Before surgery, insulin-mediated glucose dis-
posal was markedly depressed in patients as compared
with controls, whether in absolute terms (ie, micromoles
per minute from the tracer determined glucose rates of
disappearance; Table 2) or as theM value from the clamp
(P .0002, Figure 3). At 2 months after surgery, insulin-
mediated glucose disposal had increased to levels no lon-
ger significantly different from controls and remained es-
sentially unchanged at 1 year (Table 2 and Figure 3).
Plasma FFA concentrations at fasting and during the
meal were significantly higher in patients than controls
before surgery and gradually reverted to normal levels af-
ter surgery (Table 1 and Figure 4). In contrast, plasma
glucagon concentrations, which were higher in patients
than controls at baseline, increased approximately 2-fold
early after surgery (P  .05), and returned to presurgery
levels at 1 year (Table 1 and Figure 4). The estimated
prehepatic insulin to glucagon molar concentration ratio
was significantly higher in patients than controls before
surgery and decreased significantly after surgery (Table 1
and Supplemental Figure 1, published on The Endocrine
Society’s Journals Online web site at
http://jcem.endojournals.org). At
baseline, plasma total GLP-1 con-
centrations were similar in controls
and patients; after surgery, GLP-1
responses to the MTT were mark-
edly increased at 2 months and re-
mained high at 1 year (Table 1 and
Figure 4).
Remitters (n 6) had similar age,
diabetes duration, andbaselineBMI,
HbA1c, and fasting plasma glucose
levels asnonremitters (n9)buthad
lost slightly more weight at 1 year
(16 vs 13 kg, P ns).With regard to
metabolic changes, insulin sensitivity
improved to a similar extent in remit-
ters and nonremitters, whereas -cell
glucose sensitivity increased signifi-
cantly (P  .01) less in nonremitters
(from11 [17] to24 [22] at 2months to
16 [18] pmol  min1  m2  mM1
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Table 2. -Cell Function Parameters, EGP, and Insulin-Mediated Glucose Disposala
Controls Patients Before
Patients at
2 Months
Patients at
12 Months Pb
Fasting ISR, pmol  min1  m2 83 [53] 115 [52]c 83 [22] 61 [38] .0005
Total insulin output, nmol  m2 77 [46] 80 [51] 62 [19] 52 [37]c ns
-Cell glucose sensitivity,
pmol  min1  m2  mM1
96 [73] 19 [12]c 30 [14]c 31 [26]c .02
Rate sensitivity, pmol  m2  mM1 934 [981] 187 [247]c 605 [436] 453 [453]c .004
Potentiation factor, fold 1.52 [0.47] 1.29 [0.44]c 1.11 [0.43] 1.49 [1.09] .02
Clamp insulin, pmol/L 633 [363] 531 [132] 418 [63]c 418 [107]c .009
Fasting EGP, mol  min1 696 [91] 869 [239]c 733 [213] 806 [233] .0004
Clamp EGP, mol  min1 27 [116] 271 [133]c 168 [170]c 150 [75]c .0006
Insulin-mediated glucose
disposal, mol  min1
1608 [1480] 1235 [356]c 1658 [558] 1701 [305] .02
Abbreviations: ISR, insulin secretion rate; ns, not significant.
a Data are median [interquartile range].
b P  .05 for the comparison of before and 2 and 12 months by repeated-measures ANOVA.
c P  .05 vs controls.
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at 12months) than in remitters (20 [4] to 32 [interquartile
range 12] to 46 [33]). This was also the case for rate sen-
sitivity (from 247 [127] to 508 [342] to 610 [697]
pmol  m2  mM1 in remitters, P .03, vs 166 [293] to
692 [390] to 212 [455] in nonremitters).
Discussion
The patients in this study were nonobese but had long-
standing, poorly controlled diabetes despite intensive an-
tihyperglycemic therapy (which included insulin in two
thirds of them). As expected, they presented profound in-
sulin resistance, in peripheral tissues (as reduced insulin
mediated glucose uptake under euglycemic conditions), in
the liver (as elevated fasting EGP and reduced EGP sup-
pressionduring the clamp), and in adipose tissue (manifest
as raised FFAs in the face of hyperinsulinemia). Further-
more, all indices of -cell function were severely compro-
mised; in particular, -cell glucose sensitivity (ie, the in-
trinsic ability of the-cell to sense and respond to dynamic
glucose changes in a timely andquantitatively appropriate
fashion) was only 20% of that of age- and BMI-matched
nondiabetic controls. Insulin release was therefore sus-
tained at near-normal levels by the elevated glucose
concentrations.
In the patient group as a whole, BPD induced a modest
weight loss and a marked amelioration of glycemic con-
trol. By the stringent criteria adopted here, 6 of 15 patients
were in remission at 1 year postop-
eratively, whereas considerable de-
grees of improvement were obtained
in each of the other 9 patients. Cor-
respondingly, both insulin resistance
and -cell dysfunction abated to a
substantial and statistically signifi-
cant extent in the group. Of note,
-cell glucose sensitivity increased in
the face of a reduction in insulin out-
put, thereby relieving the secretory
burden on the -cell.
Despite these improvements, at 1
year after surgery, when weight had
stabilized, -cell function was still,
on average, only approximately
30% of that of nondiabetic controls
(Table 2 and Figure 2), indicating
that a substantial fraction of the
-cell dysfunction in long-standing
diabetes cannot be reversed by this
surgical approach. In line with this,
full remission was observed in a mi-
nority of patients, and even in those
patients, -cell glucose sensitivity at 1 year was only ap-
proximately 50% of normal and rate sensitivity was 30%
reduced.Presumably, in this kindofpatients, diabetesmay
recur at a relatively high rate at later times after surgery as
the disease progresses or whether weight is regained or
insulin resistance worsens. In previous work in 15 nono-
bese (BMI  30 kg/m2) patients with long-term diabetes
treated with BPD, follow-up at 2 years showed mainte-
nance of satisfactory glycemic control, although the acute
insulin response to iv glucose was still far from normal
(26). Clearly, more data from longer periods of follow-up
are needed to assess the durability of diabetes remission in
nonobese T2D patients undergoing BPD. However, it is
relevant to note that the outcome of this bariatric proce-
dure may be more favorable in severely obese diabetic
patients.Wepreviously reportedonagroupofnoninsulin-
treated,morbidly obeseT2Dpatients (with ameanBMIof
49.5 kg/m2 and relatively preserved -cell glucose sensi-
tivity), in whom BPD induced near normalization of day-
long glucose profiles and -cell sensitivity 2 years after
surgery (12). In another series of 15 obese (BMI 30–35
kg/m2) patients, the outcome was intermediate between
those of nonobese and severely obese T2D patients (26).
The question arises of whether the reduced efficacy of
BPD in leaner as compared with very obese T2D patients
is related to the smallerweight loss occurring in the former
than in the latter. The insulin sensitivity data in the present
patients do not fully support this explanation. In fact, the
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euglycemic clamp data show that in-
sulin-mediated glucose disposal was
restored to normal values already 2
months after surgery, when weight
loss was incomplete, and, more im-
portantly, equally in remitters and
nonremitters. This was also the case
in a previous series including nondi-
abetic, glucose-intolerant, and dia-
betic subjects with severe obesity
(11), in whom clamp-derived insulin
resistance resolved at even earlier
times after BPD, regardless ofweight
loss and diabetes status. Therefore,
the effect of BPD on peripheral insu-
lin sensitivity is very likely to be, at
least in part, independent of weight
loss. Moreover, in the face of BPD-
induced resolution of insulin resis-
tance, the worse outcome of glyce-
mic control of the nonobese T2D
patient presumably is the conse-
quence of poorer initial degree and
stunted postoperative recovery of
-cell function. The current data in
remitters vs nonremitters, and previ-
ous results (11, 12), are compatible
with this conclusion.
The pathophysiological picture of
BPD stands in contrast with that of
gastric bypass surgery, where we (9)
and others (8) have found that the
long-term improvement in insulin
action is essentially proportional to
the degree of weight loss. Taken to-
gether, these lines of evidence con-
firm what we had argued from a re-
view of the available literature (21)
and from a comparison of historical
data (31), that BPD, but not gastric
bypass, exerts a specific, weight-
independent effect on insulin
resistance.
The new, and somewhat unex-
pected, finding in the present series is
that hepatic insulin sensitivity (as the
EGP), if enhanced by surgery, was
still impaired at 1 year, ie, at a time
when insulin-mediated glucose dis-
posal by peripheral tissues was fully
restored (Table 2). This dissociation
could be causally linked with the de-
terioration of the prehepatic insulin
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to glucagon ratio during the meal observed after surgery
(Table 1 and Supplemental Figure 1). Before the opera-
tion, both fasting and insulin-mediated EGP were abnor-
mally high in the patients despite a significantly higher
insulin to glucagon ratio, thereby signaling a severe degree
of hepatic insulin resistance. After surgery, EGP was im-
provedbut still abnormal, likely on account of the reduced
insulin to glucagon ratio.
With regard to the hormonal changes, the large and
persistent rise in the GLP-1 response to the meal is con-
sistent with previous reports (32, 33) and may be conse-
quent upon the rapid delivery of food to the distal parts of
the gastrointestinal tract. Enhanced GLP-1 release very
probably contributed to the observed improvement in
-cell function, although abatement of glucose toxicity
must have played an additional part. The stimuli for the
heightened glucagon response, however, are more uncer-
tain. Higher GLP-1 concentrations should suppress glu-
cagon release, so one potential explanation is the drop in
insulinemia with the attendant weakening of its restraint
on -cell activity.
In summary, in nonobese patients with long-standing
T2D biliopancreatic diversion improved metabolic con-
trol in all but induced remission in only one third of them.
Althoughmodest weight loss contributed to the outcome,
increases in both insulin sensitivity and -cell function
were primarily responsible for bringing down glucose and
HbA1c levels. Peripheral insulin sensitivitywas restored to
control levels already 2months after surgery and similarly
in remitters and nonremitters, implying aweight-indepen-
dent effect of the operation. Hepatic insulin sensitivity,
however, was still compromised 1 year after surgery, pos-
sibly because of an unfavorable prehepatic insulin to glu-
cagon concentration ratio. In contrast, -cell dysfunction
was still prevailing at 1 year, especially in nonremitters.
Thus, the initial extent of -cell incompetence emerges an
important predictor of the metabolic outcome of BPD.
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Soluble Human Leukocyte Antigen-G Expression and
Glucose Tolerance in Subjects with Different Degrees
of Adiposity
Anna Solini,* Elza Muscelli,* Marina Stignani, Loredana Melchiorri,
Eleonora Santini, Chiara Rossi, Brenno Domingues Astiarraga, Roberta Rizzo,
and Olavio Roberto Baricordi
Department of Internal Medicine (A.S., E.M., E.S., C.R., B.D.A.), University of Pisa, I-56100 Pisa, Italy;
and Section of Medical Genetics (M.S., L.M., R.R., O.R.B.), Department of Experimental and Diagnostic
Medicine, University of Ferrara, I-44121 Ferrara, Italy
Context: Type 2 diabetes mellitus (T2DM) and obesity are characterized by a low-grade inflam-
mation, which might be related to the development of insulin resistance. Human leukocyte anti-
gen-G (HLA-G) shows antiinflammatory and tolerogenic properties, including the modulation of
CD8 T-cell cytotoxicity and regulation of CD4 T-lymphocyte function. These functions are par-
tially shared with IL-10, whose levels are reduced in insulin-resistant states.
Objective: The aimwas to explore the relationship between HLA-G and themetabolic and inflam-
matory pattern of obesity or T2DM.
Patients and Main OutcomeMeasures: Soluble HLA-G, IL-6, and IL-10 were measured and related
with metabolic and biochemical parameters in 230 volunteers with normal glucose tolerance,
impaired glucose tolerance, or T2DM by oral glucose tolerance test.
Results: sHLA-G, detected in 144 subjects (sHLA-G positive), was more frequent in T2DM or im-
paired glucose tolerance subjects than in normal glucose tolerance (218.6; P 0.0001), and its
plasma levels increased progressively across the classes of glucose tolerance. sHLA-G-positive in-
dividuals had higher body mass index, systolic blood pressure, and cholesterol levels; a reduced
degree of insulin sensitivity; and almost 2-fold higher levels of IL-6, a cytokine related to insulin
sensitivity,whereas IL-10was similar. In the sHLA-G-positive subgroup, by amultivariate regression
model, sHLA-Gwas significantly related to 2-h glucose, the area under insulin curve, and IL-6 levels
(multiple r2  0.14; P  0.001), independently of age, gender, and body mass index.
Conclusions: A frequent expression of sHLA-G, linked to a typical biomarker of insulin resistance
like IL-6, seems to characterize subjects with an impaired glucose metabolism. (J Clin Endocrinol
Metab 95: 3342–3346, 2010)
Human leukocyte antigen-G (HLA-G) is a member ofthe class of Ib-HLAmolecules characterized by low
allelic polymorphism and restricted tissue expression. In
contrast to classical HLA-I antigens, HLA-G has different
protein isoforms: HLA-G1 to -G4 as membrane-bound,
andHLA-G5 to -G7 as solublemolecules. Themembrane-
boundHLA-G1, its soluble counterpartHLA-G5, and the
soluble HLA-G1 isoform, produced by the proteolytic re-
lease of the membrane-bound HLA-G1, are the most in-
vestigated isoforms.
HLA-G modulation was first evident on the surface of
cytothrophoblast cells and associatedwith the tolerogenic
microenvironment at the fetal-maternal interface (1). Fur-
ther research has detected HLA-G antigen expression in
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thymic epithelial cells and cornea. The interest in HLA-G
antigens rapidly increased because of its ability to modu-
late natural killer and CD8 T-cell cytotoxicity and reg-
ulate the functions of CD4T-lymphocytes and dendritic
cells. Moreover, the induction of regulatory T cells via
HLA-G has been recently reported, confirming their
tolerogenic function in innate and adaptive responses (2–
4). Recently, the expression ofHLA-Gmolecules has been
associatedwith several autoimmunediseases, likeCrohn’s
disease and rheumatoid arthritis, viral infections, tumors,
and organ transplantations (5–8). Overall, these results
confirm the role ofHLA-Gmolecules in the induction and
maintenance of antiinflammatory environments.
HLA-G expression is up-modulated by different bio-
logical molecules as interferons and IL-10. IL-10, a pleio-
tropic cytokine secreted by different cells, plays an impor-
tant role in the regulation of the immune response, mainly
inhibiting proinflammatory molecules, altering antigen
presentation and T-cell activation pathways, and stimu-
latingB-cell proliferation anddifferentiation. IL-10 shares
withHLA-Gimmunoregulativepropertiesand,possibly, the
induction of immune tolerance; furthermore, IL-10 inhibits
cellular responses through expression of HLA-G (9, 10).
The relationships between IL-10 and metabolic abnor-
malities are not fully elucidated. Cotreatment with IL-10
prevents IL-6-induced defects in both hepatic and skeletal
muscle insulin action in rats (11), and low IL-10 circulat-
ing levels aredescribed inobese individualswithmetabolic
syndrome and in type 2 diabetic patients (12, 13). The
negative associations of IL-10with insulin resistance, type
2 diabetes mellitus (T2DM), and the metabolic syndrome
(12) suggest its role in contrasting the inflammatory state
of these patients.
T2DM patients are frequently obese, obesity being a
major risk factor for diabetes. Both conditions are char-
acterized by a low-grade inflammation, possibly related to
the development of insulin resistance (14).Cross-sectional
studies show positive correlations between inflammatory
molecules and markers of insulin resistance, and several
prospective studies reported inflammatory markers pre-
dicting T2DM; among these, IL-6 is recognized as an im-
portant correlate of insulin resistance (15). No studies
have so far explored the relationship betweenHLA-G and
either the metabolic and inflammatory pattern of obesity
and diabetes or the different degree of glucose tolerance;
therefore,we designed a study to specifically address these
issues.
Subjects and Methods
A total of 230 voluntary participants were consecutively re-
cruited among those attending our outpatient clinic for meta-
bolic diseases. Exclusion criteria were age higher than 70 yr,
chronic heart or lung disease, cancer, systemic inflammatory
disease, and kidney failure. All subjects gave their informed con-
sent. Height and weight were recorded, sitting blood pressure
(BP) was measured three times, and a fasting venous blood
sample was obtained. Subjects underwent a 75-g oral glucose
tolerance test, classifying them into three groups according to
American Diabetes Association criteria: normal glucose tol-
erance (NGT), n  118 (49 males/69 females); impaired fast-
ing glucose (IFG) and/or impaired glucose tolerance (IGT),
n 77 (34males/43 females); andT2DM, n 35 (15males/20
females).
Biochemical parameters
Plasma glucose was measured by glucose oxidase technique
and plasma insulin by RIA (Linco Research, St. Louis, MO).
Plasma total and high-density lipoprotein cholesterol and trig-
lycerides were assayed spectrophotometrically by an automatic
colorimetric system (Cobas Miras; Roche, Basel, Switzerland).
Insulin sensitivity was evaluated using the oral glucose-derived
insulin sensitivity index (OGIS) (16), which provides a validated
estimation of glucose clearance during the euglycemic hypergly-
cemic clamp. Areas under time-concentration curves were cal-
culated by the trapezoidal rule.
Cytokine and soluble HLA-G (sHLA-G) assay
Highly sensitive IL-6 and IL-10 concentrationswere analyzed
in duplicate using commercially available ELISAs (R&D Sys-
tems, Minneapolis, MN). The intraassay and interassay coeffi-
cients of variation (CVs) for IL-6 were 4.0 and 6.9%, respec-
tively. The detection limit for IL-10 was less than 3.9 pg/ml.
HLA-G determination
Total sHLA-G antigen concentrations (sHLA-G1 from pro-
teolytic degradation of membrane HLA-G1 antigens and
HLA-G5 from alternative splicing) were investigated by ELISA.
Then 20 g/ml of MEM-G9 monoclonal antibody (EXBIO
Praha, Vestec, Czech Republic) was used as capture antibody,
and anti-2 microglobulin-horseradish peroxidase-conjugated
monoclonal antibody (Dako, Glostrup, Denmark) as detection
antibody. sHLA-G concentration (mean of triplicate plasma
samples)was estimatedbyabsorbance at 450nmonamicroplate
reader (Wallac Victor-3; PerkinElmer, Waltham, MA). The in-
traassay CV was 1.4%, and the interassay CV was 4.0%. The
limit of sensitivity was 1.0 ng/ml. Samples with sHLA-G level
below the detection limit were indicated as 0 ng/ml.
Statistical analysis
Data are given as mean  SEM. Group comparisons were
carried out by Mann-Whitney or ANOVA and post hoc Bon-
ferroni/Dunn test for normally or nonnormally distributed
variables. Associations between categorical variables were ex-
amined by 2 tests. Relationships between variables were
tested by Spearman correlation and multiple regression mod-
els. Adjustment for covariates was carried out by ANCOVA.
Analyses were performed using Statview software (SAS Insti-
tute Inc., Cary, NC).
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Results
T2DM subjects were significantly heavier and older than
NGT and IFG/IGT (both P  0.0001). Gender distribu-
tion was similar; systolic BP increased progressively from
NGT to IFG/IGT and T2DM. Insulin sensitivity was re-
duced in both IFG/IGT and T2DM, whereas the plasma
glucose and insulin responses to oral glucose [area under
the insulin curve (AUIC)] were significantly higher (both
P  0.0001) in IFG/IGT and T2DM.
sHLA-G was detected in 144 subjects (sHLA-G posi-
tive), being less frequent in NGT (negative/positive sub-
jects, NGT  57/61; IFG/IGT  14/63; and T2DM 
15/20; 2  18.6; P  0.0001). sHLA-G positivity was
similar between males and females and more frequent in
overweight and obese than in lean subjects (52.4 and 77%
vs. 34.9; 2  27.9; P  0.0001).
When the study group was stratified according to
sHLA-G presence, sHLA-G-positive individuals had
higher body mass index (BMI), systolic BP, and plasma
cholesterol (Table 1); they also displayed higher areas un-
der the curve of both glucose and insulin, and reduced
insulin sensitivity (OGIS value). Because these variables
are related to obesity, the results were adjusted for the
BMI: systolic BP, total cholesterol, and both 2-h glucose
and area under the glucose curve (AUGC) remained
significantly higher in sHLA-G-positive individuals.
Moreover, in sHLA-G-positive subjects, therewas a pro-
gressive, significant increment of sHLA-G plasma levels
fromNGT to IFG/IGT (P 0.05) and T2DM (P 0.007)
(Fig. 1A).
IL-6, a cytokine related to insulin sensitivity and in-
creased in subjectswith impaired glucosemetabolism (P
0.0003 by ANOVA), was almost 2-fold higher in sHLA-
G-positive than in sHLA-G-negative subjects (3.150.29
vs. 1.72  0.14 pg/ml; P  0.004 by ANCOVA), irre-
spective of BMI. However, IL-10 levels, frequently asso-
ciated with the presence of sHLA-G, were similar [6.45
0.42 vs. 6.44  0.42 pg/ml; P  not significant (ns)].
In the whole study group, AUGC was directly associ-
ated to BMI, fasting insulin, and AUIC (rho 0.38, 0.71,
and 0.62; all P  0.0001) and inversely to OGIS (rho 
0.61; P  0.0001).
In the sHLA-G-positive subgroup, after adjustment for
BMI, sHLA-G concentrations were directly related to sys-
tolic BP (r  0.32; P  0.05), total cholesterol (r  0.16;
P 0.04), 2-h glucose (r 0.38; P 0.002), AUGC (Fig.
1B), and IL-6 plasma levels (Fig. 1C).
In a multivariate regression model, sHLA-G was sig-
nificantly related to 2-h glucose (partial r  0.22; P 
0.03), AUIC (partial r0.27; P 0.01), and IL-6 (par-
tial r  0.22; P  0.04) (multiple r2  0.14; P  0.001).
In this model, age, gender, and BMI were not significant
covariates; furthermore, replacing 2-h glucose with
AUGC did not change the results. In the sHLA-G-positive
subgroup, by a multiple regression model, AUGCwas as-
sociated with age, AUIC, and OGIS, and with sHLA-G
(multiple r2  0.48; P  0.0001).
Discussion
This study shows for the first time an association between
degree of glucose tolerance and either presence and in-
creased plasma levels of sHLA-G; moreover, HLA-G is
directly related with IL-6, a cytokine involved in the sub-
TABLE 1. Anthropometric and metabolic characteristics of the study subjects by sHLA-G presence
sHLA-G negative sHLA-G positive P Adjust P
n (males/females) 86 (41/45) 144 (62/82) nsa
NGT/(IFG/IGT)/T2DM (n) 57/14/15 61/63/20 0.0001a
Lean/overweight/obese (n) 28/29/29 15/97/32 0.0001a
BMI (kg/m2) 29.0  0.8 34.5  0.7 0.0001
Age (yr) 46  1 45  1 ns
Systolic BP (mm Hg) 129  1 133  1 0.02 0.05
Diastolic BP (mm Hg) 80  1 82  1 0.02 ns
Total cholesterol (mmol/liter) 4.92  0.11 5.24  0.09 0.01 0.004
HDL cholesterol (mmol/liter) 1.30  0.04 1.27  0.03 ns ns
LDL cholesterol (mmol/liter) 2.74  0.12 3.14  0.09 0.01 0.06
Triglycerides (mmol/liter) 1.34  0.10 1.36  0.06 ns ns
Uric acid (mol/liter) 304  11 321  7 ns ns
Fasting glucose (mmol/liter) 5.73  0.16 5.63  0.10 ns ns
2-h glucose (mmol/liter) 7.21  0.32 7.92  0.21 0.0001 0.01
Fasting insulin (pmol/liter) 45  3 89  4 0.0001 ns
AUIC (nmol  liter1  2 h1) 32.27  2.52 54.13  3.25 0.0001 ns
OGIS (ml  min1  m2) 417  7 374  6 0.0001 ns
Data are expressed as mean  SEM. P, By Mann-Whitney U test; adjusted P, P value adjusted for BMI. HDL, High-density lipoprotein; LDL, low-
density lipoprotein.
a By 2 test.
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clinical inflammatory statusdescribedduring the courseof
obesity and T2DM.
Several reports have evaluated the influence of sHLA-G
levels in different autoimmune diseases; despite some con-
trasting results, a positive function for increased sHLA-G
levels has been reported in skin and neurological diseases,
allergy, rheumatological and gastrointestinal diseases (5,
6, 17). Although T2DM and obesity are not autoimmune
diseases, we found increased plasma concentrations of
sHLA-G molecules in patients carrying these metabolic
abnormalities. In comparison with controls, higher
sHLA-G levels are present even in early stages of altered
glucose tolerance, like IFG and IGT, and progressively
increase across the different stages of glucose tolerance.
Theseobservations are further confirmedbyage-, gender-,
andBMI-independent correlationswithmetabolic param-
eters like glycemia and insulinemia in response to glucose
ingestion. In addition, the correlationwith blood pressure
and cholesterol levels suggests that sHLA-Gmight also be
involved in other components of the metabolic syndrome.
sHLA-G is of special interest because it contributes to
control CD4 and CD8-T-cell activities, dendritic cell
maturation, and regulatory T-cell production, thus play-
ing an important role in innate and adaptive immunity.
Although a major impairment of the humoral innate im-
munity has not been described in T2DM, studies have
shown decreased functions (chemotaxis, phagocytosis,
killing) of diabetic polymorphonuclear cells and mono-
cytes/macrophages compared with controls (18). Our ob-
servation of higher sHLA-G levels in the incipient alter-
ations of glucose metabolism reinforces the involvement
of the immune system in the inflammatory condition that
characterizes the development or progression of diabetes.
A possible link between obesity, T2DM, and HLA-G
could be the chronic local inflammation in adipose tissue,
where cells of the innate immune system,particularlymac-
rophages, are crucially involved (19). An important
marker of the adipose tissue inflammation is the increase
of IL-6. In accordance with this hypothesis, we found
higher IL-6 levels in sHLA-G-positive subjects, with a di-
rect relationship between the concentrations of the two
molecules, thus suggesting sHLA-G as a further putative
marker of the subclinical inflammation accompanying
glucose metabolism alterations.
In physiological condition, activated CD14 mono-
cyte cells are themain responsibility for sHLA-G secretion
in plasma. This production is strictly dependent on IL-10
cytokine, secreted in the microenvironment in response to
inflammatory stimuli (20), and a positive relationship ex-
ists between IL-10 and sHLA-G levels (21). We found
similar IL-10 concentrations in sHLA-G-positive and
-negative subjects, with no correlation between thesemol-
ecules. IL-10 has been recently suggested as a protecting
factor toward deterioration of insulin sensitivity (22),
with lower circulating levels in obesity and T2DM (12,
13), as observed as a trend also in our study group (data
not shown). We may speculate that the lack of such cor-
relation, found in other diseases like psoriasis and asthma
(17, 21), could be the consequence of a certain degree of
insulin resistance described in early stages of glucose tol-
erance impairment.
In conclusion, we show for the first time that HLA-G is
frequently expressed in subjects with an impaired glucose
metabolism and is linked to a typical biomarker of insulin
resistance like IL-6. Further studies in a larger study cohort
are needed to confirm these observations, to clarify the
precise origin of sHLA-G molecules, and to investigate
FIG. 1. A, sHLA-G levels, expressed as mean  SEM, according to
glucose tolerance status. a, P  0.05; and b, P  0.007 vs. NGT group
by ANOVA and post hoc Bonferroni/Dunn test. B and C, Relationship
between sHLA-G concentration and AUGC (B) (rho  0.29; P  0.001)
and IL-6 (C) levels (rho  0.22; P  0.02).
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their potential role in the pathogenesis of the metabolic
disturbances during the course of obesity and T2DM.
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Acute Effect of Roux-En-Y Gastric Bypass on
Whole-Body Insulin Sensitivity: A Study with the
Euglycemic-Hyperinsulinemic Clamp
Marcelo M. O. Lima, Jose´ C. Pareja, Sarah M. Alegre, Sylka R. Geloneze,
Steven E. Kahn, Brenno D. Astiarraga, E´linton A. Chaim, and Bruno Geloneze
Laboratory of Investigation on Metabolism and Diabetes/Gastrocentro (M.M.O.L., J.C.P., S.R.G., B.D.A.,
B.G.) and Departments of Surgery (J.C.P., E.A.C.) and Internal Medicine (S.M.A., B.D.A.), State University
of Campinas (UNICAMP), Campinas, Sa˜o Paulo, 13081-970, Brazil; and Division of Metabolism,
Endocrinology, and Nutrition (S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health
Care System and University of Washington, Seattle, Washington 98108
Context: Insulin resistance ameliorates after bariatric surgery, yet there is still a need for data on
the acute effect of Roux-en-Y gastric bypass (RYGBP) on insulin sensitivity.
Objective: The objective of the study was to describe the acute effect of RYGBP on insulin sensi-
tivity, measured by both the euglycemic-hyperinsulinemic clamp and homeostasis model assess-
ment insulin resistance index (HOMA-IR).
Design and Setting: Evaluations were conducted before and 1 month after RYGBP at State Uni-
versity of Campinas (Sa˜o Paulo, Brazil).
Patients: Patients included 19 premenopausal womenwithmetabolic syndrome aged 35.3 (6.7) yr,
bodymass index45.50 (3.74) kg/m2 [mean (SD)]. Sixhadmild type2diabetes, seven impairedglucose
tolerance, and six normal glucose tolerance.
Interventions and Main Outcome Measures: The volunteers underwent RYGBP either alone or
combined with omentectomy. Euglycemic-hyperinsulinemic clamp, HOMA-IR, nonesterified fatty
acids, leptin, ultrasensitive C-reactive protein, adiponectin, and IL-6 were assessed at baseline and
4.5 (0.9) wk postoperatively.
Results: Fasting glucose decreased [99.2 (13.1) to 83.6 (8.1) mg/dl, P 0.01] alongwith a reduction
in fasting insulin [30.4 (17.0) to 11.4 (6.3) mU/liter, P  0.01]. M value did not improve postoper-
atively [25.82 (6.30) to 22.02 (6.05) mol/kgFFM  min] despite of a decrease in body weight [114.8
(14.5) to 102.3 (14.5) kg, P 0.001]. This finding was discordant to the observation of an improve-
ment in HOMA-IR [3.85 (2.10) to 1.42 (0.76), P  0.01]. Nonesterified fatty acids increased. Leptin
and C-reactive protein decreased. IL-6 and adiponectin remained unchanged.
Conclusions:Amonthafter RYGBP, fastingglucosemetabolism improves independentof a change
in peripheral insulin sensitivity. (J Clin Endocrinol Metab 95: 3871–3875, 2010)
Insulin resistance is related to the degree of obesity anddecreases after weight loss (1, 2). Long-term, mas-
sive weight loss after bariatric surgery generally pro-
motes a proportional increase in insulin sensitivity (IS)
(1). Moreover, the short-term postoperative improve-
ments in IS and metabolic syndrome components, es-
pecially glucose tolerance, are greater than expected for
the body mass index (BMI) change and have been pre-
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sumed to be due to caloric restriction and an enhanced
incretin effect (1).
The homeostasis model assessment insulin resistance
index (HOMA-IR), a surrogate marker of IS, improves
within the first month after different bariatric procedures
(1, 3). In fact, nearly all of the long-term improvement in
HOMA-IR observed after bariatric surgery occurs be-
fore clinically meaningful weight loss. Studies using the
euglycemic-hyperinsulinemic clamp have demonstrated
long-term (3 to 24 months) improvements in IS after
Roux-en-Y gastric bypass (RYGBP) and biliopancreatic
diversion (BPD) (4–6). However, few studies have as-
sessed the shorter-term effects using the clamp technique
after either BPD (7–9) or RYGBP (10).
In a 2-yr follow-up, our group previously showed a
greater enhancement of IS after BPD compared with
RYGBP (3). There is also evidence for evenmore dramatic
differences between these two operations in the short
term. After BPD, most of the long-term improvement was
achieved within 7–10 d, before significant weight loss, in
subjects with glucose tolerance ranging from normal to
type 2 diabetes (7, 8). In contrast, it has been shown in
nondiabetic subjects that HOMA-IR reduction was not
accompanied by a change in IS measured using the clamp
technique 14 d after RYGBP (10) or in subjects with glu-
cose tolerance ranging from normal to diabetes using the
frequently sampled iv glucose tolerance test 1 month after
RYGBP (11). The authors of these studies hypothesized
that hepatic IS (represented by HOMA-IR) improves ear-
lier than peripheral IS (the main aspect of whole-body IS
measured by the iv glucose tolerance test and clamp) after
RYGBP.
RYGBP is the most performed obesity surgery world-
wide, yet there is a need for specific data on the short-term
effects of this technique on whole-body IS. The present
study assessed the acute effects of RYGBPon IS,measured
by both the euglycemic-hyperinsulinemic clamp and
HOMA-IR, 1 month postoperatively across a range of
glucose tolerance including type 2 diabetes. This work is
a portionof a randomized trial on the long-termmetabolic
effects of total greater omentectomy, a potential ancillary
procedure to obesity surgery.
Subjects and Methods
Nineteen grade III obese (BMI 40 kg/m2), premenopausal
women, aged 35.3 (6.7) yr [mean (SD)], with the metabolic syn-
drome based on International Diabetes Federation criteria (12),
participated in a prospective trial that had been approved by the
Institutional Ethics Review Board at State University of Campi-
nas. All participants provided written informed consent before
participation. They underwent a RYGBP between March 2006
and February 2008 and were randomized to simultaneously re-
ceive a total greater omentectomy (n  10 of 19) to study its
long-term metabolic effects (1, 6–8, and 12–18 months after
surgery).
Subjects were classified by a standard oral glucose tolerance
test as normal glucose tolerance (n6), impaired fasting glucose
and impaired glucose tolerance (n 7), and type 2 diabetes (n
6), of whom three, four, and three, respectively, were random-
ized to omentectomy. Four diabetic subjects had been diagnosed
within 1–3 yr, were not taking any glucose-lowering agent, and
had a glycosylated hemoglobin less than 7%.
Evaluationswere performedat baseline and4.5 (0.9)wkafter
surgery for IS, biochemistry, anthropometric measures, and
body composition, the latter by electric bioimpedance (Biody-
namics Corp., Seattle, WA).
To quantify IS, a 180-min euglycemic-hyperinsulinemic
clamp (4)wasperformed.For this, aprimedcontinuous iv insulin
infusion (40 mU/m2  min) was administered. Fasting glycemia
was maintained (variation  5%) by a variable rate glucose
infusion and blood glucose determination (glucose oxidase) ev-
ery 5 min by YSI 2700 biochemistry analyzer (Yellow Springs
Inc., Yellow Springs, OH). If fasting hyperglycemiawas present,
it was corrected to a target of 100 mg/dl by the initial iv insulin
infusion. IS was calculated as the glucose infusion rate (GIR) in
the last 60 min (steady state), corrected for the glucose distribu-
tion space and adjusted to fat-free mass (FFM), resulting in the
M value. Other indexes of IS were calculated from the M value:
glucose metabolic clearance rate (MCRg M/steady state gly-
cemia) and M adjusted for steady-state insulin (M/I).
HOMA-IRwas calculated using theHOMACalculator (ver-
sion 2.2.2, http://www.dtu.ox.ac.uk) (13).
Serum samples were analyzed for basal and steady-state in-
sulin (ELISA;BayerCorp.,Tarrytown,NY)aswell asbasal levels
of nonesterified fatty acids (NEFAs; ELISA; Wako Chemicals,
Richmond, VA), leptin, ultrasensitive C-reactive protein (us-
CRP), IL-6, and adiponectin (ELISA; R&D Systems Inc., Min-
neapolis, MN).
SPSS (version 12; SPSS Inc., Chicago, IL) was used for sta-
tistical analysis. Wilcoxon signed-rank tests were used to com-
parebaseline topostsurgerydata;Mann-WhitneyU tests to com-
pare omentectomy subgroups and Kruskal-Wallis tests to
compare glucose tolerance subgroups. Pearson correlation co-
efficient was used to assess bivariate correlations. Data are pre-
sented as mean and SD [mean (SD)]. Postsurgery change in the
variables was calculated as the percent difference from baseline
values. Statistical significance was assumed if P  0.05.
Results
The anthropometric and metabolic variables at baseline
and a month after surgery are presented in Table 1. The
subgroups based on omentectomy had similar changes in
the variables aside from omentectomy being associated
with slightly greater weight loss [12.6% (2.5%) vs.
9.3% (2.5%), P 0.05]. Thus, we analyzed the pooled
data of the whole group of operated subjects.
Both fasting glucose and insulin decreased so that there
was a significant reduction in HOMA-IR [55.0%
(30.6%), P 0.01] in all subjects except two, in whom it
remained unchanged (one had normal glucose tolerance
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and the other diabetes). In contrast, IS (M value) did not
improve postoperatively, despite a significant decrease in
bodyweight (Table 1). Adjustments of theMvalue for the
steady-state insulin or steady-state glucose, expressed re-
spectively as M/I or MCRg (Table 1), did not alter the
findings and even increased the spreadof the results. There
was no relationship between the postoperative change in
steady-state insulin and change in M value. Despite no
change in the average M value, it did improve in four
subjects (27 to 58%), decreased in nine (19 to
68%), and was considered stable in six (11 to 7%)
based on the intrasubject variability of approximately
10% found in the literature (14).
Table 2 presents the data based on glucose tolerance
subgroups. The changes in the variableswere not different
among subgroups with the exception of fasting glucose
(P0.05).Type2diabetes remittedwithin the firstmonth
after surgery in all cases based on the fasting glucose, and
3months after surgery, all had a glycosylated hemoglobin
less than 6%.
IS (M value and HOMA-IR) did not correlate with
body weight, BMI, FFM, fat mass, or percentage of body
fat either before or after surgery. Also, the change in IS did
not correlate with the change in these variables.
After surgery, NEFAs increased, leptin and us-CRP de-
creased, and there was no significant change in IL-6 and
adiponectin (Table 1). Leptin was lower in the omentec-
tomy subgroup both at baseline and after surgery but the
change was similar between the subgroups (Table 1).
None of these variables correlated with each other or the
M value, HOMA-IR, fasting insulin, and glucose, either
before or after surgery. Their baseline and postsurgery
values and change did not correlate with the change in IS.
Discussion
This study represents the first description of the acute ef-
fect of RYGBP on whole-body IS using the gold standard
method, the euglycemic-hyperinsulinemic clamp, across a
range of glucose tolerance including type 2 diabetes. IS
measured by the clamp did not increase within a month
after surgery among premenopausal women. This finding
was discordant to the observation of an improvement in
HOMA-IR. Because HOMA represents essentially he-
patic IS,whereasM ismore ameasure of peripheral IS, this
suggests differential effects in the short period after
TABLE 1. Anthropometric and metabolic variables at baseline and 1 month after RYGBP in the whole group or
based on omentectomy
Variables
Whole group (n  19)
[mean (SD)]
Omentectomy (n  10)
[mean (SD)]
Control (n  9)
[mean (SD)]
Baseline After surgery Baseline After surgery Baseline After surgery
Body weight (kg) 114.8 (14.5) 102.3 (14.5)a 115.0 (14.0) 100.8 (14.5)a 114.6 (15.9) 104.0 (15.1)a
BMI (kg/m2) 45.5 (3.7) 40.5 (4.2)a 45.0 (4.4) 39.4 (4.7)a 46.1 (3.0) 41.8 (3.2)a
FFM (kg) 64.1 (7.7) 58.9 (7.3)a 64.2 (7.1) 58.8 (7.4)a 64.1 (8.7) 59.0 (7.6)a
Fat mass (kg) 50.3 (7.8) 43.4 (7.9)a 50.4 (8.2) 42.0 (7.8)a 50.1 (7.7) 44.9 (8.2)b
Fat mass (%) 43.7 (2.2) 42.3 (2.7)b 43.7 (2.6) 41.5 (2.5)b 43.7 (1.8) 43.0 (2.8)
Fasting glucose (mg/dl) 99.2 (13.1) 83.6 (8.1)a 101.1 (18.0) 83.7 (11.2)c 100.3 (13.3) 84.9 (6.5)a
Fasting insulin (mU/liter) 30.4 (17.0) 11.4 (6.3)a 26.9 (13.5) 11.6 (7.5)a 34.2 (20.3) 11.3 (5.0)b
HOMA-IR 3.85 (2.10) 1.42 (0.76)a 3.64 (1.93) 1.59 (0.82)a 4.09 (2.48) 1.44 (0.67)a
M (mol/kgFFM  min) 25.8 (6.3) 22.0 (6.1) 28.2 (6.5) 22.4 (8.3) 23.2 (5.3) 22.7 (3.5)
GIR (mol/kg  min) 16.2 (4.5) 13.7 (5.0) 15.8 (3.7) 12.5 (4.9) 13.0 (3.0) 12.9 (2.2)
MCRg (ml/kgFFM  min) 4.9 (1.4) 4.7 (1.5) 5.5 (3.5) 4.8 (2.5) 4.3 (2.7) 4.7 (3.8)
M/I [(mol/kgFFM  min  pmol 
liter)  103]
34.0 (15.1) 34.6 (14.0) 34.9 (15.3) 32.7 (13.8) 27.8 (11.1) 32.0 (10.3)
Steady-state glucose (mg/dl) 94.4 (8.8) 84.7 (8.2)b 92.7 (7.8) 82.7 (10.6)b 97.7 (10.1) 86.5 (3.7)b
Steady-state insulin (mU/liter) 151.6 (48.7) 121.9 (33.0)b 148.7 (51.9) 119 (39.1)b 154.8 (47.8) 124.8 (27.7)
Adiponectin (g/ml) 5.22 (3.33) 6.04 (3.64) 6.46 (3.67) 6.12 (3.34) 4.08 (2.68) 6.29 (4.22)
Leptin (ng/ml)d 73.39 (39.00) 40.52 (30.88)a 54.70 (25.9) 28.7 (24.23)b 97.7 (40.3) 54.02 (34.97)c
IL-6 (pg/ml) 3.10 (2.20) 4.25 (5.72) 2.50 (1.43) 4.63 (7.85) 4.00 (4.16) 4.16 (2.69)
us-CRP (mg/dl) 1.37 (0.67) 0.77 (0.63)a 1.16 (0.63) 0.76 (0.81) 1.64 (0.69) 0.83 (0.42)b
NEFAs (mg/dl) 67.96 (25.66) 98.98 (43.43)a 71.63 (20.87) 106.88 (42.30)b 56.40 (25.94) 96.16 (45.40)
Control, RYGBP without omentectomy; M, clamp insulin sensitivity index (GIR adjusted to FFM).
a P  0.01, Wilcoxon test (after surgery vs. baseline).
b P  0.05, Wilcoxon test (after surgery vs. baseline).
c P  0.05, Wilcoxon test (after surgery vs. baseline).
d There was a difference in the leptin values between the subgroups (P  0.05, Mann-Whitney U test) both at baseline and after surgery but not in
its change.
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RYGBP and is in keepingwith the known differential IS of
the liver and peripheral tissues (13).
The reason(s) for our observation of no change in IS
with the clamp study is unclear. One possible explanation
relates to body composition. Both fat and FFM loss con-
tributed largely to the initial weight reduction and the
percentageof body fat remainingwas still high.Moreover,
obesity indexes did not correlate with IS, indicating that
other factors likely determine IS in individuals with such
extreme fat mass and with limited postsurgery change.
HOMA-IR mainly reflects the interaction between he-
patic glucose output and insulin secretion in the fasting
state (15). During the clamp, in the insulin-stimulated
state, peripheral tissues account for approximately 90%
of glucose disposal, more than half occurring in skeletal
muscle (14). Caloric restriction has been proposed as a
major contributor to the acute decrease in HOMA-IR
(1, 3). Under conditions of negative energy balance,
glucose disposal (mostly insulin independent) exceeds
carbohydrate intake, thereby restricting the glucose
pool and more specifically hepatic glycogen (16). Pe-
ripheral insulin-mediated glucose disposal might even-
tually decrease due to preferential fatty acid oxidation
in skeletal muscles (16).
Selective improvement of hepatic IS regardless of pe-
ripheral change after a very low-calorie diet has been dem-
onstrated in studies using the euglycemic-hyperinsuline-
mic clamp (17). Variability in intramyocellular lipid
depletion, in contrast to amore uniform intrahepatic lipid
reduction (17, 18), could account for the divergences ob-
served in thepresent study.Major lipidmalabsorptionand
intramyocellular lipid depletion are distinct effects of BPD
(1, 19), which might enhance IS in skeletal muscle earlier
than occurs with RYGBP.
The design of our study has some limitations, although
none bear on our findings. First, we did not perform ra-
dioisotope-labeled glucose clamp studies that can differ-
entiate changes in hepatic vs.peripheral IS and studies that
assess substrate use. Second,wedid not include aBDParm
for a direct comparison with RYGBP. Third, we studied
only premenopausal women so cannot be sure that our
results apply to postmenopausal women and men, al-
though there is no reason to believe thatwould be the case.
Lastly, the small number of subjects within subgroups by
glucose tolerance make across-group comparisons unre-
liable and will require further study.
In summary, our data suggest that RYGBP affects he-
patic glucose metabolism earlier than peripheral insulin
action, which differs from observations after BPD. These
findings underscore that the outcomes of the various bari-
atric techniques differ, and there are likelymany that have
not yet been identified, some of which could provide in-
sights and new approaches to the treatment of obesity,
diabetes, and related disorders.
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TABLE 2. Main anthropometric and metabolic variables at baseline and 1 month after RYGBP based on glucose
tolerance category
Variables
Normal tolerance
(n  6) [mean (SD)]
Impaired tolerance
(n  7) [mean (SD)]
Type 2 diabetes
(n  6) [mean (SD)]
Baseline After surgery Baseline After surgery Baseline After surgery
Body weight (kg) 113.1 (9.7) 100.3 (11.4)a 119.8 (12.0) 107.3 (10.7)a 110.7 (20.8) 98.5 (20.7)a
BMI (kg/m2) 43.6 (3.0) 38.7 (4.0)a 47.7 (4.0) 42.8 (4.1)a 44.9 (3.2) 39.8 (3.8)a
Fasting glucose (mg/dl) 86.2 (4.4) 85.0 (5.2) 100.9 (7.1) 86.8 (8.5)a 115.0 (16.9) 80.7 (12.4)a
Fasting insulin (mU/liter) 23.8 (7.7) 12.5 (8.7)a 29.9 (15.2) 12.6 (6.2)a 37.5 (24.3) 8.9 (2.9)a
HOMA-IR 2.89 (1.05) 1.57 (0.99)a 4.25 (2.14) 1.79 (0.70)a 4.36 (2.9) 1.16 (0.34)a
GIR (mol/kg  min) 16.5 (3.0) 12.7 (5.4) 12.4 (2.9) 11.7 (2.9) 14.8 (4.0) 14.2 (2.0)
M (mol/kgFFM  min) 28.9 (5.4) 21.5 (9.1) 22.6 (5.5) 20.8 (4.5) 26.5 (7.3) 25.7 (4.4)
MCRg (ml/kgFFM  min) 6.0 (1.3) 4.5 (1.8)
a 4.1 (0.8) 4.3 (1.1) 4.8 (1.4) 5.7 (1.3)
M/I (mol/kgFFM  min  pmol 
liter)  103
36.4 (6.1) 28.2 (12.2)a 26.7 (9.3) 32.2 (12.3) 32.4 (21.5) 37.5 (11.0)
Steady-state glucose (mg/dl) 87.4 (6.7) 85.3 (3.3) 98.2 (10.7) 87.7 (7.4) 99.2 (3.5) 79.3 (11.0)a
Steady-state insulin (mU/liter) 133.5 (24.7) 134.1 (34.8) 155.3 (57.9) 116.2 (34.6)a 165.3 (57.2) 115.2 (31.2)
M, Clamp insulin sensitivity index (GIR adjusted for FFM).
a P  0.05, Wilcoxon test (after surgery vs. baseline).
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Context:Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type
2 diabetes. The underlying mechanisms (incretin effect, -cell function, endogenous glucose pro-
duction) are not well known.
Objective: The aim of the study was to examine mechanisms of the antihyperglycemic effect of
DPP-4 inhibitors.
Design, Setting, and Patients: We administered a mixed meal with glucose tracers ([6,6-2H2]-
glucose infused, [1-2H]-glucose ingested), and on a separate day, a glucose infusion matched the
glucose responses to the meal (isoglycemic test) in 50 type 2 diabetes patients (hemoglobin A1c
7.4  0.8%) and seven controls; 47 diabetic completers were restudied after 6 wk. Glucose fluxes
were calculated, and -cell function was assessed by mathematical modeling. The incretin effect
was calculated as the ratio of oral to iv insulin secretion.
Intervention: We conducted a 6-wk, double-blind, randomized treatment with sitagliptin (100
mg/d; n  25) or placebo (n  22).
Results: Relative to placebo, meal-induced changes in fasting glucose and glucose area under the
curve (AUC) were greater with sitagliptin, in parallel with a lower appearance of oral glucose
[difference (post-pre)AUC353 915 vs.146 601mol  kg1  5h] andgreater suppression
of endogenous glucose production. Insulin sensitivity improved 10%, whereas total insulin secre-
tion was unchanged. During the meal, -cell glucose sensitivity improved (19[29] vs. 5[21]
pmol  min1  m2  mM1;median [interquartile range]) and glucagonAUCdecreased (19.6 7.5
to 17.3  7.1 ng  ml1  5 h), whereas intact glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 AUC increased with sitagliptin vs. placebo. The incretin effect was un-
changed because sitagliptin increased -cell glucose sensitivity also during the isoglycemic test.
Conclusions: Chronic sitagliptin treatment improves glycemic control by lowering the appearance
of oral glucose, postprandial endogenous glucose release, and glucagon response, and by improv-
ing insulin sensitivity and -cell glucose sensing in response to both oral and iv glucose. (J Clin
Endocrinol Metab 97: 2818–2826, 2012)
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-Cell dysfunction is a key pathogenetic defect in pa-tients with type 2 diabetes mellitus (T2D); worsen-
ing of -cell function marks the progression of the disease
and is a main target for treatment (1).
Glucagon-like peptide-1 (GLP-1) and glucose-depen-
dent insulinotropic polypeptide (GIP) potentiate glucose-
induced insulin release; in addition,GLP-1 also suppresses
glucagon release and slows down gastric emptying (2).
Enhanced insulin release, in concert with a reduction in
glucagon concentration, reduces the postprandial rise in
glucose concentrations. Although it is still somewhat un-
certain whether and to what extent the GLP-1 response is
reduced in T2D patients (3), the incretin effect—opera-
tionally defined as the potentiation of insulin release by
oral vs. iv glucose—is compromised in T2D (4, 5). Al-
though the secretion of GLP-1 is often reduced, the insuli-
notropic effect of both GLP-1 and GIP is severely com-
promised (6).
Infusion of GLP-1 in T2D patients augments insulin
release, leading to normalization of glucose concentra-
tions (7, 8). In rodents,GLP-1 also regulates islet-cellmass
andmorphology (9). BothGLP-1 andGIP have very short
half-lives because several peptidases clear them from
plasma in a few minutes; among them, dipeptidyl pepti-
dase IV (DPP-4)plays aquantitatively important role. Spe-
cific inhibition of DPP-4 delays clearance of GLP-1 and
GIP, thereby augmenting active incretin levels. Sitagliptin,
an orally active DPP-4 inhibitor, has been shown to im-
prove glycemic control in T2Dpatients (10). Although the
increase in intact GLP-1 byDPP-4 inhibition is likely both
to improve glucose-induced insulin secretion (11, 12) and
maximal insulin response (13) and to decrease glucagon
levels (12, 14, 15), it is not knownwhether chronic DPP-4
inhibition with sitagliptin restores the incretin effect in
T2D patients. Improved insulin secretion in response to
oral and iv glucose without changes in incretin effect was
demonstrated for the DDP-4 inhibitor vildagliptin (16).
Balas et al. (12) reported a decrease in endogenous glucose
production (EGP) and unchanged rates of plasma glucose
appearance and disappearance after vildagliptin. How-
ever, DPP-4 inhibitors differ in their structure and phar-
macokinetic andpharmacodynamicproperties (17), and it
is not clearwhether effects are a class effect or unique. The
downstream action of sitagliptin on peripheral glucose
utilization, EGP, and oral glucose handling in diabetic
patients has not been examined.
The aim of this study was to assess the mechanism of
action of chronic DPP-4 inhibition by measuring the in-
tegratedmetabolic response to sitagliptin in T2Dpatients.
Subjects and Methods
Study population
Fifty patients with T2D diagnosed within the past 5 yr were
recruited into the study. Inclusion criteria were either sex, age
between 30 and 70 yr, and body mass index (BMI) between 20
and 40 kg/m2. At screening, antihyperglycemic therapy-naive
patients had to have hemoglobin A1c (HbA1c) between 7 and
10%, whereas patients on treatment (monotherapy or low-dose
oral combination therapy) had to have HbA1c between 6.5 and
10%. After 4 wk of washout and before randomization, fasting
plasma glucose (FPG) was required to range from 7.2–14.4
mmol/liter. Exclusion criteria were: unstable body weight; his-
tory of malignancy in the last 5 yr; significant cardiovascular
disorderwithin the last 6months; treatmentwithmore than12.5
mg daily of thiazide, -blocker therapy; monotherapy or com-
binationwith peroxisome proliferator-activated receptor- ago-
nists in the last 12 wk; pregnant women or women expecting to
conceive within the study duration; plasma creatinine of 1.5
mg/dl or greater; alanine aminotransferase and aspartate ami-
notransferase greater than 2.0  upper limit of normal; abnor-
mal TSH levels; triglycerides greater than 3.39 mmol/liter; cre-
atinine clearance less than 60 ml/min; and blood pressure of
160/95 mm Hg or greater.
Seven subjects with FPG less than 5.6mmol/liter participated
as controls in all baseline experiments.
Study design and protocol
T2D patients were randomized to sitagliptin (100 mg/d) or
placebo for 6 wk in a double-blind design with an equal fraction
of drug-naive and treated patients in each group.
Each subject underwent two studies within 2–7 d, both before
andafter treatment.The first studywasameal tolerance test (MTT;
53% carbohydrate, 30% fat, 17% protein, 560 kcal), and the sec-
ond was an isoglycemic iv glucose infusion [isoglycemic test (Iso-
G)]. For theMTT, a primed-constant infusion of [6,6-2H2]glucose
(0.28 mol  min1  kg1; prime 28 mol  kg1 [FPG]/5) was
administeredthroughouta3-hbasalperiodandduringthe5-hmeal
test.At time0, subjects ingested (in10min) themeal consistingof
one egg, 50 g of parmesan cheese, and 75 g of an aqueous solution
of D-glucose labeledwith [1-2H]glucose.On the Iso-G, tracerswere
not used, and the plasma glucose profile of the MTT was repro-
duced by a variable iv glucose infusion, using an ad hoc-developed
algorithm.Bloodwascollectedat the same time-pointsof theMTT.
Measurements
Fat-free mass (FFM) was measured by electrical bioimped-
ance using aBodyCompositionAnalyzermodelTB-300 (Tanita,
Tokyo, Japan); fat mass was then obtained as the difference
between body weight and FFM.
Tracer enrichment of [6,6-2H2]-glucose and [1-
2H]-glucose
was measured by gas chromatography/mass spectrometry
(model 5985B; Hewlett-Packard, Fullerton, CA) using electron
impact ionizationand selective ionmonitoringatmass-to-charge
ratio 202/200 and 205/200.
Plasma glucose was measured by the glucose-oxidase tech-
nique (Beckman Glucose Analyzers; Beckman, Fullerton, CA),
plasma insulin and C-peptide by electro-chemiluminescence (on
a COBASe411; Roche, Indianapolis, IN), and glucagon by RIA
(Millipore, Billerica,MA). Sampleswere assayed for totalGLP-1
immunoreactivity using anantiserum(no. 89390) specific for the
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C terminal, which reacts equally with intact GLP-1 and the pri-
mary (N-terminally truncated) metabolite (18). Intact GLP-1
was measured using an ELISA (19). The assay is a two-site sand-
wich assay involving two monoclonal antibodies—GLP-1F5 as
a catching antibody (C-terminally directed), and Mab26.1 as a
detecting antibody (N-terminally directed) (20). For both assays,
the detection limit was below 1 pmol/liter, and the intraassay
coefficient of variationwas below5%at 20pmol/liter. Active (N
terminal) GIP was assayed by RIA using a polyclonal antiserum
98171, raised in rabbits, that is N-terminally directed and does
not recognize N-terminally truncated peptides. It has a cross-
reactivity of 100%with human GIP1–42 and less than 0.1 with
human GIP3–42, GLP-1 (7–36) amide, GLP-1 (9–36) amide,
GLP-2 (1–33), GLP-2 (3–33), and glucagon. The detection limit
is approximately 5 pmol/liter, with an ED50 of 48 pmol/liter.
Intra- and interassay coefficients of variation are less than 6%
and less than 15%, respectively (21).
Calculations
Glucose fluxeswereexpressedperkilogramofFFMbecause this
normalization minimizes differences due to sex, obesity, and age
(22). During the last 20min of the tracer equilibration period, glu-
cose concentrations and [6,6-2H2]-glucose enrichment were stable
in all subjects. Therefore, EGP was calculated as the ratio of [6,6-
2H2]-glucose infusion rate to the plasma tracer enrichment (tracer-
to-tracee ratio, TTR6,6; mean of three determinations). After glu-
cose ingestion, the total glucose rate of appearance (RaT) was
calculated from TTR6,6 using Steele’s equation (23). Before apply-
ing Steele’s equation, plasma TTR6,6 data were smoothed using a
spline fitting to stabilize the calculation of derivatives. The plasma
glucoseconcentrationresulting fromtheabsorptionof ingestedglu-
cose (exogenous glucose concentration) was calculated from the
product of total plasma glucose concentration and the ratio of
plasma [1-2H]-glucose TTR to the [1-2H]-glucose TTR of the in-
gested glucose. The plasma glucose concentration resulting from
endogenous glucose releasewas obtained as the difference between
total and exogenous glucose concentration. TTR of endogenous
glucose and oral glucose rate of appearance (RaO)were calculated
as described (23). The tracer-determined rate of glucose disappear-
ance (Rd) provided a measure of insulin-mediated total-body glu-
cose disposal, whereas the metabolic clearance rate of glucose
(MCR) provided another index of insulin sensitivity.
-Cell function was assessed with the use a previously de-
scribed mathematical model (24). Briefly, the model consists of
a model fitting the glucose concentration profile (to smooth and
interpolate plasma glucose concentrations), a model describing
the dependence of insulin (or C-peptide) secretion on glucose
concentration, and a model of C-peptide kinetics, i.e. the two-
exponential model proposed by Van Cauter et al. (25), in which
the model parameters are individually adjusted to the subject’s
anthropometric data. For the purpose of the present analysis, we
report themost important parameter, namely, the dose-response
relationship between insulin release and plasma glucose concen-
trations; themean slope of the dose-response function is taken to
represent -cell glucose sensitivity.
Insulin sensitivitywas estimated from the plasma glucose and
insulin responses to MTT between times 0 and 120 min by the
Oral Glucose Insulin Sensitivity (OGIS), a validated index (26).
Areas under time-concentration curves (AUC) were calculated
by the trapezium rule.
The incretin effect was operationally defined as the ratio of
oral to iv (O/IV) for all insulin secretion measures (4). This cal-
TABLE 1. Anthropometric and metabolic
characteristics of the study subjects
Controls T2D Pa
n (males/females) 7 (4/3) 47 (14/33)
Age (yr) 59.6  6.0 56.1  7.3 ns
BMI (kg  m2) 28.8  2.3 29.9  4.2 ns
HbA1c (%) 5.7  0.2 7.4  0.8 0.0001
FPG (mmol/liter) 5.56  0.33 9.28  1.89 0.0001
Fasting plasma insulin
(pmol/liter)
41 22 67 53 0.03
Fasting plasma
glucagon (pg/ml)
48  15 53  21 ns
OGIS (ml  min1 
kgFFM
1)
9.47  1.22 6.33  1.15 0.0001
Data are expressed as mean  SD or median interquartile range. ns,
Nonsignificant.
a For the comparison of controls vs. T2D patients, by Mann-Whitney
test.
TABLE 2. Glucose concentrations and fluxes during the meal test (Meal) and the isoglycemic test (Iso-G)
Study Controls
Placebo Sitagliptin
PaPre Post Pre Post
Glucose AUC (g  dl1  5 h) Meal 35.0  1.7b 63.0  12.6 64.7  16.3 59.5  11.3 48.8  9.0 0.0001
Iso-G 35.8  1.6 64.9  13.1 66.3  16.1 60.9  11.0 50.0  9.1 0.0001
Glucose incremental AUC (g  dl1  5 h) Meal 6.1  1.5b 16.4  5.8 17.8  7.1 16.3  7.0 10.8  5.6 0.0001
Iso-G 6.6  2.2b 15.5  6.9 18.0  7.5 15.8  7.1 10.0  5.5 0.0001
RaO AUC (g  5 h) Meal 55  6 53  5 56  9 55  11 50  13 0.017
Intravenous glucose AUC (g  5 h) Iso-G 51  16 50  15 53  12 48  11 43  13 0.015
Fasting EGP (mol  min1  kg1) Meal 9.0  1.6 9.2  1.6 9.0  1.6 9.1  1.3 8.7  1.2 0.02
EGP AUC (g  5 h) Meal 21  8 22  8 21  8 22  6 19  6 0.16
RaT AUC (g  5 h) Meal 76  9 74  8 77  13 77  11 69  13 0.005
Rd AUC (g  5 h) Meal 77  10 72  9 74  17 74  11 68  14 0.043
Fasting MCR (ml  min1  kg1) Meal 1.67  0.32b 1.10  0.19 1.08  0.25 1.17  0.23 1.24  0.18 ns
MCR AUC (ml  kg1  5 h) Meal 783  130b 438  117 432  116 460  134 505  138 0.08
Data are expressed as mean  SD. Pre, Before treatment; post, after treatment; ns, nonsignificant.
a For the placebo-adjusted difference between baseline and 6 wk of sitagliptin treatment.
b P  0.0001 for the comparison of controls vs. all diabetic patients by Mann-Whitney test.
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culation cancels the impact of glucose levels per se, which were
matched by protocol.
Statistical analysis
Data are given as mean SD or median [interquartile range]
for non-normally distributed variables. The latter were trans-
formed into their natural logarithms for use in statistical testing.
Differences between control and T2D subjects were analyzed by
Mann-Whitney test. Treatment responses were analyzed by an
analysis of covariance model with change from baseline as the
outcome variable and baseline values and prior antidiabetic
treatment as covariates. The time-course of glucose fluxes was
analyzed by repeated measures ANOVA, modeling treatment
(sitagliptin vs. placebo), week (baseline and end of study), and
MTT time as factors. Univariate associations were tested by
Spearman regression (rho value). A P value 0.05 was consid-
ered statistically significant.
Results
Three of the 50 patients dropped out after randomization
(two from the placebo group—one due to hyperglycemia,
the other due to personal reasons; one from the sitagliptin
group after an adverse event, i.e. canalithiasis, not drug-re-
lated). The other 47 patients completed all studies. Age and
BMI were similar between patients and controls, whereas
baseline HbA1c, fasting glucose, and insulin concentrations
were higher in patients; all baseline characteristics were sim-
ilar between patients randomized to sitagliptin or placebo.
Insulin sensitivity was markedly reduced in
patients (Table 1).
Both in the fasting state (from8.94 1.67
to 8.08  1.31 mmol/liter; P  0.01 for the
placebo-adjusted change) and in response to
the meal (P  0.0001 for placebo-adjusted
total and incremental AUC), plasma glucose
concentrations were lower with sitagliptin
than placebo (Supplemental Fig. 1, published
on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org; and
Table 2).
Glucose fluxes
At baseline, RaO peaked at 30 min, with
a smaller secondary rise at 120–180min, in
similar amounts and time-course in controls
and patients. At the end of 5 h, oral glucose
was still appearing in the peripheral circu-
lation at rates significantly different from
zero in all groups;RaO totaled three fourths
of the load, on average, in patients and con-
trols alike. Sitagliptin treatment was asso-
ciated with a lower RaO (change from pre-
treatment, difference  353  915 vs.
146 601mol  kg1  5 h of placebo;P 0.017), but
without distortion in the time pattern (Fig. 1). Baseline
fasting EGP was similar between placebo and sitagliptin;
at wk 6, it was lower after sitagliptin than placebo (Table
2). During the meal, EGP was suppressed by approxi-
mately 50% on average in both controls and patients. In
the sitagliptin group,EGPsuppressionafter treatmentwas
greater than in the placebo group (difference AUC 
181 448 vs.41 409 mol  kg1  5 h); although
short of statistical significance as AUC, the difference was
significant (P 0.006) when analyzed as time-course (by
repeated measures ANOVA) (Fig. 2). Consequently, total
rate of glucose appearance (RaT RaO EGP) and dis-
appearance (Rd) were both reduced by sitagliptin treat-
ment (Table 2). The total amount of glucose infused over
the 5 h of the Iso-G was similar in patients and controls;
after sitagliptin but not placebo, this amount was signif-
icantly reduced (by9%)becauseof the lowerglucose levels
achieved. The baseline glucose MCR was reduced in pa-
tients compared with controls in the fasting state; during
the meal, MCR increased by approximately 50% in con-
trols and by only approximately 30% in the patients. At 6
wk, meal-induced MCR tended to be higher in the sita-
gliptin group than the placebo group (P  0.08 for the
placebo-adjusted change) (Table 2). A similar approxi-
mately 10% improvement in OGIS (6.31 1.09 vs. 7.13
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FIG. 1. RaO and EGP in T2D patients before (pre) and after (post) 6 wk of treatment
with sitagliptin (A) or placebo (B). The shaded areas are the mean  SE for the control
group.
J Clin Endocrinol Metab, August 2012, 97(8):2818–2826 jcem.endojournals.org 2821
1.28 ml  kgFFM
1  min2; P  0.004 for the placebo-ad-
justed change) supports improved insulin sensitivity.
-Cell function
The insulin response to the meal was assessed as the in-
sulin AUC, incremental AUC, and total output. For none of
these measures was there any difference between controls
and patients at baseline; furthermore, neither sitagliptin nor
placebo changed these parameters significantly, except for
the incremental insulinAUC,whichwas lower after sitaglip-
tin vs. placebo. Likewise, when these parameters were cal-
culated for the isoglycemic experiment, theywere all system-
atically lower than seen with the meal, but
without differences between controls and pa-
tients or between treatments. Fasting insulin
secretion rates were comparable throughout
(Table 3).
In contrast, when -cell functionwas an-
alyzed as model-derived -cell glucose sen-
sitivity (-GS), this was markedly lower at
baseline in patients compared with controls
(Table 3). Moreover, sitagliptin treatment
was associated with a significant improve-
ment in -GS compared with placebo dur-
ing both the meal and the isoglycemic study
(Fig. 2).
Because of the matched glucose levels
during the isoglycemic study and meal test,
the incretin effect could be quantified as the
O/IV of the insulin secretory responses. As
shown in Table 3, for all concentration and
secretion parameters, the incretin effect was
only marginally (and not significantly) re-
duced in patients as comparedwith controls
at baseline and was not significantly changed by treat-
ment. The same was true of the incretin effect on -GS
(Table 3).
Hormones
The glucagon response to the meal was higher in pa-
tients as comparedwith controls (Fig. 3). After sitagliptin,
the glucagon response decreased (AUC from19.6 7.5 to
17.3  7.1 ng  ml1  5 h; P  0.04 for the placebo-ad-
justed change). On the isoglycemic study, glucagon levels
were suppressed in both controls and patients; sitagliptin
induced a nonsignificant decrease in this response.
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FIG. 2. Insulin secretion rates against concomitant plasma glucose concentrations
during the MTT and the isoglycemic glucose infusion in controls (con) and in T2D
patients before (pre) and after (post) 6 wk of treatment with sitagliptin (A) or
placebo (B).
TABLE 3. Insulin concentrations,  -cell function parameters and incretin effect during the MTT and Iso-G
Study Controls
Placebo Sitagliptin
PaPre Post Pre Post
AUCInsulin (U  liter
1  5 h) Meal 10.6 16.3 11.9 7.9 12.1 7.8 11.3 12.0 10.3 10.5 ns
Iso-G 4.7 3.4 5.0 4.2 5.0 4.5 6.0 4.1 6.0 3.9 ns
O/IV 2.4 1.0 2.3 0.9 2.3 0.9 2.2 0.6 2.0 0.7 ns
Incremental AUCInsulin (U  liter
1  5 h) Meal 8.7 14.7 7.4 5.1 7.1 5.6 8.4 10.5 7.6 9.3 0.01
Iso-G 3.0 1.5 1.7 1.3 1.6 1.8 2.2 2.4 2.4 2.2 ns
O/IV 3.4 3.7 4.4 5.0 5.0 3.0 4.1 2.2 3.4 1.5 ns
Fasting ISR (nmol  m2  5 h) Meal 33 9 32 17 29 18 33 13 30 19 ns
Iso-G 36 23 35 17 30 20 32 13 32 8 ns
Total insulin output (nmol  m2  5 h) Meal 82 59 74 35 77 36 74 45 82 46 ns
Iso-G 45 26 50 19 48 22 51 26 52 14 ns
O/IV 2.0 0.5 1.7 0.6 1.7 0.5 1.7 0.4 1.6 0.6 ns
-GS (pmol  min1  m2  mM1) Meal 98 115b 33 30 35 33 31 36 53 52 0.01
Iso-G 45 35b 15 12 14 11 13 10 24 27 0.002
O/IV 2.9 1.2 2.1 1.4 2.5 2.2 2.6 1.4 2.1 1.5 ns
Data are expressed as median interquartile range. Pre, Before treatment; post, after treatment; ISR, insulin secretion rate; ns, nonsignificant.
a For the placebo-adjusted difference between baseline and 6 wk of sitagliptin treatment.
b P  0.0001 for the comparison of controls vs. all diabetic patients by Mann-Whitney test.
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At baseline, total GLP-1 response was blunted in T2D
(AUC 4.1 [1.6] vs. 8.1 [6.6] nmol  liter1  5 h of con-
trols,P0.003; incrementalAUC1.6 [1.5] vs.3.6 [4.5]
nmol  liter1  5 h, P  0.01), as was the GIP response
(incremental AUC  9.3 [4.8] vs. 14.5 [3.9] nmol  li-
ter1  5 h; P  0.01). At 6 wk, the GIP response was
decreased with sitagliptin (3.82 3.10 vs. 1.11 3.37
nmol  liter1  5 h of placebo; P  0.004), whereas the
total GLP-1 response was unchanged (0.94  1.65 vs.
0.56  2.15 nmol  liter1  5 h; P  nonsignificant).
Intact GLP-1 response was lower in controls (0.50
[0.30] nmol  liter1  5 h) than in patients (0.65 [0.49]
nmol  liter1  5 h; P  0.05). After treatment, intact
GLP-1 increasedwith sitagliptin (from0.74 [0.66] to 1.18
[0.70] nmol  liter1  5 h) but not placebo (from 0.55
[0.43] to 0.49 [0.58] nmol  liter1  5 h; P  0.005, pla-
cebo-adjusted). Intact GIP response was marginally
smaller (P  0.06) in patients than controls (5.4 [1.8] vs.
7.0 [2.1] nmol  liter1  5 h). After
treatment, intact GIP increased with
sitagliptin (from 5.6 [1.9] to 8.9 [3.6]
nmol  liter1  5 h) but not placebo
(from 4.8 [1.4] to 5.5 [1.3] nmol  li-
ter1  5 h; P  0.0001, placebo-ad-
justed) (Fig. 3).
Correlations
In the whole diabetic cohort, the
changes in fasting glycemia at 6wkwere
reciprocally related to the changes in
OGIS (rho  0.74; P  0.0001) and
-GS (rho  0.39; P  0.008). Like-
wise, the treatment-induced changes in
the incrementalglucoseAUConthemeal
test were reciprocally related to both
OGIS (rho  0.40; P  0.007) and
-GS (rho0.29; P 0.05).
Discussion
The T2D patients recruited for this
study were middle-aged, overweight/
obese, and in fair glycemic control.
They showed the typical phenotype of
insulin resistance and -cell dysfunc-
tion butwere not insulinopenic. After a
4-wk pharmacological washout, 6 wk
of sitagliptin monotherapy lowered
both fasting and postmeal plasma glu-
cose levels.
The mechanisms underlying the im-
proved glucose control were multiple:
1) the systemic recovery of the glucose present in the meal
was lower, by roughly 7 g over 5 h; 2) EGP was more
effectively suppressed during meal absorption; 3) -cell
glucose sensitivity was 50% improved, and insulin sensi-
tivitywas 10% improved; and 4) the glucagon response to
the meal was suppressed, whereas the intact GLP-1 and
GIP fractions were increased, and total GIP levels were
decreased. All these effects were significantly different
from the placebo-induced changes and were observed in
the absence of body weight changes.
The reduced appearance of oral glucose was unex-
pected. DPP-4 inhibitors are known not to slow down
gastric emptying to any meaningful extent (10, 27), and
even the inhibitory effect of GLP-1 on gastric motility is
subject to tachyphylaxis (28). Accordingly, in our sita-
gliptin-treated patients the time-course of oral glucose ap-
pearance was not distorted—as would most likely be the
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FIG. 3. Plasma glucagon concentrations during the MTT and the isoglycemic glucose infusion
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(A and C) or placebo (B and D). Time-course of intact GLP-1 and GIP concentrations in
response to the meal (E and F).
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case with slower gastric emptying—but only shifted
downward (Fig. 2). The missing glucose might eventually
appear in the circulation, albeit at later times; however, the
absorptive capacity of the intestine is very large (29),
and there is no evidence that it is reduced in diabetes.
Therefore, a potential explanation for this finding is
that after sitagliptin treatment, more ingested glucose
was taken up in the splanchnic bed by enterocytes or
hepatocytes. That blockade of endogenous GLP-1/GIP
degradation increases hepatic glucose uptake, without
changes in nonhepatic glucose uptake, insulin secretion/
clearance, or glucagon inhibition, has been documented
in the conscious dog using vildagliptin and GLP-1 in-
fusion into the liver (30).
The improved suppression of EGP during the meal is
plausibly linkedwith the reduced rise in glucagon levels in
the sitagliptin group, confirming that the ability of GLP-1
to restrain -cell hyperactivity in diabetes is an important
component of its antihyperglycemic effect [as also ob-
served after vildagliptin (12, 31)].Moreover, higher levels
of intact GLP-1might directly suppress EGP, as suggested
by a study in normal subjects (32). This is of special im-
portance under conditions, such as a mixed meal, where
glucagon release is stimulated rather than suppressed (as
occurs with oral glucose alone), especially in diabetic
patients.
With regard to insulin secretion, fasting secretion rate
and total output in response to the meal were similar in
patients and controls, as was the integrated insulin release
during the 5 h of isoglycemic glucose infusion. Further-
more, neither sitagliptin nor placebo changed these pa-
rameters (Table 3). However, when insulin secretion was
related to the concomitant plasmaglucose concentrations,
the resulting -cell glucose sensitivity parameter was sig-
nificantly improved by sitagliptin treatment to levels
reaching 50% of those of controls (Table 3). Similar re-
sults have been observed with sitagliptin and vildagliptin
using the iv glucose tolerance test-minimal model, MTT,
or the hyperglycemic clamp technique (13, 33, 34).
In controls, the incretin effect averaged 2 when calcu-
lated as theO/IV glucose-induced insulin secretion, which
corresponds to 45 [17]% (median [interquartile range]) of
orally related secretion being induced by mechanisms
other than the glycemic excursions. In the diabetic group
as a whole, the incretin effect was marginally reduced (36
[18]%) as compared with controls. The lack of statistical
significance of this difference could be due to the small size
of the control groupand the large variability of the incretin
effect. However, it should be mentioned that our controls
were matched to the patients by age and BMI; because
obesity independently weakens the incretin hormone re-
sponse and incretin effect (5), the defect in well-controlled
T2D may be smaller than previously thought. It is also
possible that the incretin defect is attenuated by the use of
a mixed meal as opposed to the habitual quantification
based on oral glucose alone.
None of the parameters describing the classical incretin
effect (insulin area, incremental insulin area, insulin out-
put) were significantly modified by sitagliptin treatment,
not even as a trend. This result confirms the findings ob-
tained by Vardarli et al. (16) using the oral glucose toler-
ance test/Iso-G protocol in a small group of well-con-
trolled T2D patients after 13 d of vildagliptin in a
crossover design.Thepresent results extend those findings
by showing that-cell glucose sensitivitywas improvedon
both the mixedmeal and the Iso-G (Fig. 3), such that their
ratio, also an expression of the incretin effect, was un-
changed. The ability of chronic sitagliptin therapy to spe-
cifically improve glucose sensing regardless of the stimulus
is a novel observationwhose clinical relevance stems from
the fact that -cell glucose sensitivity is the major deter-
minant of glucose control (35) (cf., the correlation be-
tween changes in -GS and fasting and postmeal glycemia
in thepresentdataset).Because ivglucosedidnot stimulate
GLP-1 (or GIP) release (data not shown), it is difficult to
ascribe the improved -cell sensitivity to iv glucose to
acute gastrointestinal hormone changes. Therefore, either
the effects of GLP-1 on the -cell are carried over from the
stimulated state of 1 d to the fasting state of the next day
(as suggested in Ref. 16), or the changes in -cell function
are the nonspecific consequence of partially removing glu-
cose toxicity (or a combination of these twomechanisms).
It should be noted that, in the absence of an equipoised
comparator, it is impossible to discriminate an effect of
reduced glucose toxicity from a pharmacological effect.
With regard to this, it is of interest thatD’Alessio et al. (13)
have reported an improvement of -cell function in the
fasting state (i.e. in response to iv glucose) in parallel with
unchanged incretin concentrations, suggesting metabolic
benefits of DPP-4 inhibition beyond increased incretins
levels.
The Rd was similar between patients and controls on
account of the higher plasma glucose levels in the patients
(Table 2). After sitagliptin, Rd was lower than after pla-
cebo, owing to the lower plasma glucose levels. In fact,
when accounting for the mass-action effect of glycemia,
the MCR tended to be higher with sitagliptin (Table 2).
Because insulin secretionwas not differentially affected by
sitagliptin vs. placebo, this finding must be explained by
enhanced insulin action. This is supported by the OGIS
parameter, also indicating increased insulin sensitivity in
sitagliptin-treated patients, as also observed after 6 wk of
vildagliptin (31). Because the weight of evidence indicates
that GLP-1 does not directly enhance insulin action on
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peripheral glucose uptake (12, 36–40), the improved in-
sulin sensitivity in our sitagliptin-treated patients may re-
sult from abatement of glucose toxicity.
In summary, chronic treatment with sitagliptin repro-
duces the acute inhibitory effect that a single dose of DPP-4
inhibitor induces during a meal ingestion on EGP, glucagon
release, and improved -cell glucose sensitivity, thereby re-
straining glucose excursions in patients with type 2 diabetes
(12,15).Additionally, chronic treatment lowersoral glucose
appearance, probably by augmenting splanchnic glucose re-
tention, improves insulin sensitivity, and potentiates -cell
function in response to iv glucose. Because the incretin effect
isnotalteredbysitagliptin, thesemechanismsofglucosecon-
trolmay be, at least in part, explained by removal of glucose
toxicity.
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Abstract
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) lowers glu-
cose levels by potentiating glucose-induced insulin secretion and
inhibiting glucagon release. The question of whether GLP-1
exerts direct effects on the liver, independently of the hormonal
changes, is controversial.We testedwhether an exogenousGLP-
1 infusion, designed to achieve physiological postprandial lev-
els, directly affects endogenous glucose production (EGP) under
conditions mimicking the fasting state in diabetes.
Methods In 14 healthy volunteers, we applied the pancreatic
clamp technique, whereby plasma insulin and glucagon levels
are clamped using somatostatin and hormone replacement. The
clamp was applied in paired, 4 h experiments, during which
saline (control) or GLP-1(7–37)amide (0.4 pmolmin−1kg−1)
was infused.
Results During the control study, plasma insulin and gluca-
gon were maintained at basal levels and plasma C-peptide
was suppressed, such that plasma glucose rose to a plateau
of ∼10.5 mmol/l and tracer-determined EGP increased by
∼60%. During GLP-1 infusion at matched plasma glucose
levels, the rise of EGP from baseline was fully prevented.
Lipolysis (as indexed by NEFA concentrations and tracer-
determined glycerol rate of appearance) and substrate
utilisation (by indirect calorimetry) were similar between
control and GLP-1 infusion.
Conclusions/interpretation GLP-1 inhibits EGP under condi-
tions where plasma insulin and glucagon are not allowed to
change and glucose concentrations arematched, indicating either
a direct effect on hepatocytes or neurally mediated inhibition.
Keywords Endogenous glucose production . GLP-1 . Liver
glucose output . Pancreatic clamp
Abbreviations
EGP Endogenous glucose production
FFM Fat-free mass
GLP-1 Glucagon-like peptide-1
Ra Rate of appearance
Rd Rate of disappearance
RQ Respiratory quotient
SRIF Somatotropin release-inhibiting factor
TTR Tracer:tracer ratio
Introduction
The classical physiological actions of glucagon-like peptide-1
(GLP-1) include potentiation of glucose-induced insulin se-
cretion, suppression of glucagon release, inhibition of gastric
emptying and enhancement of satiety [1]. The opposing
effects on insulin and glucagon secretion result in reductions
of endogenous glucose production (EGP) and blood glucose
levels. The question of whether the hormone exerts direct
actions on insulin target tissues, i.e. liver, adipose and skeletal
muscle tissue, is controversial.
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GLP-1 receptors were originally not found in human liver
[2]. However, the results of more recent in vitro studies are
compatible with the presence of GLP-1 receptors in human
hepatocytes [3, 4]. Additionally, GLP-1 has been reported to
increase glucose transporter levels and insulin-mediated
glucose uptake in 3T3-L1 adipocytes [5], and glucose
transport in cultured human myocytes [6]. GLP-1 receptor
mRNA has also been described in neurons in the hepatic
portal region [7].
Studies in humans are scarce and inconsistent. Hvidberg
et al [8] concluded that the decrease in EGP and increase in
glucose rate of disappearance (Rd) during GLP-1 infusion in
healthy volunteers could be entirely explained by the
changes in insulin and glucagon concentrations. Likewise,
others [9, 10] reported that the effects of GLP-1 on EGP and
glucose disposal were abolished when co-infusing somato-
tropin release-inhibiting factor (SRIF), thereby blocking the
insulin and glucagon response to GLP-1. The same conclu-
sion was reached in experiments using somatostatin infusion
during a high-dose hyperinsulinaemic–euglycaemic clamp
[11]. In contrast, in uncontrolled studies in healthy volun-
teers, Prigeon et al used the pancreatic clamp technique to
show that fasting EGP and plasma glucose concentrations
declined ∼20% upon adding a short-term (60 min), high-
dose GLP-1 infusion [12].
With regard to the effects on whole-body glucose dis-
posal, early studies [8, 11] found no direct effect of GLP-1,
i.e. no effect that was independent of changes in insulin
concentrations, on the potentiation of glucose disappear-
ance. Subsequent work, however, reported an independent
effect of GLP-1 on the promotion of glucose disposal in
non-diabetic [13], obese [14] or diabetic participants [15].
Another potential extrapancreatic action of GLP-1 is on
lipid metabolism. Although GLP-1 receptors are not pro-
duced in adipocytes, the peptide appeared to stimulate lipoly-
sis in fat cells from obese participants [16]. In contrast,
using in situ microdialysis and local GLP-1 perfusion,
Bertin et al [17] detected no change in lipolysis or blood
flow in adipose tissue or muscle. Finally, intracerebroven-
tricular GLP-1 administration in mice [18] and peripheral
GLP-1 infusions in man [19] increased sympathetic activity.
It has not yet been determined whether this sympatho-
excitatory action is mediated by insulin.
Here, we reassessed the in vivo direct effects of physiological
GLP-1 elevations, created by exogenous administration
of GLP-1(7-37)amide, on EGP, glucose disposal, lipolysis and
indices of sympathetic activation in healthy volunteers.
Methods
Participants Healthy volunteers (n014) aged 18 to 60 years
and with a BMI <30 kg/m2 participated in the study
(Table 1). The nature and purpose of the study were care-
fully explained to all participants before they provided
written consent to participate. The study procedures were
approved by the Institutional Ethics Committee of Pisa
University.
Study design and protocol Each participant underwent two
studies within 7 to 14 days of each other. In each study, after
an overnight (12 h) fast, catheters were inserted into an
antecubital vein (for infusion of all test substances) and
retrogradely into a vein on the dorsum of the hand for blood
withdrawal. The hand was heated to 55°C to allow sampling
of arterialised venous blood. At 09:00 hours primed contin-
uous infusions of 6,6-[2H2]glucose (0.28 μmolmin
−1kg−1;
prime 28.0 μmol/kg×[fasting plasma glucose/5]) and
[2H5]glycerol (0.11 μmolmin
−1kg−1; prime 1.65 μmol/kg)
were started and continued for the duration of the study
(6 h). At time 0, constant infusions of SRIF (450 μg/h)
and glucagon (1 ngmin−1kg−1) were begun and continued
for 4 h. At time 20 min, a primed continuous insulin
(Humulin R; Eli Lilly, Indianapolis, IN, USA) infusion
(12 pmolmin−1m−2) was initiated, along with a saline drip.
During the second study, from time 60 min onward, saline
was replaced by a constant GLP-1(7–37)amide infusion
(0.4 pmolmin−1kg−1), while the plasma glucose profile of
the first study was closely reproduced through a variable
intravenous glucose infusion, using an algorithm developed
ad hoc [20]. Plasma insulin, C-peptide, glycerol, glucagon and
NEFA concentrations, as well as 6,6-[2H2]glucose and [
2H5]
glycerol enrichment were measured at pre-determined intervals.
In 13 of 14 participants, indirect calorimetry was used to
measure the respiratory quotient (RQ) and substrate oxida-
tion rates, using a continuous, open-circuit canopy system
(Metabolic Measurement Cart Horizon; SensorMedics,
Table 1 Anthropometric and metabolic characteristics
Characteristic Mean±SD Range
n 14 –
Men (n) 11 –
Women (n) 3 –
Age (years) 26±2 21–30
Waist (cm) 84±5 75–91
Hip (cm) 105±7 96–114
BMI (kg/m2) 25.5±3.7 19.0–30.0
Fasting glucose (mmol/l) 5.2±0.3 4.6–5.8
Total cholesterol (mmol/l) 4.1±0.5 3.5–5.5
HDL-cholesterol (mmol/l) 1.5±0.3 1.2–2.0
Triacylglycerol (mmol/l) 0.7±0.2 0.4–1.0
AST (μkat/l) 0.37±0.08 0.25–0.55
ALT (μkat/l) 0.28±0.07 0.15–0.43
AST, aspartate aminotransferase; ALT, alanine aminotransferase
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Anaheim, CA, USA). These measurements were collected
during the basal period (−40 to 0 min) and over the last
40 min of the study.
Fat-free mass (FFM) was evaluated using a body com-
position analyser (TB-300; Tanita, Tokyo, Japan); fat mass
was then obtained as the difference between body weight
and FFM.
Assays Plasma glucose was measured by the glucose oxi-
dase technique (Beckman Glucose Analyzers; Beckman,
Fullerton, CA, USA). Plasma insulin and C-peptide were
measured by an electro-chemiluminescence assay on a
COBAS e411 (both from Roche, Indianapolis, IN, USA).
Glucagon was measured by radioimmunoassay (Millipore,
Billerica, MA, USA). The tracer enrichment of 6,6-[2H2]
glucose and [2H5]glycerol was measured by gas chromatog-
raphy/mass spectrometry as previously described [21].
NEFA and glycerol were measured using an enzymatic
colorimetric system (Syncron; Beckman).
Plasma samples were assayed for intact GLP-1 using a
GLP-1 ELISA kit following the manufacturer’s protocol
(Millipore). The detection limit for this assay is 2 pmol/l
in 100 μl plasma.
Calculations Glucose fluxes were expressed per kg of FFM.
During the last 20 min of the basal tracer equilibration
period, plasma glucose and glycerol concentrations, as well
as 6,6-[2H]glucose and [2H5]glycerol enrichment (expressed
as tracer:tracer ratio [TTR]) were stable in all participants.
Therefore, EGP and the glycerol rate of appearance (Ra) were
calculated as the ratio of tracer infusion rate to the plasma TTR
(mean of three determinations). After starting SRIF infusion,
the total glucose and glycerol Ra were calculated using
Steele’s equation, as previously described [22]. Before apply-
ing Steele’s equation, plasma TTR data for 6,6-[2H]glucose
were smoothed using a spline fitting approach to stabilise the
calculation of the derivative of enrichment. The plasma
glucose concentration resulting from EGP was obtained as
the difference between total and exogenous glucose concen-
trations. The tracer-determined Rd provided a measure of
insulin-mediated total-body glucose disposal.
Substrate oxidation rates were calculated from gas
exchange measurements as described [23]. Areas under the
time–concentration curve were calculated by the trapezium
rule.
Statistical analysis Data are given as mean±SD. Differences
between saline and GLP-1 infusion were analysed by
Wilcoxon’s signed-rank test. The time course of glucose
fluxes was analysed by two-way, doubly repeated-measures
ANOVA, modelling infusion (GLP-1 vs saline) and experi-
mental time (and their interactions) as factors. A value of
p≤0.05 was considered statistically significant.
Results
In the control study, glucose levels began to rise ∼1 h into
the SRIF infusion and levelled off at ∼10.6 mmol/l during
the last hour; this time course was reproduced in the GLP-1
study (Fig. 1a). Upon starting SRIF infusion, insulin con-
centrations initially dropped from baseline, then returned to
the fasting value by ∼60 min in the control and test study
(p00.40). During the last hour, however, plasma insulin
levels were higher under GLP-1 infusion than under control
conditions (38±18 vs 25±7 pmol/l, p<0.002), probably
reflecting beta cell escape from SRIF blockade, as con-
firmed by the C-peptide time course (Fig. 1b, d). Plasma
glucagon concentrations also decreased from baseline fol-
lowing the start of SRIF, then rose gradually and slightly
until the end of the study, without significant (p00.18)
differences between saline and GLP-1 infusion (Fig. 1c).
The glucose Ra rose from baseline under saline and GLP-1
infusion, the time-pattern of the rise being similar in both
(Fig. 2a). Exogenous glucose infusion rates, however, were
higher with GLP-1 than saline infusion (p<0.0001); conse-
quently, EGP was lower throughout the 3 h of GLP-1
infusion (Fig. 2b). Over the time-period when pancreatic
hormones were closely superimposable between saline and
GLP-1 (i.e. between 60 and 180 min), EGP was 27% lower
(by 3.6 μmol kg−1min−1, 95% CI 2.4, 4.8, p<0.0001) with
GLP-1 than with saline (Fig. 2c). The glucose Rd increased
slightly only during the last hour of both studies (p<0.01 for
saline and GLP-1), without differences between saline and
GLP-1 (Fig. 2d).
Plasma NEFA increased from baseline until 40 min (from
0.53±0.10 and 0.54±0.03 to 0.70±0.09 and 0.72±0.04
mEq/l, respectively, for saline and GLP-1), subsequently
dropping below the basal levels, with no difference between
the two studies (AUC0–240 min 115.5±13.2 vs 110.0±9.6
mEq/l×240 min, p00.65) (Fig. 3a). The glycerol Ra averaged
2.72±0.24 and 3.11±0.22 μmolmin−1kg−1 during the base-
line period of the saline and GLP-1 studies, respectively.
During the infusion period, after an initial slight increase, the
glycerol Ra declined slowly over time and to similar degrees
under saline and GLP-1, to reach values somewhat lower with
the latter (2.01±0.92) than the former (2.43±2.01) during the
final hour of the study (Fig. 3b).
The RQ did not change between baseline (0.75±0.02 vs
0.76±0.02, saline vs GLP-1, p00.84) through to the final
hour of the study (0.76±0.03 vs 0.78±0.01, p00.33).
Accordingly, baseline rates of carbohydrate and lipid oxida-
tion were similar between the two study days and did not
change significantly with either saline or GLP-1 infusion
(Fig. 4a, b).
During saline infusion, there was no change in intact
GLP-1, whereas GLP-1 infusion raised the plasma levels
of intact hormone threefold (AUC60–180 min 239±515 vs
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441±200 pmol/l×120 min, p00.001). In the pooled
saline and GLP-1 data, there was a significant, albeit weak,
(ρ0−0.49, p00.01) reciprocal relationship between EGP and
intact GLP-1 concentrations measured over the 60–180 min
time interval.
Discussion
The present studies demonstrate that exogenous GLP-1
inhibits EGP by mechanisms that are largely independent
of changes in plasma glucose, insulin and glucagon levels.
Our experimental settings mimicked a diabetic state, i.e.
raised glucose concentrations and glucagon:insulin ratios.
Under these conditions, EGP was increased by ∼70% from
baseline, with plasma glucose rising to a plateau of
∼11.1 mmol/l. Replacing the saline with a GLP-1 infusion,
at a rate producing steady-state plasma levels approximately
in the postprandial range, caused a marked reduction of
EGP, which remained close to the starting levels. Interest-
ingly, insulin secretion during the 3rd hour of GLP-1 infu-
sion tended to rise, reflecting an escape of the beta cells
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from SRIF blockade. Therefore, quantification of the GLP-1
effect was restricted to the 2 h during which plasma insulin
and C-peptide levels were stable and superimposable
between the two studies (Fig. 1).
Previous reports [11, 24] that failed to observe a direct
inhibitory effect of GLP-1 on EGP under pancreatic clamp
conditions can probably be explained by their use of high
insulin replacement doses, which suppressed EGP com-
pletely [11] or by greater than 75% [24] in the control
studies, thereby leaving little room for a further inhibitory
action of GLP-1. In addition, we did not detect any effect on
whole-body glucose disposal, in accordance with previous
findings in healthy volunteers [9, 10]. However, we cannot
rule out the possibility that pharmacological doses of GLP-1
such as those used in previous studies [14–25] may promote
whole-body glucose uptake.
The only previous study that is indicative of a direct
effect of GLP-1 on EGP [12] was carried out in eight
healthy volunteers, who did not receive a saline infusion
control study. Moreover, exogenous GLP-1 was infused, for
a short time (60 min), at rates achieving total plasma GLP-1
concentrations that were twice as high as the steady-state
levels created by us. More importantly, the insulin replace-
ment (36 pmolmin−1kg−1) was at least twice as high as ours
(12 pmolmin−1kg−1), achieving two to three times higher
steady-state plasma insulin concentrations (thus raising plas-
ma glucose clearance by ∼50%). Thus, in Prigeon’s protocol
[12], the effect of short-lived, supraphysiological GLP-1
concentrations was tested under conditions of euglycaemia
and hyperinsulinaemia. With the present protocol, we
demonstrated that physiological GLP-1 increments prevent
EGP from increasing under conditions simulating the fast-
ing state in diabetes.
With regard to the mechanisms underlying the direct
action of GLP-1 on EGP, we measured lipolysis, as indexed
by glycerol Ra and plasma NEFA levels, and the pattern of
substrate utilisation (using indirect calorimetry). As no dif-
ferences, not even in trend, were observed between saline
and GLP-1 infusion, we can rule out the possibility that the
GLP-1-induced inhibition of EGP may have been due to a
reduction of NEFA delivery to the liver, which would stim-
ulate EGP via gluconeogenesis, or to an increase in sympa-
thetic drive, which would stimulate lipolysis and shift the
substrate oxidation pattern toward lipid oxidation.
In the present studies, the threefold elevated intact GLP-1
levels could have engaged hepatic GLP-1 receptors similar
to those on beta cells [4]. Alternatively, the GLP-1(28–
36)amide nonapeptide, which enters hepatocytes indepen-
dently of the GLP-1 receptor, may have suppressed glucose
production, as shown in mouse hepatocytes [26].
Experimental evidence for the possibility that GLP-1
may act on the liver by engaging sensors in the portal
circulation or nerve endings in the intestinal wall comes
from different animal species, but is convergent. Thus, in
insulin clamp experiments in GLP-1 receptor knockout
mice, insulin suppression of EGP was impaired and animals
became hyperglycaemic during exercise [27]. Nakabayashi
et al [28] measured changes in the impulse discharge rate of
the hepatic afferent vagus, following a bolus intraportal
GLP-1 injection in the rat. They found that the hormone
dose-dependently increased the firing rate and that this
effect could be cancelled by vagotomy. In catheterised dogs,
Johnson et al [29] found that direct infusion of GLP-1 into
the portal vein at matched plasma glucose, insulin and
glucagon concentrations resulted in a more positive net
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hepatic glucose balance, which is the net sum of EGP and
hepatic glucose uptake.
In summary, the present studies provide conclusive evi-
dence that a physiological action of GLP-1 inhibits glucose
production under conditions where its major controlling
signals, namely plasma insulin, glucagon and glucose con-
centrations, are not allowed to change. The effect is quanti-
tatively significant and does not appear to be mediated by
changes in substrate availability or sympathetic drive.
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Fig 6. Anthropometric and biochemical characteristics of T2DM 
subjects before and after BPD. 
Figure. 6 Data are means  SEM. Changes induced by BPD on A. Body mass 
index (BMI),  B. waist and hip ratio (W/H ratio), C. fasting plasma glucose (FPG) 
and  D. glycosylated haemoglobin (HbA1c). p = ANOVA for repetitive measures. 
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Figure 7: A. OGTT plasma glucose curves. FPG decreased after surgery. 2-hours OGTT 
plasma glucose also decreases  about 60% in both follow-up. Time course curves did not 
change after surgery and hyperglycaemia continues over 180 minutes. AUC glucose and 
incremental AUC glucose decreases as showed at panels B. and C. Curves: p=ANOVA 
for repetitive measures or bars: Wilcoxon signed test (*p=0.05; #p=0.01 and §p=0.001). 
P
la
s
m
a
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
 
Time (min) 
5 
10 
15 
20 
25 
0 30 60 90 120 150 180 
ANOVA p=0.0001 
0 
0.5 
1.0 
1.5 
2.0 
G
lu
c
o
s
e
 (
m
o
l.
l-
1
. m
in
-1
)
 
0 
1 
2 
3 
4 
G
lu
c
o
s
e
 (
m
o
l.
l-
1
. m
in
-1
)
 
OGTT - AUC glucose OGTT - Incremental AUC glucose B.
. 
C.
. 
§ § § § 
PRE Post 1 Post 2 PRE Post 1 Post 2 
85 
Post1 Post2 Pre 
Fig 8. Metabolic effects of  BPD on plasma glucose, insulin and 
C-Peptide.   
Figure 8. Data are mean ± SEM. A. plasma glucose curve decreases earlier after 
surgery and slightly on Post 2. B. plasma insulin curve decreases at first follow-up 
but showed an increment in plasma concentrations, mainly among the 120 minutes 
after stimulation. *p= ANOVA repeated-measures. 
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Fig 9. Metabolic effects of BPD on plasma glucagon, GLP-1 and FFA.  
Figure 9. Data are mean ± SEM. A. Glucagon, B. GLP-1 and C. FFA changes after 
biliopancreatic diversion. FFA showed levels similar to Control group at 1 year follow-up, 
whereas Glucagon and GLP-1 levels higher than. *p= ANOVA for repeated-measures 
(Pre, Post1 and Post2). 
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Fig 10. Changes in insulin secretion rate after BPD.  
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Figure 10. Data are mean ± SEM. A. plasma glucose concentration decreases during 
mixed meal without reached normal levels. B. insulin secretion rate (ISR) calculated using 
deconvolution of  C-peptide. Blue  shadow is Control group values ±1 SEM. 
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Fig .11: Effect of BPD on β-cell function.  
Figure 11. Data are mean ±SEM. Effect of BPD on β-cell function. Blue  
shadow is Control group values ±1 SEM. 
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Fig 12. Changes in -cell glucose sensitivity and rate sensitivity 
after BPD. 
Figure 12. Data are mean ±SEM Changes in -cell glucose sensitivity and 
rate sensitivity after BPD.§p=0.05 for the comparison vs. Control using Mann 
Whitney test. *p= for the comparison of  Pre, Post 1 and Post 2 by ANOVA 
repeated-measures. 
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Fig 13. Changes in insulin sensitivity after BPD. 
Figure 13. Data are mean ±SEM. Changes in insulin sensitivity (M value) after 
BPD.  *p≤0.05 for the comparison vs. Control using Mann Whitney test. 
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Figure 14. Effects of BPD on insulin sensitivity and on EGP during euglycaemic 
hyperinsulinemic clamp.§p≤0.05 for the comparison vs. Control using Mann 
Whitney test. *p= for the comparison of  Pre, Post 1 and Post 2 by ANOVA 
repeated-measures. 
Fig 14. Changes in insulin action after BPD. 
0 
20 
40 
60 
80 
100 
120 
140 
400 
600 
800 
1000 
1200 
1400 
-100 
100 
300 
500 
700 
M
/I
 (
µ
m
o
l. m
in
-1
. k
g
ff
m
-1
. p
m
o
l-1
) 
 
F
a
s
ti
n
g
 E
G
P
 (
µ
m
o
l. m
in
-1
) 
S
S
 c
la
m
p
 E
G
P
 (
µ
m
o
l. m
in
-1
) 
CT Pre P1 P2 
§ 
*p=0.0001 
*p=0.0004 
*p=0.0006 
§ 
§ 
§ § 
92 
0 
10 
20 
30 
40 
50 
0 30 60 90 120 150 180 210 240 270 300 
Time (min) 
P
re
h
e
p
a
ti
c
 i
n
s
u
li
n
:g
lu
c
a
g
o
n
 
(m
o
la
r 
ra
ti
o
) 
Figure 15. Data are mean ±SEM. Changes in prehepatic insulin:glucagon ratio 
induced by BPD. Blue shadow is Control group values ±1 SEM. *p= ANOVA 
repeated-measures for the comparison of  Pre, Post 1 and Post 2. 
*p=0.0001 
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Fig. 15. Changes in prehepatic insulin:glucagon ratio induced by BPD. 
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Table 1. Anthropometric and biochemical characteristics
#
 
 
# Data are mean  SEM. p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon signed 
rank test; * p≤0.05;  #p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
 
 
 
 
 Control Pre Post1 Post2 p1 p2 
BMI (kg/m
2
) 30.3 ± 3.6  28.3 ± 2.1 24.8  2.0§ 23.3  1.7§ 0.0007 0.0007 
Fasting glucose (mmol/l) 5.3 ± 0.1 12.2 ± 0.5
§ 
8.3 ± 0.6
§
 7.3 ± 0.4
§
 0.0007 0.0007 
Fasting Insulin (pmol/l) 63  7 105  35 46  6* 36  5# 0.003 0.0007 
Fasting Fat Free Acids ( µEq/l) 0.58  0.4 0.86  0.48§  0.71  0.36§  0.67  0.46 ns 0.0008 
Fasting Glucagon (ng/ml) 62.5  6.4 62.7  5.0 83.9   13.1 63.6  4.2 ns ns 
Fasting GLP-1 (pM) 55.5  7.5 48.3  5.9  57.1  7.5 53.2  5.0 ns ns 
Triglycerides (mmol/l) 1.0  0.1  1.9  0.2§ 1.9  0.2§ 1.9  0.3§ ns ns 
Total Cholesterol (mmol/l) 4.8  0.2 5.3  0.4 3.5  0.2§ 3.5  0.1§ 0.007 0.009 
HDL cholesterol (mmol/l) 1.0  0.1 1.2  0.1 1.0  0.1 1.1  0.1 0.01 ns 
LDL cholesterol (mmol/l) 3.2  0.2 3.3  0.4 1.5  0.1§ 1.8  0.1§ 0.002 0.01 
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Table 2. Metabolic effects of MMT on glucose metabolism, insulin and glucagon secretion and incretins
#
 
 Control Pre Post1 Post2 p1 p2 
AUC Glucose (mol
.
l
-1.
h
-1
) 1.8  0.4 5.5  0.1
§
 3.4  0.2§ 3.1  0.2§ 0.0007 0.001 
AUC Insulin (nmol
.
l
-1.
h
-1
) 94.4  12.1 71  9.9 39  2.6§ 45  5.9# 0.002 0.01 
AUC Glucagon (ng
.
ml
-1.
h
-1
) 19  1.7 21  1.6 28  3.8* 21  1.4 ns ns 
AUC GLP-1 (nM
.
l
.-1.
h
-1
) 16  1.9 17  1.8 28  3.1# 24  2.1# 0.002 0.03 
AUC Fat Free Acids (µEq
-1.
l
-1
) 69  4.8 163  16.3§ 124  16.3§ 85  11.0 0.05 0.001 
Inc. Glucose AUC (mol
.
l
-1.
h
-1
) 0.3  0.03 1.8  0.1§ 0.9  0.1§ 0.9  0.1§ 0.001 0.004 
Inc. Insulin AUC (nmol
.
l
-1.
h
-1
) 77  11.0 42  5.1* 25  2.7§ 34  6.1# 0.006 ns 
Mean Pre-hep. Ins./glucag. ratio 8.8 [8.9] 17.6 [10.5]* 13.4 [9.5] 9.6 [7.2] 0.01 0.001 
Inc. Glucagon AUC (ng
.
ml
-1.
h
-1
) 0.69  0.9 3.3  0.9 4.9  1.5* 1.6  1.2 ns ns 
Inc. AUC GLP-1 (nM
.
l
.-1.
h
-1
) - 0.2  0.1 2.3  0.5*  11.1  1.5§ 9.9  2.1# 0.001 0.004 
Inc. AUC  Fat Free Acids (µEq
-1.
l
-1
) -103  11.6 -149  22.0 -157  16.0* -118  15.2 ns ns 
#  Data are mean  SEM. p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon 
signed rank test; * p≤0.05;  #p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 3: β-cell function parameters# 
 
Control Pre Post 1 Post 2 p1 p2 
Fasting ISR (pmol
.
min
-1.
m
-2
) 84 [53] 115 [52]* 83 [22] 61 [38] ns 0.002 
Total insulin output (nmol
.
m
-2
) 77 [46] 80 [51] 62 [19]* 52 [37]* 0.04 0.06 
ß-cell glucose sensitivity  
(pmol
.
min
-1.
m
-2.
mM
-1
) 
96 [73] 19 [12]
§
 30 [14]
§
 31 [26]
§
 0.01 0.01 
Rate sensitivity (nmol
.
m
-2.
mM
-1
) 934 [981] 187 [247]
§
 605 [436]
#
 453 [453]
§
 0.004 0.04 
Potentiation factor (fold) 1.5 [0.5] 1.24 [0.44]
§
 1.11 [0.43]
#
 1.49 [1.09] ns 0.02 
Insulin clearance basal (l
.
min
-1.
m
-2
) ---- 2.85 ± 0.94 3.86 ± 0.78 3.22 ± 0.85 0.002 ns 
Insulin clearance MTT (l
.
min
-1.
m
-2
) ---- 1.65 ± 0.71 2.09 ± 0.52 1.91 ± 0.66 0.01 ns 
#  Data are median [IQR] or mean ± SEM .  p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 
by Wilcoxon signed rank test; * p≤0.05;  #p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 4: Euglycaemic hyperinsulinaemic clamp data
#
 
 Control Pre Post1 Post2 p1 p2 
M (µmol/KgFFM
-1.
min
-1
) 40 [26] 19 [3]
§ 
36 [19] 34 [9] 0.0007 0.0007 
M/I (µmol.min
-1
kgffm
-1
.pmol
-1
) 54 [59] 38 [8]
* 
82 [41] 84 [23] 0.0007 0.0007 
Fasting Plasma Insulin (pmol/l) 58 [33] 65 [48] 40 [24]
* 
34 [8]
#
 0.002 0.0007 
SS Clamp Plasma Insulin (pmol/l) 633 [363] 531 [132] 418 [63]
§ 
418 [107]
§ 
0.0008 0.005 
Rd clamp (umol
.
min
-1
) 1608 [1480] 1235 [357]* 1658 [558] 1701 [305] 0.01 0.001 
EGP (µmol.min-1) 696 [91] 869 [239]* 733 [213] 806 [233] 0.0007 0.01 
EGP clamp (µmol.min-1) -27 [116] 271 [133]§ 168 [170]* 150 [75]* 0.003 0.008 
#  Data are median [IQR].  p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon signed rank test; 
* p≤0.05;  #p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 5. Anthropometric and biochemical characteristics divided by remitters and non remitters
#
 
 
Pre p
1 
Post 1 p
2 
Post 2 p
3 
 Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
age (years) 55  2 57  1        
BMI (kg/m
2
) 28.7  0.6 28.1  0.9 ns 25.3  0.8 24.5  0.7 ns 22.8  0.8 23.7   0.6 ns 
HbA1c% 8.4  0.5 8.6  0.5 ns 6.6  0.5 6.7  0.3 ns 5.3  0.3 6.5  0.2 0.004 
Fasting Insulin 
(pmol/l) 
73.0  12.9 114.3  54.7 ns 42.7  9.5 48.7  8.4 ns 36.6  8.2 34.7  6.0 ns 
Fasting C-peptide 
(nmol/l) 
0.98  0.64 0.71  0.95 0.04 0.66  0.61 0.68  0.90 ns 0.55  0.86 0.41  0.52 ns 
Fasting glucose 
(mmol/l) 
11.3  0.6 12.9  0.6 ns 6.4  0.4 9.5  0.7 0.007 5.7  0.5 8.3  0.4 0.005 
Fasting Fat Free 
Acids (mEq/l) 
0.8  0.8 1.0  0.1 ns 0.9  0.1 0.8  0.1 ns 0.6  0.1 0.7  0.1 ns 
Fasting Glucagon 
(pg/ml) 
56.8  6.6 66.8  7.1 ns 65.7  11.4 96.0  20.0 ns 62.9  5.6 64.2  6.3 ns 
Fasting GLP-1  
(pg/ml) 
43.4  9.9 55.2  8.1 ns 44.1  9.8 73.8  13.4 ns 48.1  7.6 56.8  6.3 ns 
# Data are mean  SEM. p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon signed rank test; * p≤0.05;  #p≤0.01 or 
§
p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 6.  Lipid profile divided by remitters and non remitters
#
 
 Pre p
1 
Post 1 p
2 
Post 2 p
3 
 Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Triglycerides 
(mmol/l) 
1.8  0.2  2.1  0.3 ns 2.1  0.3 1.8  0.2 ns 1.6  0.2 2.1  0.4 ns 
Total Cholesterol 
(mmol/l) 
4.6  0.7 5.7  0.5 ns 3.5  0.3 3.4  0.2 ns 3.5  0.2 3.5  0.2 ns 
HDL cholesterol 
(mmol/l) 
1.0  0.1 1.3  0.7 ns 1.1  0.1 0.9  0.1 ns 1.1  0.1 1.1  0.1 ns 
LDL cholesterol 
(mmol/l) 
2.7  0.6 3.6  0.5 ns 1.5  0.2 1.5  0.1 ns 1.9  0.2 1.8  0.1 ns 
# Data are mean  SEM. p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon signed rank test; * 
p≤0.05;  #p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 7. Effects of BPD on glucose metabolism, insulin and glucagon secretion and incretins divided by T2DM remission
#
 
 Pre p
1 
Post 1 p
2 
Post 2 p
3 
 Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
AUC Glucose  (mol
.
l
-1.
h
-1
) 5.4  0.3 5.5  0.2 ns 2.8  0.2 3.7  0.2 0.01 2.2  0.2 3.6  0.1 0.004 
Inc. AUC Glucose (mol
.
l
-1.
h
-1
) 2.0  0.1 1.6  0.2 ns 1.0  0.1 0.9  0.1 ns 0.5  0.1 1.2  0.1 0.01 
AUC Insulin (nmol
.
l
-1.
h
-1
) 79  8.8 66  15.6 ns 45  2.3 34  3.5 0.03 57  11.2 38  6.2 ns 
Inc. AUC Insulin (nmol
.
l
-1.
h
-1
) 57  5.3 31  5.7 0.02 32  1.3 20  3.5 0.01 45  12.3 28  6.3 ns 
AUC C-peptide (nmol
.
l
-1.
h
-1
) 664  39 424  64 ns 494  19 384  36 0.05 540  100 330  47 0.05 
Inc. AUC C-peptide (nmol
.
l
-1.
h
-1
) 369  26 212  42 0.01 297  22 181  29 0.02 357  94 209  37 ns 
AUC GLP-1 (nM
.
l
.-1.
h
-1
) 15  2.6 19  2.4 0.05 26  5.0 30  4.2 ns 21  3.2 27  2.7 ns 
Inc. AUC GLP-1 (nM
.
l
.-1.
h
-1
) 17  0.6 2.8  0.7 ns 13  2.0 9.5  2.2 ns 11  3.3 9.5  2.9 ns 
AUC Glucagon (ng
.
ml
-1.
h
-1
) 19  2.2 23  2.1 ns 25  6.0 31  5.2 ns 20  2.6 21  1.7 ns 
AUC FFA (µEq
-1.
l
-1
) 131  22 183  21 ns 134  21 117  12 ns 69  23 93  12 ns 
Inc. AUC FFA (µEq
-1.
l
-1
) -139  18 -156  37 ns -144  24 -166  22 ns -102  36 -126  14 ns 
# Data are mean  SEM. p1 and p2 are respectively for the comparison of Pre vs. Post 1 and Pre vs. Post 2 by Wilcoxon signed rank test; * p≤0.05;  
#
p≤0.01 or §p≤0.001 for the comparison vs Control using Mann Whitney test. 
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Table 8: β-cell function parameters divided by remitters and non remitters. 
 Pre p
1 
Post 1 p
2 
Post 2 p
3 
 Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Fasting ISR  
(pmol
.
min
-1.
m
-2
) 
132[17] 34[51] 0.02 81[20] 86[28] ns 85[35] 57[24] 0.07 
Total insulin output 
(nmol
.
m
-2
) 
90[8] 44[37] 0.05 64[11] 52[25] ns 53[37] 43[29] ns 
ß-cell glucose 
sensitivity 
(pmol
.
min
-1.
m
-2.
mM
-1
) 
20[4] 11[17] ns 32[12] 24[22] 0.07 46[33] 16[18] 0.006 
Rate sensitivity 
(nmol
.
m
-2.
mM
-1
) 
247[127] 166[293] ns 508[342] 692[390] ns 610[697] 212[455] ns 
Potentiation factor 
(fold) 
1.34[0.5] 1.19[0.4] ns 1.17[0.5] 1.11[0.4] ns 1.8[1.1] 1.3[0.6] ns 
Insulin clearance 
basal 
(l
.
min
-1.
m
-2
) 
3.1±0.3 2.7±1.4 ns 3.7±0.3 3.9±0.3 ns 3.3±0.5 3.2±0.3 ns 
Insulin clearance 
MTT 
(l
.
min
-1.
m
-2
) 
1.8±0.3 1.5±0.2 ns 2.3±0.3 2.0±0.1 ns 2.2±0.3 1.8±0.2 ns 
# Data are median [interquartile range] or are mean  SEM . p1, p2 and p3 for the comparison remitters vs non-remitters at baseline, 2 months and 
1 year respectively by Man-Whitney test. 
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Table 9: Euglycaemic hyperinsulinaemic clamp data by remitters and non remitters
#
 
 Pre p1
 
Post 1 p2
 
Post 2 p3
 
 Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
Remitters 
Non 
remitters 
 
M (µmol/KgFFM
-1.
min
-1
) 20 [5] 19 [2] ns 39 [6] 24 [16] 0.07 38 [10] 31 [9] 0.05 
M/I 
(µmol
.
min
-1.
 kgffm
-1.
pmol
-1
) 
38 [7] 36 [9] ns 94 [17] 68 [44] ns 90 [41] 81 [19] ns 
SS Clamp Plasma Insulin 
(nmol/l) 
532 [95] 513 [147] ns 423 [67] 408 [67] ns 385 [136] 431 [63] ns 
Rd clamp (umol
.
min
-1
) 1294 [388] 1235 [330] ns 1863 [348] 1526 [662] ns 1734 [681] 1701 [212] ns 
EGP (µmol.min-1) 
827 [264] 958 [231] ns 717 [139] 802 [248] ns 775 [196] 807 [231] ns 
EGP clamp (µmol.min-1) 
266 [121] 291 [185] ns 38 [143] 203 [100] 0.06 145 [48] 176 [115] ns 
# Data are median [interquartile range]. p
1
, p
2 
and p
3
 for the comparison remitters vs non-remitters at baseline, 2 months and 1 year respectively 
by Man-Whitney test. 
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